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ABSTRACT
ZINC METABOLISM IN THE STREPTOZOTOCIN (STZ)-DIABETES
FEBRUARY 1995
AIZHONG FU B.S., BEIJING MEDICAL UNIVERSITY
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor R. Glenn Brown
Hyperzincuria in diabetics has been regarded as the culprit depleting body zinc
stores. Studies were designed to assess rates of 65Zn absorption and retention as a possible
compensation mechanism; to assess zinc concentrations and distribution among body
compartments, and to assess the kinetics of 65Zn metabolism in STZ-diabetic rats.
The rates of 65Zn absorption and retention were not significantly different between
STZ-diabetic and control rats. However, STZ-diabetic rats had significantly higher rates
of 65Zn absorption (16.88%) and retention (34.36%) when they were "Post-fasted" than
when they were "Prior-fasted" (9.04% and 18.68% respectively). These differences were
also present in control rats at a lesser degree (14.86% and 30. 19% for "post-fasting" and
1 1 .76% and 23.25% for "prior-fasting" respectively) This observation suggests that
dietary pattern affects 65Zn absorption and retention. The results indicate also that STZ-
diabetic rats are capable of absorbing and retaining enough zinc to meet body needs.
The STZ-diabetic rats had higher zinc levels in all tissues analyzed when they were
on diet adequate for zinc, with significant increases in liver, duodenum, pancreas and
femur; they had significantly higher zinc levels in liver and muscle but decreased plasma
zinc levels when fed the diet marginal for zinc; on zinc-supplemented diet, they had
significantly higher zinc levels in liver, kidney, duodenum, muscle and femurs, but
decreased plasma zinc levels. Plasma zinc levels, a common measure of zinc status, did not
reflect dietary zinc intake of STZ-diabetics. Endogenous zinc secretion was not decreased
as judged by measuring 65Zn in feces and duodenum. Whole body mean zinc
concentrations (WBMZC) were significantly higher in STZ-diabetic rats on all three
vi
dietary zinc levels. This increased WBMZC in diabetes may be the result of both increased
absorption and tissue catabolism during diabetes. One may conclude that to accommodate
zinc from increased tissue catabolism, the liver functions to store and sequester zinc from
the circulation; while the kidney is overloaded and secreted it. Hyperzincuria in diabetes in
this regard is a salvage of increased body zinc level. The diabetic bone may have disorders
in utilizing Zn during Zn deficiency as judged by its kinetics and decreased 65Zn specificity.
The whole body mean concentrations of copper and iron of STZ-diabetics were also
increased, suggesting similar disorders.
vii
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CHAPTER 1
INTRODUCTION AND OBJECTIVES
Diabetes mellitus, particularly insulin-dependent diabetes mellitus (IDDM) is a
chronic and potentially disabling disorder. The disease and its many complications are a
major public health and clinical concern because of its impact on affected countries and
national health cost (Rubin et al. 1994). Diabetics are frequently reported to have, among
many other metabolic abnormalities, hyperzincuria, which is an increased excretion ofZn
via urine (Canfield et al. 1984; Heise et al. 1988; Kiilerich et al. 1990, Raz and Havivi
1989; Fu 1991; Nakamura et al. 1991, Meltzer et al. 1962). The cause of the hyperzincuria
is far from clear. Long-term hyperzincuria may lead to depletion of body Zn stores and
development of a Zn deficiency. This may further aggravate the disease manifestation and
cause other clinical problems such as stunted growth, delayed sexual maturation,
decreased immune function and many other health problems in diabetics At present, how
these diabetics maintain their Zn status and compensate for the extra losses of Zn via urine
is not understood.
The true status ofZn nutrition in diabetic subjects is unknown. Development of
techniques for assessing Zn status in diabetes mellitus have been unsuccessful. The
commonly used approaches to assessing Zn status are analysis of Zn concentrations in
plasma or serum, blood components, and tissues like muscle and bones Zn concentration
in plasma or serum, the most frequently used measure in assessing Zn status, may not be a
good indicator ofZn status. Plasma or serum Zn levels of diabetics were reported to be
either decreased (Car et al. 1991; Rosner and Gorfien 1968; Melinkeri et al. 1990), or
increased (Mateo et al. 1975; 1978; Nobles et al. 1986). Mononuclear concentrations of
Zn were regarded as a more accurate measure of Zn status (Prasad 1988), but levels of
leukocyte Zn in diabetes are also inconsistent (Raz and Havivi 1989; Kumar and Jaya Rao
1974; Pidduck et al. 1971; Raz and Havivi 1989; Pai et al 1988). The same are also true
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for assessing erythrocyte Zn (Sjogren et al. 1985; Raz and Havivi 1989; Rosner and
Gorfien 1968) and muscle Zn levels (Failla and Kiser 1981; Levine et al. 1983).
The uncertainty of Zn status in diabetes has led studies to measure Zn absorption
and endogenous secretion as the sources ofZn compensating for urinary losses (Heise et
al. 1988; Johnson and Canfield 1985; Craft and Failla 1983; Kiilerich et al. 1990). The
ability to absorb dietary Zn was not significantly altered and the total amount ofZn
absorbed was increased in diabetic animals due to their increased food intake. The
increased Zn absorption in STZ-diabetic animals may be due to their swollen intestine
(Craft and Failla 1982; Gourley et al. 1983), stimulated digestive enzymes (Olson and
Roger 1971), decreased lumen to mucosal flux ofZn (Ghishan and Greene 1983), and
decreased intestinal secretion of endogenous Zn (Johnson and Canfield 1985). The only
study on Zn absorption in human IDDMs (Kiilerich et al. 1990) reported a decreasing 65Zn
absorption, which is contradictory to all these animal studies mentioned above. Studies in
this laboratory did not show an obvious benefit to human IDDMs from Zn
supplementation (Fu, 1991; Cunningham et al. 1994), suggesting Zn status in diabetics is
not significantly altered.
The present study tried to resolve these uncertainty on Zn metabolism in diabetes
mellitus by three approaches: first, a study on the effect of feeding pattern on four-hour Zn
absorption and retention in diabetes; second, a detailed analysis of tissue Zn distribution
and concentrations under both Zn depletion and supplementation; third, kinetics ofZn
metabolism in diabetes at the whole body and tissues levels with the following three
objectives:
1 . To assess 65Zn absorption and retention as a mechanism of compensation
for hyperzincuria in STZ-diabetic rats; to compare the effects of post-fasting and
prior fasting on the rates of
65Zn absorption and retention; To explore what other
variables relate to
65Zn absorption.
2. To assess the Zn status of diabetics by analyzing whole body and tissue
Zn levels in STZ-diabetic rats and by studying the effect of diets which contain
different amounts of Zn, e.g. Zn-depleted, normal and Zn-supplementation, on
2
tissue Zn concentration and distribution in STZ-diabetic rats in comparison with
their controls;
3. To determine kinetics of S5Zn metabolism, e.g. whole body retention of
65Zn, turnover rate of 65Zn, excretion of 65Zn in urine and feces and 65Zn retention
at the tissue or organ levels within 12 days after 65Zn administration in STZ-
diabetic rats in comparison with that of their controls.
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CHAPTER 2
LITERATURE REVIEW
2.1 Introduction to Diabetes Mellitus and Zinc
2.1.1 Diabetes Mellitus: A Disorder of Metabolism
Diabetes mellitus is a genetically-determined disorder characterized by disturbed
metabolism of carbohydrate, fat, and protein caused by a relative or absolute insufficiency
of insulin and/or varying degrees of insulin resistance (Fajans 1990, Olefsky and Molina
1991). The disease is chronic and potentially disabling in nature. It represents a major
public health and clinical concern. People with diabetes mellitus are at increased risk in
developing chronic complications which affect wide variety of body systems (Rubin et al.
1994).
There are two types of primary diabetes mellitus: Type 1 diabetes mellitus or
insulin-dependent diabetes mellitus (IDDM) and Type 2 diabetes mellitus or non-insulin-
dependent diabetes mellitus (NIDDM). The two types of diabetes mellitus are distinct
entities, differing in etiology, pathophysiology and treatment.
IDDM is caused by P-cell destruction which results in insulin deficiency Factors
which lead to beta-cell destruction are not clearly understood (Lernmark 1991). Generally,
genetics, autoimmunity, and environmental factors have all been considered to cause
IDDM (Warram et al. 1987; Rossini et al. 1988; Oldstone et al. 1991). The degenerative
changes noticed in all forms of diabetes appear to have a common etiology which involves
hyperglycemia. The disturbances in metabolism due to insulin deficiency or insulin
resistance during hyperglycemia in diabetes mellitus can be summarized as follows
(Davidson 1991):
1 . Substrate anabolism decelerates;
2. Tissue catabolism accelerates;
3. Levels of stress hormones increase (epinephrine, norepinephrine, glucagon,
Cortisol, and growth hormone);
4. Plasma glucose rises;
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5. Plasma pH decreases because of fatty acid release and ketone body production.
The major complications of diabetes mellitus are listed in Table 2.1. The major
causes for morbidity and mortality in patients with diabetes come from the long-term
microvascular complications. The microvascular complications result in an increased
incidence of heart disease and cerebrovascular episodes (stroke, hemorrhage, etc.) as well
as peripheral vascular occlusion resulting in amputations. Diabetic retinopathy and
nephropathy stemming from vascular changes eventually develop into blindness and renal
failure respectively. Diabetes is the most common cause of blindness in the United States.
Kidney transplants from renal failure due to diabetes are performed more frequently than
for any other causes (Diabetes Surveillance 1980-1987). The mechanisms of the diabetic
complications are thought to be due to the prolonged effect of hyperglycemia on polyol
(such as sorbitol) formation and its subsequent accumulation in tissues which causes tissue
damage (Kinoshita, et al. 1990) and/or glycosylation of important structural proteins,
thereby affecting their functions. A recent hypothesis proposed that systematic
hyperinsulinemia and hepatic hypoinsulinemia are both responsible for the vascular
complications of the disease, but the hypothesis needs to be tested (Gwinup and Elias
1991).
Diabetes is one of the major public concerns due to its huge medical costs on both
the patients and the nation. Approximately 1 in 500 children less than 18 years of age in
the United States are affected by IDDM (Laporte et al. 1981). Diabetics (both IDDM and
NIDDM) accounted for 4.5% of U. S. population in 1992, but accounted for 14.6% of
total U. S. health care expenditure (105 billion), the per-capita expenditure for diabetes
($1 1,157) is four times that for the non-diabetics ($2604) (Rubin et al. (1994). Of all
diabetes mellitus diagnosed, about 90% are NIDDM. The prevalence ofNIDDM
increased as much as 10-20 fold during the last half century, perhaps as a result of both
increasing longevity and an increased incidence of obesity (Davidson and DiGirolamo
1991).
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Table 2.1. Diabetic Complications
Eyes
Diabetic retinopathy
Non-proliferative (background)
Proliferative
Cataracts
Subcapsular (snowflake)
Nuclear (senile)
Nervous system
Peripheral neuropathy
Distal, symmetric sensory loss
Motor neuropathy
Foot drop, wrist drop
Mononeuropathy multiplex
(diabetic amyotrophy)
Cranial neuropathy
Cranial nerve III, IV, VI, VII
Autonomic neuropathy
Gastrointestinal neuropathy
Resting tachycardia
Loss of sweating
Postural neuropathy
Gastroparesis
Diabetic diarrhea
Urinary bladder atony
Impotence (may be also
secondary to pelvic
vascular disease)
Bones and joints
Diabetic cheirarthropathy
Dupuytren's contracture
Charcot's joint
Kidney
Intracapillary glomerulosclerosis
Disfuse
Nodular
Infection
Pyelonephritis
Perinephric abscess
Renal papillary necrosis
Renal tubular necrosis
Following dye studies
(urogram, arteriogram)
Skin
Diabetic dermopathy (skin spots)
Necrobiosis lipodica diabeticorum
Candidiasis
Foot and leg ulcers
Neurotropic
Ischemia
Cardiovascular system
Heart disease
Myocardial infarction
Cardiomyopathy
Gangrene of the feet
Ischemic ulcers
Osteomyelitis
Unusual infections
Emphysematous cholecystitis
Malignant externa
Necrotizing fasciitis
Necrotizing myositis
Mucor meningitis
* From Greenspan F. S. and Forsham P. H. (eds): Basis & Clinical Endocrinology, 2nd ed.
1986; East Norwalk, Connecticut: Appleton-Century-Crofts. P. 523-574.
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2.1.2 Zn: An Essential Nutrient
Zn is indispensable for all forms of life and critical to transmission of genetic
messages, differentiation, development, growth, and the ultimate preservation of species.
It is such an essential element that no disorders are known to be associated with its
excessive accumulation (Vallee and Falchuk 1993). However, its antagonistic effect on
Cu, and the many side effects through inappropriate uses can not be ignored (Cunnane
1988). Zn deficiency has been frequently reported in both developing countries as well as
developed countries (Sandstead 1991) and is manifested in variety of clinical disorders
(Table 2.2).
The major function of Zn is as a co-factor in many enzymes (Girchev and Tzachev
1988). Zn has been found in all six categories of enzymes; a total 160 enzymes from
different species are reported to have Zn as a component (Galdes and Vallee 1983).
Functions ofZn in these enzymes include catalytic, structural, regulatory, and non-
catalytic (neither involved directly in catalysis nor essential for structural function)
functions involved in DNA, RNA and protein synthesis (Falchuk 1988; Hurley 1981).
Normal secretion and function of several hormones, including insulin may depend
on a normal Zn status. Deficiencies ofZn influence growth hormone, somatomedin, and
glycosaminoglycan formation, resulting in growth impairment (Bolze et al. 1987). Zn is
involved in insulin synthesis and secretion (Kirchgessner and Roth 1983). Zn deficiency
causes hypogonadism, thereby decreasing the ability of testes to secrete sex-hormones
(Abbasi, et al. 1980; Bunce, 1988). During Zn deficiency, plasma levels and functioning of
some other hormones, such as prolactin, thyroid hormone, corticosteroids are also
affected (Hambidge et al. 1986). It has been demonstrated that Zn is directly involved in
the binding of some hormones to their plasma membrane receptors and subsequently alters
signal transduction across plasma membranes (Anonymous 1991). Zn also affects the
structure of hormone receptors (Vallee and Falchuk (1993).
Zn improves wound healing (Henkin 1974) and vision (Smith et al. 1974). A
recent hypothesis suggests that aging process may be due to an intracellular Zn deficiency,
which affects some of the "overly-vulnerable" Zn enzymes, resulting in accumulation of
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useless (or toxic) materials, altered production of essential proteins, neoplastic changes
and cell death. Zn ions exert an inhibitory effect on the functional components of the cell
membranes (Chvapil, 1976; Bettger and O'Dell 1993). Zn affects the functional activity of
macrophages, polymorphonuclear leukocytes and possibly some other cells. Zn is thus
able to relieve the inflammatory reaction of the system (Chvapil 1 976). A recent study
demonstrated that the concentration of red-cell membrane Zn correlated well with osmotic
frangibility during Zn depletion and repletion (Jahanning and O'Dell 1989).
Zn deficiency has marked effects on almost all components of the immune system:
decreased antigen response, decreased cell-mediated response, and decreased performance
of normal cell function (Fraker et al. 1987). Zn deficiencies in animals increase
susceptibility to a number of bacterial, viral, and parasitic challenges (Keen 1990).
Peripheral blood neutrophils from patients with acrodermatitis enteropathica (a genetic
disorder of Zn metabolism) were defective in their chemotactic activity, and this defect
could be reversed successfully by treating the patients with Zn.
Zn deficiency influences sexual maturation, fetal growth and development, and
labor (Girchev and Tzachev 1988; Apgar 1992). Taste and smell (Henkin et al. 1974), as
well as brain and peripheral nerve function (Prohaska 1987; O'Dell et al. 1990) are all
inhibited by Zn deficiency.
Zn status is altered by wide varieties of diseases. Decreased Zn status has been
reported in gastrointestinal diseases (McClain et al. 1988), liver disease (Sullivan and
Burch 1976), cancer (Schrauzer 1977), diabetes mellitus (Kiilerich et al. 1990), sickle cell
anemia (Prasad 1986), renal disease (Prasad 1986), and cystic fibrosis (Halsted and Smith
1970). It has been hypothesized that Zn has a universe role in cellular function (Burnet
• 1982). Metabolic abnormalities in Zn Deficiency are listed in Table 2.3.
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Table 2.2 Clinical Features of Zn Deficiency
Skin and hair lesions
Loss hair, Alopecia,
Skin dry and hard
Scaly, cracking, fissures and thickening
Bleeding
Abnormal feather (birds)
Inflammation
Oesophageal parakeratosis
Reduced feeding consumption and utilization of food
Catabolism
Growth retardation
Increased urinary nitrogen and sulphur
Impaired reproduction
Reduced testicle size
Decreased libido
Lower spermatogenesis
Retarded sexual maturity
Skeletal malformation
Impaired immune responses
Impaired wound healing
Behavioral disturbance
Lethargy
Reduced learning ability
Emotional stability
Anemia
Hepatosplenomegaly
Night blindness
Impaired taste (hypogeusia)
Aging
Modified from Solomon, 1988.
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Table 2.3 Metabolic Abnormalities in Zn Deficiency
Decreased circulating Zn
Decreased albumin synthesis
Decreased serum alkaline phosphatase activity
Decreased carboxypeptidase activity (intraduodenal)
Decreased alcohol dehydrogenase (retina, testis)
Decreased RNA polymerase activity (liver)
Decreased nucleoside phosphorylase activity (lymphocytes)
Elevated serum RNase activity
Increased serum ammonia
Impaired glucose metabolism
Decreased insulin response
Disordered prostaglandin sensitivity
Decreased testosterone level
Decreased white cell chemotaxis
Impaired T-lymphocyte function
Decreased serum thymic factor
Decreased resistance to infections
Increased resistance to autoimmune disease
Decreased intestinal disaccharidase activity
Elevated 3-hydroxyglutamyl coenzyme A reductase
Abnormalities of retinal pigments
Decreased collagen synthesis
Decreased platelet function
Modified from Solomons, 1988.
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2.2 Zinc and Diabetes Mellitus
2.2.1 Introduction
A history of relationship between Zn and diabetes mellitus traces back more than
60 years. The discovery that crystalline insulin contained considerable quantities of Zn
(Scott 1934) stimulated many investigations into the physiological role of Zn in insulin
synthesis, storage, secretion and peripheral metabolism, and ultimately its role in diabetes
mellitus. As early as 1937, Hove (Hove et al. 1937) noted a small difference in glucose
tolerance in Zn deprived rats compared with normal animals. Vikbladh in early 1951 tried
to assess Zn status by determining serum Zn levels in insulin-treated diabetics. Tarui
(1963) reported hyperzincuria was a prominent feature of experimental diabetes. Since
these early experiments, Zn metabolism and assessment of Zn status in diabetes mellitus
have been under active study. The possible links between Zn and diabetes mellitus are
listed in Table 2.4.
Table 2.4 Possible Links between Zn and Diabetes Mellitus
Links Mechanisms
Zn and insulin
Insulin synthesis,
Insulin storage
Insulin secretion
Insulin degradation
Zn and proinsulin
Zn and glucose tolerance
Zn and insulin-like activity
Hyperzincuria
Insulin from most species contains Zn
Pancreas contains large amount of Zn
Co-secretion of Zn and insulin from pancreas
Zn deficiency decreases insulin secretion
Zn deficiency increases insulin degradation
Proinsulin contains 5 moles of Zn, it is soluble
Zn may also be involved in the conversion of
proinsulin to insulin
I
Zn deficiency results in glucose intolerance
May involve insulin resistance, decreased tissue
sensitivity to insulin
Zn deficiency may decrease secretion of insulin-
like substance
Extra loss of Zn from urine in diabetes
1
1
2.2.2 Roles of Zn in Insulin Metabolism and Glucose Tolerance
2.2.2.1 Zn and Insulin Synthesis in the Islets of Langerhans
Several lines of evidence suggest that Zn is essential for insulin metabolism but its
direct roles are still speculative. It is likely that Zn facilitates the processing and packaging
of insulin (Cunnane 1988a). Insulin is synthesized at the ribosome as a single-chain
polypeptide, preproinsulin. Removal of the N-terminal leader sequence yields proinsulin,
which aggregates into hexamers with two Zn atoms per hexamer connected to the six
histidines. Proinsulin is a highly soluble molecule itself, and its solubility is primarily
enhanced by the weak binding ofup to 30 atoms of Zn per hexamer. Removal of the
connecting peptide and exposure of non-polar residues of proinsulin dramatically decrease
both its Zn binding capacity and solubility. As a consequence, insulin precipitates and is
packaged into the beta cell storage vesicles as the two Zn hexamers ready for releasing by
appropriate stimulus (Maske 1957; Vallee 1959; Chvapil 1976; Yoshinaga and Ogawa
1975). The study by Epand et. al. (1984) showed that stripping pancreatic granules ofZn
may induce diabetes. They found that the diabetogenicity of Zn chelators was correlated
with their ability to sequester Zn. The diabetogenicity of alloxan, a commonly used drug to
induce diabetes in animals, is also correlated to its ability to chelate pancreatic Zn ions
(Maske 1957; Lowry et al. 1954).
However, it has also been shown that Zn is not an obligatory component of insulin
synthesis. Cultured islet cells have been found to synthesize insulin in Zn-depleted media
for 9 days (Howell et al. 1978; Hoftiezer et. al. 1985). Moreover, the fact that the active
form of circulating insulin is a Zn-free monomer (Blundell et. al. 1972; Goldman and
Carpenter 1974) is also contradictory to the indispensable role of Zn in insulin
metabolism..
At the whole body level, whether or not insulin metabolism is affected by dietary
Zn intake is unclear. Pancreatic Zn concentration may be influenced by dietary intake
(Southon et al. 1988; Williams and Mills 1970) and Zn deficient diets have also been
associated with a decreased granulation in the beta-cells (Boquist and Lernmark 1969).
While Zn supplementation increases insulin content and granulation of the pancreatic
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islets; it also decreased the abnormally high insulin-secretion response to glucose by
pancreatic islet cells from ob/ob mouse (Begin-Heick et al. 1982). However, other studies
(Huber and Gershoff 1973) found no significant effect of high levels of dietary Zn (1200
ppm) on pancreatic insulin content compared with low level ofZn (1 ppm).
2.2.2.2 Zn and Insulin Secretion
It should be pointed out that the pancreas contains a large amount of Zn, but only
a small percentage of Zn is associated with insulin (Figlewicz, et al. 1984). A concurrent
change in Zn and insulin contents within the islets of Langerhan suggests Zn may be
involved in insulin secretion (Grosby and Schmid-Formby 1985). Very high concentration
of Zn in the media stimulates in vitro insulin secretion from pancreas (Flgelwicz et al.
1981). When the pancreas was derived from Zn deficient rats, the effect of glucose on
insulin release was markedly diminished (Huber and Gershoff 1973). Serum insulin in
lambs was decreased when they were fed on a Zn deficient diet but normal in lambs fed on
diets either marginal or adequate for Zn (Droke et. al. 1993), suggesting under normal
conditions, serum insulin level may not be affected. However, it was also observed that
animals fed Zn depleted diet had decreased levels of serum insulin and insulin-like growth
factor- 1 (Dorup et al. 1991).
Formby Grosby and Schmid-Formby (1985) showed that extra-granular Zn efflux
from the islets of Langerhans was sensitive to secretagogues and cellularly-active agents
but was not related quantitatively to insulin secretion. Pancreatic islets have been shown to
secrete less Zn when stimulated by glucose, but when stimulated by stronger
secretagogues, the secretion ratios ofZn to insulin gradually increased. This increase in Zn
secretion was sustained over a long time period (Figlewicz et al. 1984; Florence et al.
1984).
Southon, et al. (1988) reported that genetically diabetic mice, 4-5 weeks of age,
fed a diet low in Zn for 28 days had higher levels of fasting-blood-glucose and liver
glycogen, but their fasting blood insulin level was unaffected. These authors suggested
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that this may be an adverse effect of decreased Zn-intake on glucose utilization in the
genetically diabetic mice, which may precede any significant plasma insulin change.
2.2.2.3 Zn and Proinsulin
Zn, as an indispensable component of proinsulin, is thus associated with insulin
metabolism. The conversion of proinsulin to insulin in vitro is decreased in a Zn-deficient
media (Howell et al. 1978; Grant et al. 1972) suggesting that the conversion of proinsulin
to insulin is a Zn-dependent process. Zn also increases proinsulin stability and decreases
insulin solubility (Gold and Grodsky 1984). Zn may affect the conversion process of
proinsulin to insulin through its effect on some enzymes which may be involved in the
process. As an example, it is known that carboxypeptidase B loses about 50% of its
activity in Zn-deficient rats (Kirchgessner and Roth 1983; Steiner et al. 1974). However,
serum proinsulin concentration has also been shown not to be influenced by Zn deficiency
in some other studies (Howell et al. 1978).
2.2.2.4 Zn and Glucose Intolerance
Zn deficiency may impair glucose tolerance. Hove et al. (1937) reported
differences in glucose tolerance curves between Zn-deficient and ad libitum-fed control rat
after oral-glucose dosing. Using intraperitoneal glucose injection, Quartman et al. (1966)
found decreased glucose tolerance of Zn-deficient rats compared with pair-fed control
animals after an extended experimental period and an overnight fast. This has also been
seen in other studies using Chinese hamsters (Boquist and Lernmark 1969; Hueber and
Gershoff 1973). In human beings with dwarfism and symptoms ofZn deficiency,
decreased glucose tolerance was also observed (Sandstead et al. 1967).
The relationship between Zn deficiency and glucose intolerance may be underlined
by the observation that Zn deficiency may blunt insulin secretion. Kirchgessner and Roth
(1983) observed that Zn-deficient animals lack the second phase of insulin secretion in
response to glucose injection. However, Reeves and O'Dell (1983) concluded that the
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diminished insulin synthesis and secretion do not adequately explain the observed effect of
Zn deficiency on glucose metabolism.
Several explanations have been proposed to account for Zn deficiency affecting
glucose intolerance. The effect of Zn on glucose tolerance in some of the studies appears
to be related to the route of glucose administration. A significant increase in plasma
glucose occurred in the Zn-deficient animals when glucose was injected intraperitoneally,
however, no difference was found in the rate of metabolism of orally administered glucose
between Zn-deficient and Zn-supplied rats (Hendricks and Mahoney 1972). On the other
hand, Quartman and Florence (1972) did not find any effect ofZn deficiency on glucose
tolerance when glucose was administered intraperitoneally. They attributed this lack of
effect to the pattern of food intake. The difference in results noted between oral glucose
dosing and intraperitoneal or intravenous glucose injection might be due to a greater
stimulation of insulin secretion in response to oral glucose (Fasel et al. 1970). However,
Brown, et al. (1972) did not find any effect ofZn deficiency on glucose tolerance after
oral administration
,
suggesting there may be other factors involved.
The rate of insulin degradation increased in the Zn-deficient rats as they became
much more resistant to hypoglycemic coma than Zn-repleted rats (Hendricks and
Mahoney 1972; Quartman et al. 1966). These observations are supported by the
observation that higher Zn levels in cultural media increase insulin binding to liver plasma
membranes and subsequently decrease insulin degradation (Arquilla et al. 1978).
Zn deficiency may induce an insulin resistance in peripheral tissue similar to that
noted in some cases of diabetes meilitus (Baer et al. 1985; Reeves and O'Dell 1983). Fat
cells require insulin for the uptake of glucose. The considerable decline in glucose
utilization by fat cells in Zn-deficient meal-fed rats is most readily explained by one of two
mechanisms: either circulating insulin levels are low or the response of fat cells to insulin is
decreased. The study by Park et al. (1989) clearly showed that rats with pure Zn
deficiency displayed a considerable glucose intolerance, but the effect is not due to lower
level of circulating insulin rather to peripheral resistance to insulin action, since these
animals had normal levels of serum glucagon, and slightly elevated serum insulin. Since
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Zn-deficient rats manifested an increased corticosterone as well as increased plasma
glucose, corticosterone has been hypothesized to take a part in the impaired glucose
tolerance (Park, et al. 1989).
2.2.2.5 Zn and Insulin-Like Substance
Sera from both animals and humans contain insulin-like substances which possess
high specific biological activity but which differ biochemically from insulin. It was
observed that sera from Zn-deficient animals had an increased insulin-like activity, which
may be a compensatory mechanism to decreased insulin secretion in response to a glucose
load (Kirchgessner and Roth 1983). Droke et al. (1993) found that serum insulin-like
growth factor- 1 was decreased in Zn deficient animals while this decrease was not seen in
animals fed on marginally Zn deficient and adequate Zn diets.
Zn itself possesses a stimulatory effect similar to insulin on carbohydrate
metabolism (May and Contoreggi 1982). Concentrations of Zn between 250 and 1000 uM
have been found to stimulate 3-O-methylglucose transport and glucose metabolism to C02
and other intermediates; and Zn ions stimulate the pentose phosphate cycle and inhibit
lipolysis (May and Contoreggi 1982). The effect of Zn ions on glucose oxidation and
lipolysis was inhibited by extracellular catalase, suggesting this effect of Zn may related to
hyperoxide generation, as well as the direct effect ofZn ions on intracellular metabolism.
Coulston and Dandona (1980), who used the rate of lipogenesis by rat epididymal
adipocytes as an index of the biological potency of insulin, found that Zn had a potent
stimulatory effect on lipogenesis in vitro. This effect was similar to and independent of
insulin, and Zn was found to have an additive effect when incubated together with insulin
in the in vitro medium (Coulston and Dandona 1980). A recent report (Thorne and
Lockwood 1991) indicates that Zn inhibits proteolysis, which is also one of the effects of
insulin. These effects of Zn were unique since other cations, such as Co
+2
,
Mn+2
,
Fe
+2
,
and
Cr+3
,
have no effect.
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2.2.2.6 Hyperglycemic and Glucosuria Action of Zn
Some studies have shown that Zn exhibits both hyperglycemic and glycosuric
effects, which may explain the significantly increased plasma glucose levels in rats tested
Zn either intraperitoneally or orally (Etzel and Cousins 1983). The increase in serum
glucose after administration of Zn was prompt, within 1 5 minutes, and it returned to
normal within 4 hours. Significant depletion of hepatic glycogen suggests it is a
glycogenolytic process. Adrenalectomy completely eliminated the hyperglycemic effect of
Zn, and adrenergic blockade was also effective in preventing the hyperglycemic effect,
suggesting the effect depends on an intact adrenal gland (Etzel and Cousins, 1983). As
early as 1918, it was noted that when animals such as cats and dogs dosed with Zn salts in
the form of malate or acetate, significantly greater amounts of sugar was excreted in the
urine (Salant and Wise 1918). This effect of Zn has not been reported since then, however.
The above review summarizes the available findings concerning the relationship
between Zn and insulin, glucose metabolism and the possible links between Zn and
diabetes mellitus. Although data are inconsistent, the influence of Zn on insulin and
glucose metabolism can not be excluded. It is likely that normal Zn nutrition is an
important factor to ensure normal metabolism of insulin and glucose, however, the
mechanisms are still not clear.
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2.2.3 Alterations of Zn Metabolism in Diabetes Mellitus
2.2.3.1 Experimental Studies
2.2.3.1.1 Increased Urinary Zn Excretion
Urinary Zn excretion increases dramatically as animals develop diabetes (Tarui,
1963). Both pancreatomized dogs and alloxan-treated rabbits exhibited a 5 to 8 fold
increase in urinary Zn after a latent period of 2-3 days. A transient increase in urinary Zn
excretion occurred within 24 hours after treating rabbits with alloxan and a permanent
hyperzincuria began 2 to 3 days later (Tarui, 1963). Ikeda and Kotake (1986) observed
that Zn was substantially excreted as its complex with xanthurenic acid (XA). Insulin
added to the vascular perfusate directly inhibits excretion of Zn by the in vitro perfused
dog kidney (Vander et al. 1983). Acute infusion of glucagon increases Zn excretion in the
same manner (Victery et al. 1982), suggesting that the hormonal imbalance present in
diabetes mellitus may be responsible for hyperzincuria. Similarly, Lau and Failla (1984)
found that diabetic rats excreted 3.4-. 5.0- and 4.9-times more Zn, Cu and Fe respectively
than the control rats. Insulin treatment of diabetic rats significantly reduced the quantity of
the micronutrients in their urine. The study also showed that the enhanced urinary output
was not associated with reduction in plasma, liver and kidney concentrations of these
metals. Decreased plasma insulin levels appear to be a major determinant factor for
hyperzincuria (Vander et al. 1983). The same authors (Vander et al. 1983) observed that
infusion of insulin alone caused decreased urinary Zn excretion and a physiological level of
insulin exerts an inhibitory effect on Zn excretion. Insulin has also been shown to prevent
the increase in Zn excretion caused by somatostatin (Vander et al. 1983). The above
studies indicate that hyperzincuria in diabetic subjects is the natural result of insulin
deficiency.
Based upon a recent understanding of diabetic nephropathy, diabetic hyperzincuria
may be related to alteration of kidney structure and function. The diabetic kidney could be
leaky to Zn and other metals due to hypertrophy and hyperfiltration. Zn may also be
excreted as conjugated with albumin or alpha-globulin, since these components are also
present early in the diabetic urine (Marshall 1991).
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2.2.3.1.2 Uncertainty in Plasma Zn Level
The fact that hyperzincuria occurs in diabetes raised concern for a possible Zn
deficiency in diabetics and studies have been undertaken to assess Zn status in diabetes.
The commonly used approach is to assess Zn levels in plasma or serum. Plasma or serum
Zn levels were elevated in streptozotocin-induced diabetic rats (Burke and Fenton 1989;
Failla and Kiser 1981; Failla and Gardell 1985). Serum Zn was decreased in the genetically
diabetic mice and ob/ob mice (Levine et al. 1983; Begin-Heick et al. 1982), but not in
streptozotocin-induced diabetic mice (Levine et al. 1983). The two types of diabetes
should differ in their etiology and plasma insulin level. These differences in the response of
either plasma or serum Zn levels may indicate the two types of diabetes influence Zn
metabolism by different mechanisms.
2.2.3.1.3 Alterations of Zn Concentrations in Tissue
While tissue Zn concentrations of diabetic animals are altered, but they may not
necessarily be deficient. Measurement of tissue Zn levels of spontaneously diabetic BB
Wistar rats with hyperphagia, hyperglycemia, glucosuria, polyuria, polydipsia and impaired
weight gain (but without ketosis) showed that, besides of elevated urinary Zn, these
animals had significantly increased Zn levels in plasma, liver, and kidney but no changes
were found in duodenum, muscle, and spleen (Failla and Kiser 1981; Failla and Gardell
1985). By pair-feeding Zn to diabetic and control rats, it has been shown that hyperphagia
of diabetic rats was not a factor for the accumulation of these metals. Failla and Kiser
(1981 ) suggested that the hormonal imbalance influenced trace metal metabolism in the
diabetic rats.
The differences between the spontaneous and chemically induced diabetes noted
previously are also apparent in terms of the concentrations ofZn found in tissues. While
Zn concentrations in femurs and seaim were decreased in the genetically diabetic mice, no
difference in serum and tissue Zn concentrations was noted in the streptozotocin-induced
diabetic mice (Levine et al. 1983). However, Southon et al. (1988) reported that the
genetically diabetic mice that consumed a marginal Zn depleted diet for 28 days from 4-5
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weeks of age exhibited only a minimal effect on the Zn status as indicated by growth rate,
food intake, and femur and pancreatic Zn concentrations. Donaldson et al. (1988) found
that decreased femur Zn content in the genetically diabetic mice disappeared when the
data were expressed on a dry ash basis, suggesting that low femur Zn concentration may
reflect a generalized depletion rather than a specific depletion ofZn in the genetically
diabetic mice.
Diet composition was observed to be associated with tissue Zn levels in STZ-
diabetic rats (Johnson and Evans 1984). They found that duodenal Zn concentration was
higher in diabetic rats when they were fed "high" mineral diets compared with rats fed
"low" mineral diet. Femur Zn was also higher in diabetic rats fed a "high" protein rather
than a "low" protein diet. However, hepatic and kidney Zn levels seemed to be not
influenced by these factors.
Increased Zn levels in liver and kidney of diabetic animals were a characteristic
finding in the diabetic rats (Failla and Kiser 1983). The Zn in the livers and kidneys of
diabetic animals are mostly in the form of Zn-metallothionein in the soluble fraction of the
cells. This event may represent a biological adaptation process by sequestrating Zn in
response to stress. Hallmans and Lithner (1980) applied acute heat-trauma to diabetic rats
and showed that alterations in Zn metabolism were greater in the diabetic rats when
compared with controls. It was also suggested that there was a sequestration of serum Zn
by the liver and an increased Zn absorption from gastrointestinal tract occurred in diabetes
(Hallmans and Lithner 1980). Burke et al. (1988) reported that the membrane bound Zn
did not seem to be affected although the lipid profile of the db/db mice was altered.
2.2.3.1.4 Altered Zn Absorption As One of the Compensation Mechanisms for
Urinary Zn Losses in Diabetic Animals
Craft and Failla (1982) reported that absorption ofZn by diabetic animals were
increased two fold, which may explain the increased urinary Zn losses. They (Craft and
Failla 1983) subsequently observed that Zn absorption by diabetic animals was the same as
that of normal controls per 20 cm duodenal loop by an in-situ, ligated-loop technique, but
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Zn absorption per gram of dry mucosa was decreased by 45-53%. The overall absorption
ofZn was increased due to a 50% increase in mucosal mass. In experimental diabetes, a
number of intestinal brush border hydrolases and transport systems have been shown to be
increased (Olson and Rogers 1971; Younoszai and Schedl 1972; Caspary et al. 1972).
There was a considerable increase in the total membrane volume from the diabetic rats,
although the ratio of lipids to protein was found to be similar (Gourley et al. 1983). These
data suggest that one of the mechanisms of diabetic animals to maintain Zn balance is
through hypertrophy of their mucosal tissue to augment the absorption of Zn.
Intestinal Zn transport measured by a single pass perfusion technique indicates that
the relative lumen to mucosal flux of Zn was significantly decreased in all segments of gut
from diabetic rats (Ghishan and Greene 1983), as was intestinal excretion of endogenous
Zn (Johnson and Canfield 1985). Net absorption ofZn from jejunal segments was also
decreased in streptozotocin-induced diabetic rats, and treatment with insulin had no effect
on net Zn absorption (Song and Mooradian 1988). It is debatable whether Zn absorption
of this segment represents total Zn absorption in rats, since studies have shown that the
major site ofZn absorption may shift with Zn status (Schwarz and Kirchgessner 1975).
2.2.3.1.5 Increased Zn Turnover in Diabetic Animals
Whole body retention of 65Zn in carcass and in carcass+liver was lower in alloxan-
diabetic rats than in controls 50 hours after the injection. The total Zn concentrations of
various tissues (liver, pancreas, spleen, kidney, heart and muscle) of the diabetic rats,
however, were higher than in the control rats either expressed on fresh weight or dry
weight basis (Hallmans et al. 1984). Since Zn levels in several tissues of these rats were
not decreased, even in the presence of hyperzincuria, a faster turnover rate of Zn in
diabetes may be implied.
2.2.3.1.6 Zn Deficiency in Diabetic Pregnancy
Fetuses from diabetic rats have lower liver Zn concentrations and a higher
frequency of malformations than fetuses from control dams (Uriu-Hare et al. 1989;
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Eriksson, 1984). The similarities between malformations seen in fetuses from diabetic rats
and those from purely Zn deficient rats suggest that the teratogenic effect of diabetes may
be partially due to a Zn deficiency (Uriu-Hare et al. 1989; Eriksson 1984). These studies
also showed that diabetes during pregnancy can amplify the teratogenic effects of mild
maternal Zn deficiency and the maternal diabetic condition also alters the transport of Zn
and Cu across diabetic placentas and/or alters Zn and Cu retention of fetuses of the
diabetic mothers (Uriu-Hare et al. 1989). Adequate Zn intake significantly improved fetal
growth, high Zn-diets further improved fetal length and weight, but, supplementation of
Zn did not decrease the frequencies of malformation (Uriu-Hare et al. 1989).
2.2.3.1.7 The Effect of Zn Supplementation in Diabetic Animals
Begin-Heick et al. (1982) found that levels ofZn in plasma and tissues were
significantly lower in diabetic ob/ob mice when compared to lean controls. Consequently,
Zn supplementation (1000 ppm) restored plasma Zn to normal and even elevated Zn in
some tissues. Moreover, Zn supplementation was found to increase the insulin content and
granulation of the pancreatic islets. Zn supplementation also decreased the abnormally
high insulin secretory response of the ob/ob mouse islets to glucose. The existence ofZn
deficiency in diabetes mellitus may be inferred from these data and the benefit of Zn
supplementation may be seen. Levine et al. (1983) showed that Zn supplementation had a
positive effect on femur Zn levels but had no significant effect on serum, liver and kidney
Zn levels. Zn supplementation seems to have little influence on Zn status in the genetically
diabetic mice. As regard to the femur Zn content, Donaldson et al. (1988) found that
lower femur Zn may not be a specific depletion, but reflected a generalized decrease in
bone mineral content.
Summary: Animal studies indicate hyperzincuria is a prominent feature of diabetes
mellitus. However, even in the presence of greater loss of Zn from urine, there is generally
no specific depletion ofZn in the diabetic animals. Zn absorption in diabetic animals may
be increased because of the hypertrophy of the small intestine and the stimulation of a
number of enzymes involved in absorption. Zn secretion back into the intestine may be
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deceased in order to compensate for the increased loss ofZn from urine. Turnover of Zn
in diabetic animals may be increased due to the hyperzincuria and increased absorption of
the metal. Some mechanisms may exist in the diabetic animals to regulate their altered Zn
metabolism. The above review also indicates a lack of data on the effect of Zn deficiency
and insulin treatment on Zn status during diabetes mellitus. Zn supplementation may be
beneficial as shown in some of the studies.
2.2.3.2 Human Studies
2.2.3.2.1 Evidence of Zn Deficiency in Diabetes Mellitus
Hyperzincuria is a persistent phenomena observed in diabetic subjects (Kiilerich et
al. 1990; Raz and Havivi 1989; Fu 1991). Long term hyperzincuria may deplete their body
Zn stores (Kiilerich et al. 1990). Diabetic patients suffer from persistent ulcers of the
lower extremities and animal experiments suggest that diabetes decreases wound-healing
and the histopathology is similar to Zn deficiency (Engel et al. 1981). This similarity is
further reinforced when it is noted that Zn supplementation completely restores normal
wound healing in diabetics . The decrease in the activity of Zn-dependent thymic hormone
has been observed in diabetics and in vitro addition of Zn to diabetic plasma samples
restore the hormone (Mocchegiani et al. 1989). More recently, Zn absorption by diabetics
has been observed to be depressed, providing evidence of possible Zn deficiency exists in
diabetic subjects (Kiilerich et al. 1990)
2.2.3.2.2 Hyperzincuria in Human Diabetes Mellitus
Daily urinary Zn excretion in both IDDM (Nakamura et al. 199; Fu 1991) and
NIDDM (Meltzer et al. 1962; Kinlaw et al. 1983) subjects was 2 to 5 times higher than
that of their non-diabetic controls . It appears that diabetics selectively excrete more Zn
than other minerals, such as lead, cadmium, molybdenum, tin, nickel, bismuth, and cobalt
(Meltzer et al. 1962). Moreover, the hyperzincuria seems to be a persistent phenomenon
in the diabetic subjects (Tarui 1963). In some studies, females seemed to excrete more
urinary Zn than males (Mateo et al. 1975).
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The cause of excessive urinary Zn loss in diabetics, however, remains obscure.
Studies have indicated the increased urine volume was not the cause of hyperzincuria
(Bain et al. 1988; Heise et al. 1988; Tarui 1963; Fu 1991), so polyuria is not an cause for
the observation. Urinary Zn excretion tended to decrease as control of diabetes improved
(Tarui 1963), treatment of subjects with insulin even for a short duration has been
observed to cause Zn excretion to subside (Viberti et al. 1979). Urinary Zn excretion was
reported to be correlated to urinary protein loss (Heise et al. 1988; Aronoff et al. 1981).
Further, urinary protein excretion correlated significantly with duration of diabetes and
with diabetic complications (Aronoff et al. 1981). The cause of hyperzincuria due to
damage of kidneys may be implied, however, no significant correlation has been found
between hyperzincuria and microalbuminuria (Brun et al. 1988), suggesting that many
other factors are involved.
Some studies found that urinary Zn excretion was related to glycemic controls
(namely glycosylated hemoglobin, fasting plasma glucose and urinary glucose levels) of
the diabetic subjects (Canfield et al. 1984, Fu 1991). Lower concentrations of urinary
glucose were found to be significantly related to lower levels of urinary Zn excretion
(Kiilerich 1985, Pidduck et al. 1970). These observations suggest that the cause of the
hyperzincuria in diabetes mellitus is due to excretion of glucose. However, some other
studies also reported that glycemic control was not correlated to urinary Zn excretion
(Heise 1988), and an inverse correlation was also reported (Sjogren et al. 1986).
Glycosylation of blood proteins in diabetes was implicated as one of the causes for
hyperzincuria in diabetes mellitus (Dolhofer and Wieland 1980). Glycosylation of serum
proteins interfere with their Zn binding capacity, thus more circulating Zn may be chelated
by small amino acids and peptides and secreted subsequently via urine (Canfield et al.
1984). Glycosylation of serum albumin was found to correlate strongly (r=0.88) with the
percentage of HbAl (Dolhofer and Wieland 1980). Furthermore, urinary excretion of
glycosylated amino acids and glycosylated peptides in diabetes was reported to be much
greater (Brownlee et al. 1975). Thus it is possible that Zn may be excreted as albumin-Zn
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or alpha-globulin-Zn, as these proteins could be leaked through hyperfiltration by the
hypertrophied kidney.
Diabetes mellitus results in a number of other humoral changes, which may be
possible causes of hyperzincuria. Blood glucagon is increased in diabetes mellitus
(Pidduck et al. 1970). Glucagon infusion significantly increased Zn excretion without
increasing the ultrafiltration rate (Victery et al. 1981). Hyperzincuria in diabetics may be
related to their reduced absorption of Zn in the renal tubules as has been reported
(Krausova et al. 1990).
2.2.4 Zn Status of Human Diabetic Subjects
Despite the presence of hyperzincuria, Zn status, as assessed by plasma Zn, blood
cell Zn and even muscle Zn in human diabetic subjects are inconsistent among studies.
This may reflect the inaccuracy of the inadequacy of methodologies used to assess Zn
status and cast doubt on the validity of the present approach to assess Zn status during
diabetes mellitus (Raz and Havivi 1989; Abdulla 1983; Hambidge et al. 1988; Lifschitz
and Henkin 1971). It also points out the need for more reliable approach to evaluate the
Zn status of diabetic subjects.
2.2.4.1 Uncertainty of Plasma or Serum Zn Concentrations
Plasma Zn levels of diabetics were reported to be either higher (Mateo et al. 1975;
1978; Nobles et al. 1986) or lower (Car et al. 1991; Rosner and Gorfien 1968; Melinkeri
et al. 1990), or similar to those of their study controls (Pidduck et al. 1970; McNair et al.
1 98 1 ; Nakamura et al. 1991). Low serum Zn was also found in some patients with
NIDDM (Niewoehner et al. 1986; Melinkeri et al. 1990). The differences in plasma or
serum Zn levels in diabetic subjects among studies can not be easily explained.
Glycemic control seemed not to be correlated to plasma Zn levels in some of the
studies (Canfield et al. 1984; Hayes et al. 1987; Mocchegiani et' al. 1989; Niewoehner et
al. 1986). However, duration of diabetes and diabetic complications seemed to associated
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with lower plasma Zn (Nobels et al. 1986; Walter et al. 1991), suggesting that duration
and severity of diabetes are possible risk factors in developing Zn deficiency.
Higher plasma Zn levels accompanying higher blood-glucose concentrations have
been reported (Canfield et al. 1984; Heise et al. 1988). Higher plasma-Zn levels which
occurred in the diabetic subjects may reflect a catabolic state rather than a better Zn status
(Fell et al. 1973; Heise et al. 1988). Canfield et al. (1982) reported that higher plasma Zn
levels in diabetic children and young adults were inversely correlated with age and
duration of diabetes. High plasma-Zn accompanied with high insulin level in the NIDDM
patients has been reported to reflect either a deficiency of insulin or a chronic
hypersecretion of insulin in diabetic patients (Mateo et al. 1978).
Results of plasma Zn levels in diabetic subjects varied widely from different studies
(Chooi et al. 1976; Chooi et al. 1976; Kumar et al. 1974). Methodology employed among
studies may be one source of the confusion. Different determination methods could
account for 25% of the differences in plasma Zn levels (Wilkins et al. 1972). It is known
that serum Zn undergoes a circadian variation (Lifschitz and Henkin, 1971; Hetland and
Brubakk, 1973), which may also contribute to the above differences. These may make the
results among different studies incomparable. However, within the same studies the same
method was used to determine the Zn level in plasma or serum, thus it is also unlikely
methodology could play any significant role within each individual study.
Age and sex may be other factors contributing to differences reported in
concentrations of plasma Zn in diabetics. There has been reported that age was
significantly and negatively correlated with plasma Zn level (Lindeman et al. 1971).
Females may have a lower plasma Zn level than males (Melchior et al. 1989; Sjogren et al.
1986; Kiilerich 1985; Nobles et al. 1986). The subjects recruited in each study may
contribute to the difference on the reported values due to age and sex differences,
however, it can not be confirmed.
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2.2.4.2 No Evidence of Lower Erythrocyte Zn Concentration in Human Diabetics
A recent study has observed that erythrocyte Zn level ofIDDM was shown to be
somewhat lower, but not significantly due to the small sample size (Fu 1991). However,
other studies did not find any difference between IDDM and their controls (Sjogren et al.
1985; Raz and Havivi 1989; Rosner and Gorfien 1968). The significance of using
erythrocyte Zn as an indicator ofZn status in diabetes may deserve further study.
2.2.4.3 Uncertainty of Leukocyte Zn Concentration in Human Diabetics
Leukocyte Zn has been shown to be sensitive to changes in Zn status (Prasad
1991; Prasad 1988; Rabbani et al. 1987), and provided a basis for using leukocyte Zn level
as an indicator of Zn status. A significantly decreased leukocyte Zn level was observed in
some studies (Kumar and Jaya Rao, 1974; Pidduck et al. 1971; Raz and Havivi 1989; Pai
et al. 1988), and Pai et al. (1988) found that diabetic subjects had significantly lower Zn
levels in plasma, lymphocytes, granulocytes and platelets. However, a recent study shows
that no significant difference in leukocyte Zn levels either at baseline or after a month of
Zn supplementation between diabetics and the controls (Fu 1991). Raz and Havivi (1989)
also observed that NIDDM did not have decreased leukocyte Zn level when compared
with their non-diabetic control subjects.
2.2.4.4 No Change in Muscle Zn Concentration in Human Diabetics
A single determination of muscle Zn level showed no significant difference
between diabetics and their non-diabetic controls (Sjogren et al. 1985). These values were
243 ng/mg fat free dry substance (FFDS) in the IDDMs and 258 ng in their controls (P>
0.05). It has been reported that depletion of up to 30% ofbody Zn content in rats did not
alter the muscle Zn content, even if Zn levels in other tissues such as liver, bone and testes
were significantly decreased (Jackson et al. 1982). These studies may suggest muscle Zn is
not sensitive to Zn depletion.
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2.2.4.5 The Effect of Zn Supplementation in Human Diabetics
Normal subjects with Zn deficiency respond positively to Zn supplementation
(Wilkins and Dreosti 1972; Weismann and Hayer 1985). In a recent study 50 mg Zn daily
in the form of Zn gluconate was given as a supplement to IDDM and no significant
different responses were found between diabetics and their non-diabetic controls (Fu
1991). Niewoehner et al. (1986) supplemented 220 mg Zn sulfate to 9 NIDDMs with low
serum Zn levels and significantly increased their serum Zn from 63 ug/ 100 ml to 110
ug/100 ml, suggesting that extremely large doses of Zn are effective in increasing serum
Zn in Zn deficient diabetic subjects. Recent studies indicate a beneficial effect of Zn
supplementation in diabetics with thyroid failure (Arreola et al. 1990) and gonadal
disfunction (Arreola et al. 1991). These studies may suggest Zn deficiency may be present
in a subset of diabetic subjects.
2.2.4.6 Uncertainty in Zn Absorption in Human Diabetics
Individuals with diabetes were thought to have an increased rate ofZn absorption
rates to compensate for Zn loss since no obvious signs ofZn deficiency were observed
(Heise et al. 1988). However, data from Zn absorption in NIDDM patients revealed a
decreased response to an oral Zn tolerance test (Kinlaw et al. 1983), as indicated by a
delayed increase in plasma Zn levels within 4 hours of the test. By using the whole-body-
count radioisotope Zn technique, Kiilerich et al. (1990) revealed absorption of 65Zn tended
to be lower in IDDM, but not significantly so. They hypothesized that intracellular Zn
depletion with time in insulin-dependent diabetics may occur. However, the decreased
retention of 65Zn may be a result of higher urinary Zn output and a faster turnover of body
Zn.
2.2.4.7 Higher Zn Intakes by Human Diabetics
Zn intake by individuals with diabetes did not differ from their controls. (Hayes
and Kohrs 1987; and Heise et al. 1988; Fu, 1991). The reported values (mg/d) were 12.2
versus 1 1.2; 8.5 versus 8.5 and 9.66 vs 6.69 mg/day in the diabetic subjects and in non-
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diabetic controls respectively in the above three studies. Zn intake was significantly higher
for IDDMs in one of the studies (Fu 1991). The recommended dietary Zn intake is 15
mg/day for males and 12 mg/day for females (National Research Council 1989). The daily
Zn intakes of adults in the United States, as estimated from duplicated food composites of
self-selected diets, were in the range of 6-12 mg/day (Holden et al. 1979; Kinard et al.
1989; Kant et al. 1989). It seems that the Zn intakes of diabetic subjects are adequate
when compared with these figures.
Summary: Urinary Zn increased one to three fold in diabetic subjects as compared
with their non-diabetic controls. A single determination of plasma or serum Zn, even cell
Zn and muscle Zn level has not been able to show the existence of Zn deficiency in
diabetic subjects. Other parameters such as response to Zn supplementation, plasma
protein Zn saturation, distribution of Zn in plasma proteins reveals existence of a possible
Zn deficiency. Dietary intake of Zn between diabetic subjects and their controls is not
different. However, 65Zn retention and Zn absorption may be impaired in diabetic subjects.
Whether or not there is a depletion of Zn store in the diabetics could not be confirmed. It
is apparent that a kinetic approach may be needed to determination the alteration ofZn
metabolism in diabetes mellitus.
2.2.5 The Value ofA Simple Determination of Zn Levels in Plasma and Blood
Components in Assessing Zn Status in Diabetes Mellitus
The fact that Zn balance can be maintained by minimal intake of 1.7 mg/day (King
1 990) suggests that the homeostasis ofZn in the human body is strictly controlled,
presumably by absorption and excretion. Unlike other nutrients, when the intake is
insufficient, stores or functional reserves are mobilized. A functional store or reserves for
Zn has been unidentified (Golden 1989). The response of the human body to Zn deficiency
is to adjust the growth rate and tissue catabolism (King 1990). Thus, Zn levels in plasma
and other functional parameters are rarely affected. There is no single parameter believed
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to reflect Zn status, despite attempts that have been made (Thompson 1991; Aggett
1991).
2.2.5.1 Plasma Zn
Plasma Zn is the most frequent used parameter in assessing Zn status. However,
caution should be taken when one explains the changes in plasma Zn levels. Plasma Zn is
easily influenced by dietary, physiological, and pharmacological factors (Abdulla 1983; Fu
1991), age and sex (Lindeman et al. 1971), diurnal variation (Hetland and Brubakk 1973;
Henkin and Lifschitz 1971) and length of time between blood drawn and separation
(English and Hambidge 1988). Plasma Zn concentrations may fall when plasma volume
expands inappropriately (Tuttle et al. 1983) and stress (Disilvestro and Cousins 1984).
However, it is believed in both simple human and animal experimental Zn deficiency,
plasma Zn concentrations did fall (Thompson 1991), suggesting plasma Zn level may be
reflective in Zn deficiency.
2.2.5.2 Plasma Total, Albumin- and Macroglobulin-Bound Zn
Attempts to improve the accuracy of plasma Zn assays leads to determination of
Zn distribution between plasma albumin-bound Zn and macroglobulin-bound Zn with the
mathematical addition of the two equal to total Zn (Giroux 1975). Elevated plasma total
Zn does not seem to produce a concurrent increase in plasma albumin-bound Zn, and the
distribution of albumin-bound Zn and macroglobulin-bound Zn within plasma remained
similar before and after Zn supplementation (Fu 1991). Similar results was reported by
Heise et al. (1988), in which, both albumin-bound Zn and macroglobulin-bound Zn were
higher in the IDDMs. There is a big range of normal macroglobulin-bound Zn level, from
2% to 40% (Parisi and Vallee 1970; Kiilerich and Christiansen 1984; Giroux 1975; Giroux
et al. 1976). A report that decreased plasma macroglobulin Zn occurred in a group of
patients with chronic renal failure, thus an increased plasma albumin-bound Zn may be
implied (Kiilerich and Christiansen 1986). It was reported that albumin Zn was
significantly correlated with total plasma or serum Zn (Kiilerich and Christiansen 1984),
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however, alpha-macroglobulin Zn did not correlate with alpha-macroglobulin
concentrations, suggesting that not all alpha-macroglobulin in human serum are Zn
metalloproteins (Kiilerich and Christiansen 1984). It has also been reported that serum
albumin could have more than 1 6 available binding sites, with only a limited number of
sites occupied by Zn in most of the situations (Hambidge 1988). Therefore, decreases or
increases in this fraction may not be necessarily related to Zn status. It, therefore, does not
seem to be a better indicator ofZn status over simple plasma Zn.
2.2.5.3 Plasma Protein Zn Binding Capacity
It was demonstrated that plasma protein Zn binding capacity decreased with an
increase in Zn intake and the pattern of change in plasma protein Zn binding capacity in
IDDMs was different from that of the controls (Fu, 1991). This suggests that the
parameter may have some value in assessing Zn status in the diabetes. Zn binding capacity
of plasma has been shown to be sensitive in experiments with rats before and after
injection of Zn (Roth and Kirchgessner 1980) and in pregnant women (Argemi et al.
1988). This parameter, thus, may need exploring.
2.2.5.4 Erythrocyte Zn level
Erythrocytes have a longer turnover time compared to serum proteins (About 30-
40 days, Thompson 1991), so their Zn level does not appear to change. Erythrocyte Zn
level is not influenced by age and sex factors (Lindeman et al. 1971), or current dietary Zn
intake (Fu 1991). Erythrocyte Zn has been shown not to be related to any other Zn
parameters (Fu 1991). A possible explanation for this may be that erythrocyte Zn is not
related to the present Zn status, namely Zn intake, plasma Zn, or even leukocytes Zn level.
It has been shown that depletion ofZn for up to 9 weeks did not change the value of
erythrocyte Zn in the humans (Baer and King 1984). However, erythrocyte Zn is reduced
in diabetes mellitus (Fu, 1991).
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2.2.5.5 Leukocyte Zn level
Leukocyte Zn concentration has been suggested to be a sensitive measure in
assessing Zn status (Prasad 1988; Jones et al. 1981). However, several sub-sets of white
blood cells each have different half life and content ofZn (Aggett 1991). The result of
mononuclear cell Zn determination is, therefore, dependent on the purity of the sample
separated. This has been remained a problem. There have been reports that the Zn content
of blood cellular components are not sensitive indicators ofZn deficiency in rats (Milne et
al. 1985). In our data, leukocyte Zn has also been demonstrated to be increased rapidly
after Zn supplementation, but no difference was detected between the diabetics and the
control (Fu 1991).
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CHAPTER 3
A SINGLE POINT FOUR-HOUR STUDY ON 65ZN ABSORPTION
AND RETENTION WITH TISSUE ZN AND COPPER ANALYSIS
3.1 Introduction
Hyperzincuria, an increased urinary Zn excretion in diabetes mellitus, could deplete
body Zn stores in diabetic subjects (Kiilerich et. al., 1990). However, human subjects with
diabetes mellitus did not benefit from Zn supplementation (Fu 1991). The altered Zn status
of diabetic humans and animals has not been confirmed from the available studies (Engle
et. al. 1981; Kumar and Jaya Rao 1974, Mocchegiani et al. 1989; Pidduck et al. 1971; Raz
and Havivi 1989). Should diabetics maintain a normal Zn status despite their
hyperzincuria, compensation mechanisms or alteration of metabolism must be present in
diabetics.
A kinetic study has identified several sites of regulation of Zn metabolism:
absorption, excretion, muscle turnover, bone storage, endogenous secretion, and
erythrocyte exchange (Wastney et al. 1986). Increased Zn absorption in diabetes mellitus
may be one of the compensation mechanisms Craft and Failla (1983) reported that the Zn
absorption of the diabetic animals had an overall increase in Zn absorption due to an
increase in mucosal mass, which may compensate for the increased urinary Zn losses.
Olson and Rogers (1971) reported that intestinal brush border hydrolases and transport
systems was increased in experimental diabetic rats. There was also a considerable
increase in the total membrane volume in the diabetic intestine to augment absorption of
Zn (Caspary et al. 1972; Gourley et al. 1983, Younoszai and Schedl 1972). These data
suggest that diabetic animals may maintain Zn balance through hypertrophy of their
mucosal tissue to enhance their Zn absorption. Other possible compensation mechanisms
for Zn loss via urine in diabetics are through decreasing mucosal to lumen flux ofZn
(Ghishan and Greene 1983), and depressing intestinal excretion of endogenous Zn
(Johnson and Canfield 1985).
However, the study on human diabetics indicated an decreased Zn absorption in
diabetes (Kiilerich et. al. 1990). Song and Mooradian (1988) also reported that net Zn
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absorption of the jejunal segments was decreased in rats with streptozotocin-induced
diabetes. The difference among the above mentioned studies is most probably due to the
study designs. It is reported that fasting may alter Zn absorption in diabetic animals
(Quarterman and Morrison 1981). Sian et al. (1993) also indicated that absorption of Zn
in normal human subjects was associated with whether or not a meal was administered at
the time of absorption studied. It is therefore of interest to test whether fasting or feeding
pattern in diabetic animals may alter Zn absorption.
The present study is thus designed to test 1). whether Zn absorption and retention
are altered in diabetes; 2). whether altered Zn absorption and retention are related to
dietary feeding patterns; 3). the associations between Zn absorption and retention with
other easily measured variables, such as Zn concentrations in plasma, urine or tissues.
3.2 Materials and Methods
3.2.1 Study Animals and the Induction of Diabetes Mellitus
Male Wistar rats weighing 40-60 gm (Charles River Laboratories, Wilmington,
MA) were housed individually in suspended stainless steel cages and maintained at a room
temperature of 20-23° C. All rats were fed a semi-purified diet containing 30 mg Zn/kg
diet (Table 3.1). They had free access to food and distilled water throughout the study.
Food intake and body weight gains of animals were measured twice weekly . The
experimental protocol was approved by the University of Massachusetts at Amherst
Animal Use and Care Administrative Advisory Committee, and animals were cared for in
accordance with the National Research Council's Guide for the Care and Use of
Laboratory Animals. After two weeks of adaptation, animals were randomly assigned to
the test and control groups. Diabetes in the test group was induced by a single injection of
Streptozotocin in cold sterilized saline solution at a dose of 100 mg/kg body weight.
Blood glucose levels were measured with a commercial monitoring device (One Touch,
complete blood glucose monitoring kit, Lifescan Inc., Johnson and Johnson Company.
Milpitas, CA 95035). The increases in blood glucose levels and appearance of polyuria
were used as indicators of diabetes.
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Table 3.1 Composition of Animal Diet
Ingredient %
Casein- High Nitrogen (85% Protein)
DL-Methionine
Cornstarch
Sucrose
Celufil-Non-Nutritive Bulk
Corn Oil
AIN-76 Mineral Mixture
AIN- 76 A Vitamin Mixture
Choline Bitartrate
Zn
Cu
20.00
0.30
15.00
50.00
5.00
5.00
3.50
1.00
0.20
30.0 mg/kg
6 .0 mg/kg
Detailed composition of vitamin and salt mixtures see: 10664 AIN mineral mixture 76-
American Institute of Nutrition. American Institute of Nutrition, Ltr. Communication,
March 15, 1977; J. Nutr. 1977, 107.
3.2.2 Single Point Four Hour Study on 65Zn Absorption and Retention Rates
On the day of the absorption study, food was removed overnight (12 hours) for
about 10 rats from both the STZ-diabetic and control groups, they were fed after
65Zn
loading. This group was designated as the "prior-fasting" treatment. For the "post-fasting"
treatment, food was removed after administration of 65Zn and such held until the rats were
sacrificed four hours later. Rats in both diabetic and control groups were randomly chosen
and given about 50 ul 65Zn (containing 1 uCi radioactivity) by mouth using a 50 ul pipette.
Another 50 ul water was given to clear the mouth and ensure all the radioisotope entered
the stomach. Radioactivity was counted immediately after
65Zn dosing using a small plastic
box (4" x 2" x 2") directly under the detector, which kept the animal under counting in a
relative geometric shape. Each animal was counted for 5 minutes and the counts were
recorded for total area under the peak. Rats were then put back into the metabolic cage
for 4 hours, allowed free to access drinking water with and without food depending on the
group they were in. Urine was collected for four hours for later measurement
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radioactivity. No attempt was made to collect feces during this study because of the
irregular nature of rodent defecation pattern within a short period of time.
Four hours later after the ingestion of radioisotope 65Zn, rats were killed under
anesthesia (by injection of 0.5 ml 0 3% Sodium pentobarbital). The peritoneal cavity was
opened, blood was drawn by cardiac puncture into 7-ml heparinized vacuum tubes. The
entire gastrointestinal tract (GI) was taken out and cleared off all contents. The cleared GI
tract and blood in the vaccutainers were then put back into the peritoneal cavity, the whole
animal was then counted twice, once without the GI tract (absorption) and once with
(retention). Urine samples were also counted by the same technique as whole body
counting, the results were used for calculation of 65Zn absorption.
Whole body radioactivity was counted by a Na-I crystal 2 detector equipped
with a Cabarran multiple channel analyzer (Series 35). During whole body counting, the
following parameters were used: Output voltage 850 V, Vertical range 1048 K, memory
1/4, ADC gain 2048, Scan 31-47 A, count time 300 second.
The following formulas were used to calculate 65Zn absorption and
65Zn retention:
65Zn absorption (%) = 100 X (Carcass Count + urine count)AVhole Body count
65Zn retention (%) = 100 X (Carcass Count + GI Tract Count)/Whole Body Count
Whole Body Count = Count at 0 time after 65Zn loading
3.2.3 Tissue and Organ 65Zn Radioactivity Counting
Liver, kidney, testis, spleen, heart, femur, muscle (those muscles around the
femurs) were taken after whole body radioisotope counting. Blood samples were
separated by centrifugation at 1380 g for 15 minutes into red blood cell clot and plasma.
Radioactivity of heart, kidney, blood, spleen, liver, and testes was counted by a
scintillation counter (Gamma 4000 Counting System, Gamma Counting Spectrometer,
Beckman Instrument Inc.) for 10 minutes The same amount (50 pi) of
65Zn solution was
used as standard. All tissue samples were then kept frozen after
65Zn counting for Zn, Cu
and Fe analysis. Decay of Radioactivity of all samples was adjusted by the counts of their
standards.
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3.2.4 Organ and Tissue Zn Determination
Femurs was cleared by removing all visible tissues and ligaments; kidney, heart,
testis, and spleen were collected after washing in saline and blotting with Kimwipe paper.
AJ1 organs and tissues underwent wet-digestion in whole except liver, a portion of which
was used for digestion. Samples were put into an 1 50 ml beaker, and to each was added
10 ml concentrated nitric acid followed by heating on a hot plate at 350° C. After the first
phase of digestion, about 2 ml 70% of perchloric acid was added and heating continued. A
clear layer of residue remained at the bottom of the beaker after acid was totally
evaporated. Ten milliliter 5% diluted nitric acid was used to dissolve the contents which
were then transferred into a 15 ml conic plastic tube (Sigma, Co.). for Zn and Cu analysis
by Atomic Absorption Spectrophotometer (AAS, Model 2380, Perkin-Elmer) methods.
Plasma Zn and Cu concentrations were analyzed after direct dilution with double distilled
water and analyzed by AAS method under same conditions.
3.2.5 Statistical Analysis of Data
Statistical analysis of data was done with a computer software SAS (SAS Institute
Inc. Cary, NC). A student T-Test was used to test for difference for between groups. A
correlation procedure was used to analyze the relationship of variables.
3.3 Results
3.3.1 Body Weight and Food Intake
The initial body weight and food intake were similar for the 14 diabetic and 12
control rats before STZ-diabetes was induced (Figure 3.1). The body weight growth of
the STZ-diabetic rats (n=14) decreased after injection of STZ, while their food intake
increased significantly (Figure 3.2). A 28% weight loss was noted when compared with
the control rats (12) on day 30. STZ-diabetic rats had a 16% increased in food intake on
day 3 1 , which was significantly higher than that of their controls (P<0.000 1 ).
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3.3.2 Blood Glucose
About half of rats died within the first 5 days of injection of STZ. Diabetic rats
who were alive had some signs of inactivity and sleepiness, otherwise remained relatively
normal. STZ-diabetic rats manifested polyuria, polydipsia, and polyphagia. Blood glucose
levels were determined on day 2 and 6 after injection of STZ. Blood glucose levels of
diabetic rats were significantly higher (300-3 10 mg/100 ml) when compared to the
controls (71-76 mg/100 ml) (Figure 3.3).
3.3.3 Single Point 4-Honrs 65Zn Absorption and Retention Rates
Absorption and retention of 65Zn were measured 4 hours after the injection of 65Zn.
The results are presented in Figure 3.4 and 3.5. There was no significant difference
between STZ-diabetic rats and their controls in either 65Zn absorption or 65Zn retention
(figure 3 .4). The two different dietary treatments, namely prior fasting and post fasting,
produced different effects on 65Zn absorption and retention in STZ-diabetic rats as well as
in the control rats as seen Figure 3.5. STZ-diabetic animals that were on post-fasting
showed a significantly higher absorption and retention than those who were on prior
fasting (P<0.05). Control animals showed a significant difference in 65Zn retention, but
not
65Zn absorption. This indicates that the dietary pattern at the time of the study
significantly influenced the 65Zn absorption and retention, and diabetic animals responded
differently from their control counterparts to food availability. The fact that Zn absorption
was unaffected in the control group suggests that the absorption may indeed be the site
where diabetes exerts its influence on the time of feeding phenomena.
The overall values of 65Zn absorption and 65Zn retention were not different
significantly between STZ-diabetic animals and control animals (P=0.50). However, If
divided according to their feeding patterns,
65Zn absorption and retention were lower in
STZ-diabetic animals than their controls when they were "prior-fasted". Again the
differences were not significant. If they were "post-fasted", the STZ-diabetic animals had a
higher 65Zn absorption and retention rate compared with their controls, but the difference
was not significant.
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3.3.4 Plasma 65Zn Activity
Table 3.2 presents data of plasma 65Zn (Counts/10 minutes/ml). STZ-diabetic rats
had a higher plasma 65Zn count either with or without an overnight fasting treatment than
their controls. However, the difference was not significant (P>0.05).
3.3.5 Urine 65Zn Activity
Urine 65Zn counting results are present in Table 3.3. STZ-diabetic rats had
significantly (P<0.01 ) increased their urine 65Zn excretion when animals were "prior-
fasted" Notice also the substantially increased urine 65Zn counts when STZ-diabetic rats
were "prior-fasted" when compared with "post-fasted".
Table 3.2 Plasma 65Zn Counts of STZ-Diabetic and Control Rats
(Count/ml/minutes)
STZ-Diabetics Control
Post Fasting 11.2±3.7 (6) 9.6±2.5 (6)
Prior Fasting 4.3+1.4(5) 2.8+2.1 (5)
Average 8.1+2.3 (11) 6.2+1.9(11)
Table 3.3 Urine 65Zn Counts of STZ-Diabetic and Control Rats
(Total Count/minutes)
STZ-Diabetics Control
Post Fasting 390±86 (6) 277+19 (6)
Prior Fasting 3176+397 (6)** 208±23 (6)**
Average 1982±443 (12)* 240+17 (12)*
Significance at P<0.01 level between STZ-diabetic rats and their controls
Significance at P<0.0001 level between STZ-diabetic rats and their controls
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3.3.6 Plasma Zn Levels of STZ-Diabetic Rats and Their Controls
Data for Zn in plasma are presented in Table 3.4. It is of interest to note that the
overall values for plasma Zn concentration is not different significantly. However, if the
animals were divided according to prior fasting and post fasting treatment, significant
differences were noted in these two groups of animals. Both STZ-diabetic and control rats
had significantly lower plasma Zn concentrations if they were on a prior fasting (P<0.01).
On post fast, STZ-diabetic rats had a significantly lower plasma Zn concentration
compared with their control rats (P<0.05).
Table 3.4 Plasma Zn (mg/L) of STZ-Diabetic and Control Rats
STZ-Diabetics Control
Post-Fasting 1.05+0.06 (6)##* 1.38+0.05 (6)##*
Prior-Fasting 0.77±0.05(5)## 0.68±0.03 (7)##
Overall Means 0.92±0.06(11) 1.00±0.10 (13)
* Statistical significance at P<0.05 level between STZ-diabetic and controls.
## Statistical Significance at P<0.01 between two modes of dietary pattern.
3.3.7 Four-Hour Urine Zn Excretion
STZ-diabetic animals had significantly higher urinary Zn excretion which is the
same as noted for human diabetes and consistent with all previous studies. However, in
this study, urine Zn concentrations of STZ-diabetic rats was lower than their controls. The
increased urinary Zn excretion in STZ-diabetic animals in this study was obviously due to
their higher urinary volume (Table 3.5). This suggests that Zn loss may be due to diuresis
in diabetes.
45
Table 3.5 Four Hour Urine Zn Excretion of STZ-Diabetic Rats in
Comparison with Their Controls
STZ diabetes Controls
(n=14) (n=14)
Urine Zn Concentration (mg/L) 0.78±0. 15** 1.92±0.16**
Total Urinary Zn (mg/4 hours) 0 019+0 003** 0.009± 0.001**
Significant level of P<0.01.
3.3.8 Organ and Tissue 65Zn Counts
Radioactive 65Zn counts of liver, heart, kidney, spleen and testes are presented in
Table 3 .6. Generally speaking, liver had the highest number of counts among these organs
or tissues selected. Next greatest number of counts was found in the kidney. Testes had
the lowest counting rate among these organs. There were no significant differences either
between STZ-diabetic group and control group, or between the two modes of dietary
pattern, possibly due to the short time span in this study.
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Table 3.6 Some Organ or Tissue 65Zn Activity (Count/Min/Gram)
STZ-Diabetics Control STZ-D+Control
Post Fasting
Liver 1 587±263 (6) 1018±186 (5) 1329+182 (1 1)
Heart 24+11 (6) 26±5 (5) 25+6(11)
Kidney 286±68 (6) 172±63 (5) 235±48 (11)
Spleen 83±18(5) 66±18 (4) 75+13 (9)
Testes 23±6 (6) 11±5 (5) 17±4(11)
Prior Fasting
Liver 1151+187 (8) 905±208 (7) 1036±138 (15)
Heart 25±6 (8) 20±7 (7) 23+4(15)
Kidney 246+43 (8) 195±41 (7) 222±30(15)
Spleen 62±14(8) 40±11 (7) 52±9 (15)
Testes 21+9 (8) 17+7(7) 19±6 (15)
Average of STZ-Diabetic and Control rats
Liver 1338±160 (14) 952±139 (12)
Heart 25±5 (14) 22+4(12)
Kidney 263±30(14) 185±48 (12)
Spleen 70±11 (13) 50±10(11)
Testes 22±5 (14) 15±4 (12)
3.3.9 Zn Concentrations in Selected Organs and Tissues
STZ-diabetic rats had significantly higher femur Zn concentrations than that found
for their controls (P<0.0001). However, the total Zn content of femur was significantly
lower in the STZ-Diabetic rats than in the control rats due to the decreased weight of the
diabetic femurs. There was no significant difference in Zn concentrations in any other
organ or tissue between the STZ-diabetic and control groups (Table 3.7).
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Table 3.7 Zn Concentration of Selected Organs in STZ-Diabetic Rats and
Their Controls (fag/g wet tissue, Mean+SEM)
Organs or Tissues STZ Diabetes Controls
Femur 62.220±1.748 (13)*** 49.106±1.260 (14)***
Femur (total, ug) 24.408±0.363 (13)* 25.493+0.342(14)*
Muscle 9.492±1.604(12) 9.387±1.509 (12)
Heart 23.180±4.90(14) 20.891±2.278 (13)
Kidney 14.764±1.395 (14) 15.661±1.576 (14)
Liver 17.017±1.468 (14) 17.976±1.542 (13)
Spleen 32.565±8.273 (12) 18.981±2.597 (12)
Testis 18.095±1.478 (14) 16.006±1.028(14)
Numbers in () represent numbers of animal used.
*** Difference is significant at level of PO.0001
Difference is significant at level of PO.05.
3.3.10 Organ and Tissue 65Zn Specific Activity
When specific activities of 65Zn in some tissue and organs were calculated (Table
3.8 ). It was noted that STZ-diabetic rats had high specific activities of
65Zn in all tissues
examined. The difference between STZ-diabetic rats and their controls in kidney and urine
65Zn specific activity were highly significant (P<0.05).
Table 3.8 Specific Activity of 65Zn of Some Organs or Tissues (Counts/min/ug Zn)
Organs STZ-Diabetics Controls
No. Mean±SEM No. Mean±SEM
Heart 14 1.4+0.4 12 0.99±0.26
Kidney 14 16.3±2.70* 13 9.4±1.7*
Liver 14 69.4±9.45 12 44.2±8.6
Spleen 12 3.6+1.3 11 2.7±0.6
Testis 14 1.2+0.3 13 0.9±0.3
Plasma 10 8.8±4.6 13 6.2±2.9
Urine 14 104.3±23.3*** 13 26.7±1.7***
* Statistical significance at PO.05 level between the two groups.
*** Statistical significance at PO.0001 level between the two groups.
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3.3.11 Correlations of 65Zn Absorption and 65Zn Retention with Various
Variables
Correlations of 65Zn absorption and 65Zn retention with various variables were
calculated in order to find out which variable or variables may be associated with changes
in
65Zn absorption and 65Zn retention in STZ-diabetic and control rats. Such variables
include plasma, urine and organ Zn concentration, 65Zn count and 65Zn specificity of
various organs and tissues. These correlations are summarized in Table 3.9.
Body weight did not correlate with either 65Zn absorption and 65Zn retention. Food
intake may influence both 65Zn absorption and r,5Zn retention in STZ-diabetic rats, since
their correlation coefficients were very significant. We have seen frequently that mode of
feeding influences 65Zn absorption and retention, but these correlations were not
significant in control rats. Blood glucose was significantly higher in STZ-diabetic rats that
in control rats as shown in Table 3.2
,
however, both STZ-diabetic rats and controls rats
did not show a significant correlation between their blood glucose levels and either with
65Zn absorption, or 65Zn retention.
Plasma 65Zn was correlated significantly with 65Zn absorption, but not 65Zn
retention in STZ-diabetic rats. While in control rats, plasma
65Zn was significantly
correlated with 65Zn retention, but not with 65Zn absorption. It seems plasma
65Zn had a
different relationship with 65Zn absorption and
65Zn retention. This relation was also
different in STZ-diabetic rats than in control rats.
Plasma Zn level was significantly correlated with
65Zn absorption and 65Zn
retention in control rats only. These relationships were absent in STZ-diabetic rats.
Both urine total 65Zn count and urine
65Zn count/3 ml urine were correlated
significantly with both 65Zn absorption and
65Zn retention in STZ-diabetic rats. However,
no such correlations existed in the control rats. Similarly, urine Zn excretion, either in
terms of total excretion or concentration was also correlated with
65Zn absorption and 65Zn
retention in only STZ-diabetic rats but not in control rats.
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Table 3.9 Correlation of 65Zn Absorption and 65Zn Retention with Various
Variables
Variables 65Zn Absorption 65Zn Retention
STZ-D Control Pooled STZ-D Controls Pooled
Body Weight
Food Intake ++ — ++
Blood Glucose
Plasma 65Zn + — ++ + —
Plasma Zn — + ++ +++ ++
Urine 65Zn
Total ++ — ++ ++ ++
Count/3 ml ++ — ++ ++ ++
Urine Zn
Total — — — + +
ug/ml ++ — — ++ —
Liver 65Zn ++ ++ ++ ++ ++ ++
Kidney 65Zn + + ++ — ~
Heart 65Zn — — + — —
Spleen 65Zn — — ++ — +
Testis
65Zn — — — — —
Liver Zn — — + — +
Kidney Zn ++ — ++ ++ ++
Spleen Zn ++ — + ++ +
Heart Zn + -- ++ + ++
Muscle Zn — — —
Femur Zn + —
~
Testis —
—
—
Zn Specificity
Liver
—
Kidney
Spleen ++ ++
Heart
Testis
Plasma
+
Urine ++ ++ +
-H-
No significant correlation
+ ++ +++ Significant Correlations at P<0.05, P<0.01 and PO.001 level.
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Among organ 65Zn activities, liver was the only organ that its 65Zn count was
correlated significantly with both 65Zn absorption and 65Zn retention in both STZ-diabetic
rats and control rats. Kidney 65Zn count was only correlated with 65Zn absorption, but not
with 65Zn retention in both STZ-diabetic rats and control rats. 65Zn count of heart, spleen
and testis in both STZ-diabetic and control rats were not correlated with either 65Zn
absorption and 65Zn retention.
Zn concentrations of kidney, spleen, and heart correlated significantly with both
65Zn absorption and 65Zn retention in STZ-diabetic rats, but not in control rats.
Muscle and femur cold Zn concentration did not correlate with either 65Zn
absorption and 65Zn retention in both STZ-diabetic and control rats.
Except for spleen, 65Zn specificity of various organs, did not correlate with either
65Zn absorption and 65Zn retention in both STZ-diabetic and control rats Spleen 65Zn
specificity was significantly correlated with both 65Zn absorption and 6,Zn retention in
control rats These correlations were not present in STZ-diabetic rats. Urine 55Zn
specificity was correlated significantly with both 65Zn absorption and 65Zn retention in
STZ-diabetic rats, but these relations were absent in control rats.
3.4 Discussion
3.4. 1 The Establishment of the STZ-Diabetic Animal Models
The diabetic animal model was established by peritoneal injection of streptozotocin
(STZ) at a single dose of 100 mg/kg. After introduction of STZ, these animals manifested
polyphagia, polydipsia, and polyuria, all of which are typical of diabetes. Their urinary
volume increased dramatically within 48 hours.
The STZ-diabetic animals had a significantly increased food intake and at the same
time lost body weight (See Figure 3.1 and 3.2).
About one third of animals died after injection of STZ within five days, but the
others diabetic rats alive remained in diabetic condition without insulin treatment. The
STZ-diabetic animals had a significantly increased blood glucose level as assessed at 2 and
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6 days after STZ introduction. It may be concluded that the STZ-diabetic model was well
established.
3.4.2 No Significant Difference in the Rates of 65Zn Absorption and Retention
between STZ-Diabetic Rats and Controls
One of the objectives of this study was to find out whether STZ-diabetic rats had a
different
65Zn absorption and retention rate. The present study observed that the normal
rats had an apparent 65Zn absorption rate of 1 1-15% and 65Zn retention rate of 23-3 1% of
lavage dose within the four hours after 65Zn dosing. These number are within the range of
other studies. Cotzias et al. (1962) found that normal mouse on a normal Zn intake had a
retention rate of 22% within 4.5 hours of 65Zn loading. However, the Zn-loaded animals
absorbed only 7% of the injected dose in that study. Coppen and Davies (1987) found that
the true percentage absorption of 65Zn was within the range of 68%-86%, which is
substantially higher than the result of the present study.
Human subjects generally had an absorption rate of 30% (Cousins, 1985).
Sandstrom (1989) reported that humans absorbed 20-25% ofZn from meals providing 3-5
mg of Zn and that the absorption rate increased up to 30-40% as the meal providing lesser
amount of Zn. And even higher absorption rate (52%) and retention rate (49%) have also
been reported (Payton et al 1982). These results may reflect the differences in the study
design and the instruments used, and the results may subsequently not be comparable
directly from each other.
Craft and Failla (1983) observed an increased 65Zn absorption in STZ-diabetic rats
(34% vs 32% in controls, P>0.05), also they found that STZ-diabetic rats had a threefold
apparent Zn absorption per 100 g body weight than their controls using dietary balance
technique.
The results of Johnson and Canfteld (1985) indicated that STZ-diabetic rats
absorbed more Zn compared with that of control rats when consumed equivalent amount
of Zn; they also found that STZ-diabetic rats excreted generally a lower percentage of
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absorbed Zn via their feces. These results lead to the conclusion that the ability to absorb
Zn to meet the body requirement is preserved in STZ-diabetic rats.
The present study observed that the percentages of 65Zn absorption and retention
were not significantly different between the STZ-diabetic rats and their controls. The
results did not agree with the findings of lower 65Zn absorption in human diabetics by
Kiilerich et al. (1990). There is no ready explanation for this discrepancy between the
results of the two studies, other than the different subjects used in the two studies.
However, it may still be possible that the human diabetics could absorb more Zn if they
increased their food intake.
The results of the present study agree with the results of Craft and Failla (1983).
They determined Zn absorption of STZ-diabetic rats by feeding animals 65Zn-labeled diet
and reported a similar apparent 65Zn absorption by STZ-diabetic rats. But the total
absorbed 65Zn per 100 g body weight was two times higher in STZ-diabetic rats than in
control rats in their study. Due to the greater amount of food intakes of STZ-diabetic rats,
the total amount ofZn absorbed and retained should be higher.
The increased Zn absorption in diabetes mellitus may also be possible from some
other reasons: 1). Diabetic animals including humans have an enlarged mucosal mass
(Craft and Failla, 1983; Gourley et al 1983; Miller, et al. 1977), 2). Diabetic subjects
including both animals and humans have a depressed intestinal excretion of endogenous Zn
(Johnson and Canfield, 1985); 3). A number of intestinal brush border hydrolases and
transport systems are stimulated in diabetic animals including humans (Olson and Rogers,
1971; Younoszai and Schedl 1972; Caspary et al. 1972).
Zn absorption is regulated tightly by both body requirement, dietary intake and by
regulating excretion of Zn through both feces and urine (Vallee and Falchuk 1993;
Giugliano and Millward 1984). These same mechanisms ofZn homeostasis was also
operating in STZ-diabetics in the present study.
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3.4.3 The Significance of the Finding that Feeding After 65Zn Loading Affects 65Zn
Absorption and Retention
A significant finding of the present study is the finding that the feeding pattern had
a significant influence on 65Zn absorption and retention in the STZ-diabetic rats. STZ-
diabetics increased significantly 65Zn absorption and retention rates when they were "post-
fasted" in comparison with those that were "prior-fasted" (P<0.05). But, this phenomenon
was much less obvious in the control rats. These results suggest that some unidentified
alteration in Zn metabolism existed in diabetes.
Sian et al. (1993) noted that the absorption of exogenous Zn competed with
endogenous Zn that has been secreted into the lumen of the gastrointestinal tract in
response to a meal. Sian et al. (1993) were working with non-diabetic animals and the
observation made here with non-diabetics also shown a lesser but similar trend in 65Zn
retention, but not 65Zn absorption. It seems that the same mechanism may be at work, and
this mechanism may be exaggerated by diabetics.
Another possible explanation is that continued feeding may further exhaust insulin
secretion in STZ-diabetic animals, thus, decreasing the efficiency of absorption of Zn. In
contrast, a nil food intake may significantly spare insulin secretion, thus more metal was
absorbed because it could gain entry to the mucosa.
The increased 65Zn absorption in STZ-diabetic rats during "post-fasting" in the
present study may indicate that the STZ-diabetic rats possess the ability to alter their Zn
absorption rate to meet their body requirement for Zn. The significance of the results may
be two aspects: one is for the future study design that feeding pattern can alter the results
significantly, another is that the ability of Zn absorption in the diabetics can vary to meet
the body requirement for Zn.
Along with altered 65Zn absorption and retention, plasma Zn concentrations and
urine 65Zn excretion were also different when "prior-fasting" and "post-fasting" modes
were considered. This suggests that the feeding condition of the animals may play an
important role in regulating Zn uptake These data may help explain some of the previous
contradictory results for the effects of diabetes on Zn metabolism.
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3.4.4 Factors Associated with Zn Absorption and Retention
The rates of 65Zn absorption and retention were not correlated with body weight,
suggesting body growth is not a factor in Zn absorption. Blood glucose was also not
associated with rates of 65Zn absorption and retention, indicating severity of hyperglycemia
does not affect Zn absorption directly.
Food intake (of day 31, two days before the absorption study started) was
correlated with both 6,Zn absorption and 65Zn retention in STZ-diabetic rats, but this
correlation was absent in control rats. It may suggest the polyphagia in STZ-diabetic rats
played a role. It is generally agreed that the greater amount of Zn absorbed in diabetics is
due to their greater amount of food intake, rather than their rates of Zn absorption (Craft
and Failla 1984, Johnson and Canfield 1985).
Although the correlation of 65Zn absorption and retention with plasma 65Zn level
was significant when values of both diabetic and control were combined It became
insignificant if they were analyzed separately.
The same holds true for the correlation of 65Zn absorption and retention with
plasma Zn levels. This may suggest that the absorbed Zn may directly go into some tissue
deposit after absorption, and plasma Zn levels are tightly regulated within a small range
The significant correlation of 65Zn absorption and retention with urine 65Zn counts
in both the diabetic and control groups may indicate that urinary excretion ofZn may be a
regulatory mechanism of Zn homeostasis, which helps control the amount of Zn in the
body Zn pool. It may also indicate that hyperzincuria in diabetes may be a result of this
homeostatic regulation of body Zn metabolism.
A significant correlation of 65Zn absorption and retention was noted with urine
65Zn specificity in the STZ-diabetic rats, but not in their controls. The data, combined with
very significant correlation of 55Zn absorption and retention with urine Zn concentration,
may indicate that the more Zn is absorbed the more the urinary Zn loss. In other words,
the STZ-diabetic rats may both absorb more and excrete more Zn at the same time.
The significant correlation of 65Zn absorption and retention with Zn concentrations
in liver, kidney, and heart in the STZ-diabetic group, but not in the control group, may
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indicate that more Zn will go into these organs after absorption. This would be expected if
these organs are the repository for Zn with a short half-life and play a regulatory role in Zn
metabolism.
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CHAPTER 4
TISSUE AND ORGAN CONCENTRATIONS, CONTENTS AND BODY
COMPARTMENTAL DISTRIBUTIONS OF ZINC, COPPER AND UtON
IN STZ-DIABETIC RATS
4.1 Introduction
The intent of this study was to assess Zn, Cu and Fe status of diabetes mellitus
through analysis of concentrations of these elements in various tissues or organs. It has
been suggested that subjects with diabetes mellitus who display long term hyperzincuria
may deplete their body Zn stores (Kiilerich et al. 1990). Children with diabetes mellitus
have been reported to have a low growth velocity, also suggesting a possible secondary
Zn deficiency (Nakamura et al. 1991). A low concentration of plasma Zn in diabetics has
been seen frequently in some diabetic studies (Chooi et al. 1976; Kiilerich et al. 1985;
Kiilerich and Christiansen 1984; Kumar and Jaya Rao 1974; Melchior et al. 1989;
Mocchegiani et al. 1989; Raz and Havivi 1989; Sjogren et al. 1986; Walter et al. 1991).
However, higher levels of plasma or serum Zn have been reported also (Heise et al. 1988;
Canfield et al. 1984). It is not known whether these alterations in plasma Zn concentration
may reflect a Zn deficient status in the diabetic subject, since plasma Zn concentration may
not reflect Zn status and is easily influenced by many other factors (Abdulla 1982;
Hambidge et al. 1988; King 1990).
There are only a few studies which analyzed Zn, Cu and Fe contents of organs or
tissues of STZ-diabetic animals (Failla and Kiser 1981; Johnson and Evans 1984; Levine et
al. 1983). The results of Failla and Kiser (1981) showed that elevation of tissue Zn levels
in kidney and liver, and no significant difference in muscle, intestine and spleen between
the STZ-diabetic and control rats. Levine et al. (1983) found that STZ-diabetic rats had
decreased levels of Zn in serum, liver and kidney, but elevated amount of Zn in femur in
STZ-diabetic rats when compared with control rats. These results support an alteration of
Zn metabolism in diabetes mellitus.
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Johnson and Evans (1984) demonstrated that tissue Zn levels of STZ-diabetic rats
were influenced by dietary protein and Zn levels. They found that duodenal Zn
concentration was higher in STZ-diabetic rats when they were fed "high" mineral diets
compared with rats fed "low" mineral diet, and femur Zn was higher in STZ-diabetic rats
fed "high" protein diet than STZ-diabetic rats fed "low" protein diets. However, hepatic
and kidney Zn levels seemed not to be influenced by these factors. Hallmans and Lithner
(1980) applied acute heat-trauma to STZ-diabetic rats and showed that alterations in Zn
metabolism were greater in the STZ-diabetic rats when compared with controls. These
results suggest that there was a sequestration of serum Zn by the liver and kidney, and an
increased Zn absorption from gastrointestinal tract in diabetes. However, whether or not
Zn status in diabetes mellitus is compromised has remained to be determined
It is expected that alteration of dietary Zn intake may affect tissue Zn
concentrations If diabetics have a metabolic Zn deficiency, then feeding a Zn-depleted
diet should aggravate their Zn deficiency. On the other hand, Zn-supplementation may
also elicit a beneficial effect if metabolic Zn deficiency existed in diabetes mellitus. To test
this assumption a study was designed to assess Zn status of STZ-diabetic animals and
control animals fed different dietary Zn levels.
4.2 Materials and Methods
4.2.1 Animals and Induction of STZ-Diabetes Mellitus
The animals employed, the method of diabetes induction and the maintenance of
animals were the same as described in Chapter 3, section 3.2.1. Briefly, Wistar rats about
50 grams were randomly assigned into three dietary groups: marginal zinc deficient group
(ZD), normal zinc group (ZC) and zinc supplemented group (ZS). After two weeks of
acclimatization, half number of the animals were injected intraperitoneally with
streptozotocin in a dose of 100 mg/kg body weight. Due to the lower body weight in the
ZD group did not start inducting STZ-diabetes until one month later. The appearance of
polyuria and polydipsia and polyphagia were used as criteria of diabetes. No attempt to
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measure blood glucose since the previous experiment had shown that the hyperglycemia
already occurred as soon as the appearance of these signs.
4.2.2 Preparation of Animal Diets with Three Levels of Zn
Three different diets, ZD, ZC and ZS, were prepared and their compositions are
listed in Table 4 1 The ZC and ZS diets had the same composition as shown in Table 3.1,
except that ZC diet contained 33 mg Zn/kg and ZS diet contained 75 mg Zn/kg. The
composition for ZD diet is listed in Table 4. 1 . The Zn content of the ZD diet is 1 5 mg/kg.
Table 4.1 Composition of Marginal Zn-Deficient Animal Diet (%)
Ingredient Percentage
Celufil (cellulose fiber and fillings) 3.0
Corn oil 10.0
Dextrose 68.3
Egg albumin (Spray dried) 15.0
Zn free salt mixture 3 .7
Biotin 2 mg/kg
Vitamin Supplement 1 kg/ 100 lbs
For composition of Zinc free salt mixture see United States Biochemical, 261 1 1 Miles
Road, Cleveland, Ohio 44128.
4.2.3 Organ and Tissue Zn, Cu and Fe Determinations
Plasma, whole blood, liver, kidney, duodenum, pancreas, spleen, femur and muscle
from both the STZ-diabetic rats and their controls on ZD, ZC and ZS diets were analyzed
for their Zn, Cu and Fe concentrations. All organs or tissues underwent wet digestion
using concentrated nitric acid and perchloric acid. Kidney, spleen and femur each were
digested as a whole. Femurs was cleaned by removing all visible tissues and ligaments
before digestion. Liver, pancreas, duodenum, muscle were sampled for digestion. One
milliliter whole blood was used for digestion. Samples were put into an 150 ml beaker, to
each was added 10 ml concentrated nitric acid. They were heated over a hot plate at 350-
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500 0 C. After the first phase of active reaction, about 2 ml perchloric acid was added to
each. The acids were totally evaporated until a clear layer of residue remained at the
bottom of the beaker. With some samples it was necessary to use more nitric acid and
perchloric acid. Ten milliliters of5% (v/v) diluted nitric acid was used to dissolve the
residues. This solution was transferred into a 15 ml conic plastic tube for later AAS
analysis of Zn, Cu, and Fe under standard conditions. Plasma was diluted 4 to 6 times for
direct analysis by AAS method. Standards of Zn, Cu and Fe were prepared by dilution
with 5% (v/v) nitric acid.
4.2.4 Statistical Analysis
Statistical analysis of data was done with SAS statistics software (SAS Institute
Inc. Cary, NC, Version 6.09). A student T-Test was used to test difference between
groups. A correlation procedure was used to analyze the correlation among variables.
General Linear Model was used for multiple variant analysis and for multiple comparison.
Regression analysis was performed as necessary. A P<0.05 for all comparisons was
considered significant.
Whole body Zn, Cu and Fe contents were calculated by adding up Zn, Cu and Fe
contents of these organs or tissues analyzed. The contents of Zn, Cu and Fe of each organ
or tissue were calculated by multiplying tissue or organ Zn, Cu and Fe concentrations with
their organ weight. The total weight of plasma, blood clot, GI tract, pancreas, muscle and
bone was based on the body weight of the animal by multiplying the following figures:
plasma 0.026, blood clot 0.03, GI tract 0.0241, pancreas 0.0028, muscle 0.39, and bone
0.1 (Owen, 1964).
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4.3 Results
4.3.1 The Establishment of Streptozotocin (STZ)-Induced Diabetes
STZ-diabetes was induced by injection intraperitoneal^ 100 mg/kg body weight of
streptozotocin saline solution. The injection did not cause immediate death of animals,
however, about 10% of animals fed on ZC diet died within 24 hour. No death occurred in
animals fed on the ZS diet. About 10% of animals on ZC and ZS diets did not develop
diabetes even when given a second injection of streptozotocin solution at the same dosage.
In contrast to animals fed the ZC and ZS diets, 16 out of 20 Zn deficient animals died
within 48 hours after STZ injection. Despite the severe condition, the Zn deficient animals
alive in both diabetic and control groups barely maintained their body weight but remained
the whole study.
The presence of diabetes in the three diabetic rat groups was evident by large
amounts of urination, increased food intake and inactivity. Body weight initially decreased,
but recovered about 3 days later. The smell of their urine was very fetid, their urine
become muddy and turbid. The granules of their feces became larger and voluminous. No
attempt was made to analyze their blood glucose concentration, since previous study had
shown as soon as animals increased their urination, diabetes already existed and blood
glucose level became abnormally high. Also the added stress of blood sampling was not
considered acceptable.
4.3.2 The Effect of Zn Deficiency on Body Growth and Organ Weight of STZ-
Diabetic Rats
Zn is essential for growth and development. Zn deficient diet (3 mg/kg of food)
resulted in impaired growth and development, and barely maintained life in these animals.
Increasing dietary Zn levels to 1 5 mg/kg, which is half the amount of normal diet,
maintained body weight and improved appetite, but the impaired growth and appetite were
not fully recovered. The final dietary Zn levels of the Zn deficient diet was therefore
adjusted to 15 mg Zn/kg diet (ZD), actually a marginal Zn deficient diet. Normal diet had
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a Zn level of 33 mg/kg (ZC). and the Zn supplement diet (ZS) was adjusted to contain 75
mg Zn/kg of diet.
Table 4.2 Body Weight and Weights of Liver, Kidney and Spleen of STZ-
Diabetic and Control Rats
Diet Zn Deficient Normal Zn Supplement
Body Weight C$$$@@@
STZ-Diabetics 132+3 (5)**
Control 208+16(11)**
206+15 (13)*
256+11 (12)*
201+11(12)**
262+9(13)**
Liver Weight (g)b$$@@#
STZ-Diabetics 7.7+0.6 (5)**
Control 12.4+1.0(11)**
12.1+0.7(13)
12.2+0.7(12)
12.1+0.5 (12)
13.1+0.3 (13)
Liver Weight/Body Weight (%)c$$@@@
STZ-Diabetics 5.8+0.1(5)
Control 6.0+0.1(11)
5.8+0.2 (13)**
4.9+0.2(12)**
5.9+0.2 (12)**
5.1+0.1 (13)**
Kidney Weight (g)c$$$@@@##
STZ-Diabetics 2.0+0.2 (5)
Control 2.1+0.1(11)
3.2+0.1 (13)***
2.2+0.1 (12)***
3.2+0.2(12)**
2.5+0.2(13)**
Kidney Weight/Body Weight (%)c@@@
STZ-Diabetics 1.6+0.1(5)***
Control 1.0+0.03(11)***
1.61+0.1 (13)***
0.88+0.02(12)***
1.57+0.1 (12)***
0.95+0.1 (13)***
Spleen Weight (g)$
STZ-Diabetics
Control
0.2+0.03 (5)***
0.6+0.05 (11)***
0.9+0.3 (13)
0.8+0.03 (12)
0.6+0.1 (12)*
0.8+0.02(13)*
Spleen Weight/Body Weight (%)
STZ-Diabetics 0.2+0.02 (5)**
Control 0.3+0.02(11)**
0.4+0.1 (13)
0.3+0.01 (12)
0.3+0.02 (12)
0.3+0.01 (13)
^ ** ***. y.jest significant differences at PO.05. PO.01 and PO.0001 between STZ-diabetic and control
group: a. b, c: GLM model at PO.05. P<0.01 and PO.000 k $, $$. $$$: diet effect at PO.05, PO.01 and
PO.000 1 ; @, @@, @@@; Diabetes effect at PO.05. PO.0 1 and PO.000 1 ; #, ##. ###: Diet and group
interaction at PO.05, PO~01 and PO.0001 levels.
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The body weight of diabetic and control rats at sacrifice is presented in Table 4.2.
STZ-diabetic rats had a significant decrease in their body weight compared with their
controls at all the three dietary Zn levels (P<0.01). Animals fed on the ZD diet in both
diabetic and control groups significantly decreased body weight than animals in the other
two dietary groups (P<0.0001). Animals of both diabetic and control groups on ZS diets
had similar body weight as they did on the NC diet, suggesting that increased dietary Zn
level above normal does not further increase body growth. On the other hand, even
marginal Zn deficiency could not maintain normal body growth of the growing animals.
The whole liver weight of animals in both groups was not different significantly
when they fed the normal Zn diet and Zn-supplemented diet (Table 4.3). However, when
on a diet marginal for Zn, liver weight was significantly decreased in STZ-diabetic rats
when compared with their controls (P<0.01). Both dietary Zn levels and diabetes were the
factors affecting liver weight as assessed by the GLM model. There was also a significant
interaction between dietary Zn levels and diabetes, indicating that at the three dietary Zn
levels, diabetes had a different effect on liver weight.
Control animals on the diet marginal for Zn had a largest liver relative to their
body weight. But, when animals on the diets containing normal or increased amount of
dietary Zn, the relative weights of livers to body weight of STZ-diabetic rats were
significantly heavier than that of their controls (PO.01). Both dietary Zn levels and
diabetes were significant factors affecting the relative size of liver based on the GLM
model.
STZ-diabetic rats fed on the diet marginal for Zn had decreased significantly
kidney weight compared with STZ-diabetic rats fed on diets with adequate and
supplemented Zn (P<0.0001). While dietary Zn levels did not affect kidney weight in
control rats. In rats fed diets with adequate and supplemented Zn, STZ-diabetic rats had
significantly larger kidney weight in comparison with their controls (PO.001). GLM
analysis indicated that both dietary Zn levels and diabetes were factors that significantly
affect kidney size. There was also a significant interaction between dietary Zn levels and
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diabetes (P<0.01), indicating diabetes had a different effect on kidney weight when their
dietary Zn levels were different
Since the body weight was significantly decreased, the kidney weight relative to
body weight was not significantly affected by dietary Zn levels in STZ-diabetic rats.
However, the relative size of diabetic kidneys was significantly larger than that of the
controls at all the three levels of dietary Zn, suggesting diabetes affects kidney size. GLM
analysis indicates that only diabetes was the significant factor that affect kidney size.
Diets containing normal and increased amount ofZn had no significant effect on
both absolute or relative spleen weight in both STZ-diabetic and control groups.
However, when fed on the diet marginal for Zn, STZ-diabetic rats had significantly
decreased spleen weight either expressed in absolute weight or relative size to body
weight in comparison with the controls (P<0.0001 and P<0.01 respectively).
4.3.3 Other Effects of Dietary Zn Deficiency
Besides impaired body growth and impaired appetite, other effects of Zn deficiency
include physical inactivity, impaired hair growth and hair loss, skin impairment, and
uncontrolled urination and feces (the food bottles of these Zn deficient animals were
always contaminated with feces and urine). Their feces were sticky, thin and malodorous.
The feces and urine of Zn deficient animals could not be collected due to the
contamination of each other. The outlook of these Zn deficient animals clearly indicated
the importance of Zn, which is essential for normal growth and development of all species.
4.3.4 The Effect of Diabetes and Dietary Zn Levels on Organ and Tissue Zn
Concentrations
Zn concentrations of selected organs and tissues of both STZ-diabetic and control
rats are presented in Table 4.3 and Figure 4.1- 4.9. Values are expressed as mean+SEM.
Significance between two subject groups (diabetics and controls) and among three dietary
groups are indicated.
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Several features of the results are noteworthy. All STZ-diabetic rats on Zn diet had
higher Zn concentrations in all the organs or tissues analyzed when compared with their
controls, especially, liver and femur. On ZD diet, STZ-diabetic rats had lesser Zn levels
than their controls in duodenum, pancreas, spleen, femur and plasma. Muscle and liver Zn
concentration was significantly higher in diabetics than in control (P<0.05). Zn
concentrations found in kidney, whole blood, and femur were not significantly different
between the two groups. On the ZS diet, Zn concentrations of nearly all organs or tissues
were also higher in diabetic than in controls, except for plasma Zn concentration which
was significantly lower. The variances, in terms of standard error of means, in Zn
concentrations of organs and tissues of STZ-diabetic rats were larger than in the controls,
which may suggest that STZ-diabetic rats had a lesser control of their Zn metabolism in
response to dietary Zn changes.
4.3.4.1 Plasma Zn Concentrations of STZ-Diabetic Rats
As seen from Table 4.3 and Figure 4. 1 that STZ-diabetic rats had a 20% higher
plasma Zn concentration than their controls on NC diet. However, the difference is not
significant (P>0.05) due to a large variations of the data. The lowest level of plasma Zn
concentration occurred in STZ-diabetic rats fed on the ZD diet. Plasma Zn concentrations
of STZ-diabetic rats on the ZD and ZS diets were about 20%less than that of their
controls (P<0.05). Analysis of variance indicated that diet and diabetes were not
significant factors affecting plasma Zn concentration. A significant interaction between
diets and diabetes, suggesting the effect of diabetes on plasma Zn concentration differed at
different dietary Zn levels.
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Table 4.3 Organ and Tissue Zn Concentrations of Diabetic and Control Rats
Dietary Groups Zn Deficient Normal Zn Supplement
Plasma (mg/L)#
Diabetic
Control
0.909+0.088 (4)*
1.209+0.09 (9)*
.400+0.156(10)
.163+0.098 (10)
1.0568+0.053 (10)*
1.294+0.085 (12)*
Whole Blood (mg/L)a$
Diabetic 3.867+0.214 (5)
Control 3.773+0.113 (11)
3.414+0.209(13)
3.139+0.180(10)
3.451+0.144(10)
3.156+0.144(14)
Liver (ug/g wet wt)c$@@
Diabetic 27.018+0.969(5)** 24.561+0.920 (13)** 23.108+0.643 (12)**
Control 21.011+0.387 (11)** 20.423+0.727(11)** 20.371+0.364 (12)**
Kidney (ug/g wet wt)a@@
Diabetic 18.511+0.305 (5) 19.131+0.666 (13)
Control 18.122+0.483 (11) 17.699+0.336(11)
19.636+0.510(10)**
17.530+0.246(12)**
Duodenum (ug/g wet wt)c$$$###
Diabetic 13.667+0.927 (5)
Control 15.923+0.250 (11)
18.222+0.381 (13)*
16.836+0.275 (12)*
20.245+0.476 (12)**
17.407+0.342(12)**
Pancreas (ug/g wet wt)b$@,#
Diabetic 14.328+1.038 (5)
Control 15.478+0.766(10)
14 441+0.650 (15)*
11.131+0.785 (8)*
13.879+0.308 (10)
11.850+0.592(11)
Spleen (ug/g wet wt)a$$
Diabetic 13.591 + 1.263 (5)
Control 15.930+0.285 (11)
16.617+0.599(13)
16.288+0.083 (11)
16.581+0.663 (14)
16.859+0.342(11)
Muscle (ug/g wet wt)c$$$@@@###
Diabetic 16.035+2.062 (5)** 9.547+0.292 (12)
Control 8.254+0.509(11)** 9.106+0.474(11)
9.655+0.362(13)**
8.453+0.207 (12)**
Femur (ug/g wet wt)a
Diabetic 77.734+5.643 (5)
Control 81.299+5.322 (11)
86.286+1.953 (13)*
77.775+2.562 (11)*
91.978+2.385 (11)**
82.083+2.448 (12)**
« ** *««.p. 0 0S P 0 01 andP 0 0001 between diabetic and control groups from T-test. The following
are from GLM. a..b. c: model
significance at P
"
0.05. 0.0, and 0.0001 level-. $. $1 $$$: Die. effect at P<0.05 0.01 and O0001 level; U Stgrnflcan,
mteract.on
between dietary Zn level and diabetes at P : 0.05. 0.01 and 0.0001 levels. @, @@, era -a: Groups effect at P<0.05,
0.0
1
and 0.000
1
levels, (number): number of rats.
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4.3.4.2 Whole Blood Zn Concentrations in STZ-Diabetic Rats
STZ-diabetic rats had higher, but not significantly (P>0.05), whole-blood Zn
concentrations than their corresponding controls at all the three dietary Zn levels (Table
4.4 and Figure 4.2). Animals of both diabetic and control groups on the ZD diet had a
12% increase in whole-blood Zn concentration when compared to those on the NC and
ZS diets. It seems that dietary Zn deficiency decreased plasma Zn concentration (Figure
4.1) but it did not decreased total circulating Zn level. It also seems that more Zn was
sequestrated by blood cells within the blood when dietary Zn levels were low. Analysis of
variance revealed a significant effect of dietary Zn levels on whole-blood Zn
concentrations (P<0.05). Diet, but not diabetes, had significant effect on whole-blood Zn
levels (P<0.05). There were no significant interactions between diet and diabetes,
indicating this effect of dietary Zn level on whole blood Zn levels was independent of the
diabetic condition of the animals. The differences in effects noted between whole blood Zn
and plasma Zn concentrations must be attributed to Zn found in the various cellular
components of blood.
4.3.4.3 Liver Zn Concentrations of STZ-Diabetic Rats
At each dietary Zn level, STZ-diabetic rats had an significantly (P<0.01) higher
liver Zn concentration than that of control rats (Table 4.3 and Figure 4.3). The data are
similar to those reported by Failla and Kiser (1981, 1983). Both diabetic and control rats
had showed significant decrease in liver Zn concentrations as dietary Zn increased. Both
dietary Zn levels and diabetes significantly altered liver Zn levels (P<0.05) as confirmed by
GLM analysis. There was no significant interaction between the dietary Zn levels and
diabetes. The increased liver Zn concentrations in Zn deficiency may have important
implications that liver Zn may be used to support certain more vital life processes over
others.
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4.3.4.4 Kidney Zn Concentrations of STZ-Diabetic Rats
As indicated in Table 4 3. and Figure 4.4, kidney Zn concentrations in control rats
slightly decreased as dietary Zn was increased, but the changes were relatively small. STZ-
diabetic rats had an opposite trend showing a steady increase in kidney Zn concentrations
as their dietary Zn level increased, possibly a consequence of increased Zn absorption at
increased dietary Zn intake, and the increased workload to excrete unwanted Zn. The
differences in kidney Zn concentration between the diabetic and control rats on the ZD
and NC diets were not significant (P>0.05), but became significant (P<0.01) when they
were on the ZS diet. Diabetes, but no diet, affected kidney Zn concentration significantly
as assessed by GLM analysis. There was no significant interaction between diet and
diabetes.
4.3.4.5 Duodenum Zn Concentrations of STZ-Diabetic Rats
Table 4.3 and Figure 4.5 indicate that both diabetic and control rats showed
increased duodenum Zn concentrations as dietary Zn levels increased (P<0.0001). STZ-
diabetic rats fed on the ZD diet had lower duodenum Zn concentration than controls, but
this difference was not significant (P>0.05). However, duodenum Zn concentrations of
STZ-diabetic rats were significantly higher than those of their controls when they fed
either NC (P<0.05) or ZS (P<0.01) diets. Analysis of variance suggested that diet was a
significant factor affecting duodenum Zn level, but the effect of diabetes was not
significant (P>0.05). The significant interaction between the dietary Zn levels and diabetes
suggests that the effect of diet on duodenum Zn concentration was dependent on the
condition of the animals.
4.3.4.6 Pancreas Zn Concentrations of STZ-Diabetic Rats
As shown in Table 4.3. and Figure 4.6 that STZ-diabetic rats did not have
decreased pancreatic Zn concentrations when their dietary Zn levels were normal or
increased. Actually STZ-diabetic rats had a 20% increase in their pancreatic Zn
concentration when compared with their control rats on the diet with normal Zn level
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(P<0.05). STZ-diabetic rats on the ZD diet had a decrease, but not significantly, in their
pancreatic Zn concentration. Both STZ-diabetic and controls fed the ZS diets did not
differ significantly in their pancreatic Zn concentrations. GLM analysis showed that dietary
Zn level and diabetes were both significant factors affecting pancreatic Zn concentrations
(P<0.05). A significant interaction between the dietary Zn level and diabetes suggests
pancreas Zn concentration responded to dietary Zn levels differently between the diabetic
and control rats.
4.3.4.7 Spleen Zn Concentrations of STZ-Diabetic Rats
Both NC and ZS diets had little effect on spleen Zn concentration in either the
STZ-diabetic or control groups (Table 4.3 and Figure 4.7). However, when fed the ZD
diet, STZ-diabetic rats had a 20% decrease in spleen Zn concentrations, while the controls
had only a slight change (<2%). The lowest spleen Zn concentration was in the STZ-
diabetic rats fed the ZD diet. GLM analysis indicated that only dietary Zn level affected
spleen Zn concentration, diabetes had no significant effect on spleen Zn concentration. No
significant interaction existed between diet and diabetes.
4.3.4.8 Muscle Zn Concentrations of STZ-Diabetic Rats
STZ-diabetic rats had the greatest muscle Zn concentration on the ZD diet than
either NC or ZS diet (Table 4.3 and Figure 4.8). STZ-diabetic rats had a comparable
muscle Zn levels when they were fed the ZD and ZS diets, but these levels were
substantially lower than that when they fed the ZD diet. The control rats, on the other
hand, had relatively stable muscle Zn concentration when fed either of the three diets. The
STZ-diabetic rats had consistently higher muscle Zn concentrations at all the three dietary
Zn levels, and the differences were very significant when they were on the diets containing
either marginal Zn or supplemented Zn. Both dietary Zn levels and diabetes were
significant factors affecting muscle Zn concentrations (P<0.0001), The interaction
between dietary Zn levels and diabetes was also highly significant (P<0.0001), indicating
the differential effect of diabetes when animals fed the three dietary Zn levels.
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4.3.4.9 Femur Zn Concentrations of STZ-Diabetic Rats
STZ-diabetic rats had significantly higher femur Zn concentrations when fed the
NC or the ZS diet (P<0.05 and P<0.01, respectively, Table 4.3 and Figure 4.9) than noted
for their controls. Animals of both groups fed the ZS diet showed further increased femur
Zn concentrations than when on the NC diet. However, when they were on the diet that
was marginal for Zn, the control rats had an increased femur Zn concentrations than they
were on the NC and ZS diets, while the STZ-diabetic rats had decreased femur Zn
concentrations than they were on the NC and ZS diets. GLM analysis showed no
significant effect from either diet or diabetes, there was also no significant interaction
between dietary Zn levels and diabetes.
In summary, data in Table 4.3 and Figure 4 1 through 4.9 indicate that there was
no evidence of decreased tissue or organ Zn levels in STZ-diabetic rats when fed on the
normal Zn diets. STZ-diabetic rats even had significantly higher liver, duodenal, and femur
Zn concentrations than their controls when fed the normal diet. Feeding the ZS diet
further increased all but plasma Zn concentrations in STZ-diabetic rats, however, ZS had
no significant effect in these tissues and organs in the control rats. Intake of the ZD diet
resulted in decreased Zn concentrations in plasma, duodenum, pancreas, spleen, and
femur, but an increased Zn concentrations in liver and muscle in STZ-diabetic rats. These
changes in organ and tissues Zn concentrations suggest a redistribution of Zn among body
compartments in STZ-diabetic rats. Furthermore, these changes do not reflect Zn
deficiency in STZ-diabetic rats on the NC and ZS diets. But under condition ofZn
deficiency, diabetics tend to become Zn depleted in some of their tissues and organs.
Alternatively, they may suggest that the influence of STZ-diabetes on specific tissue or
organ may be related to both the general homeostasis of Zn and the particular function of
Zn in the tissue. The normal influence that the levels of Zn intake would have on tissue Zn
concentrations appear to be modulated by an over-riding effect of diabetes.
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4.3.4.10 Whole Body Zn Contents of STZ-Diabetic Rats
The calculated total body Zn contents (See section 4.2.4 for calculations) of STZ-
diabetic rats were consistently less when compared with that of their controls (Figure 4.10
and Table 1 in Appendix). However, due to the small body weight in STZ-diabetic rats,
total body Zn contents did not mean a Zn deficiency in STZ-diabetic rats. GLM analysis
indicates that whole body Zn contents was affected by both dietary Zn levels and diabetes
at the levels ofP<0.01.
4.3.4.11 Whole Body Mean Zn Concentrations in STZ-Diabetic Rats
Calculation of total body mean Zn concentrations of STZ-diabetic rats (Figure
4 11) revealed that STZ-diabetic rats had consistently higher Zn concentration than their
controls (P<0.0001). GLM analysis indicates that the effect of dietary Zn on body mean
Zn concentration is significant at the level of P<0.01, and the effect of diabetes is
significant at the level of P<0.0001, indicating that the significant differences in total body
mean concentrations is mainly the effect of diabetes. The results in Figure 4 .11 further
suggest that not only is there no evidence that Zn depletion occurs in STZ-diabetic rats,
but that there also may be more Zn in the body of STZ-diabetic rats.
4.3.4.12 Body Zn Distribution among Selected Organs and Tissues
Figure 4. 12 and Table 2 in Appendix summarizes results ofZn distribution among
organs and tissues of diabetic and control animals at the three dietary Zn levels. As noticed
from Figure 4. 12, the amount of Zn in bone constitutes more than half of the total body Zn
store, except for STZ-diabetic rats on the ZD diet. Muscle Zn constitutes about one third
of total body Zn. The third largest Zn reservoir is liver, which constitutes about 8-10% of
the total body Zn. Next are GI tract, kidney and spleen Zn. Zn in circulation (plasma and
blood clot) constitutes about 1% of total body Zn.
On the NC diet, the organs and tissues of STZ-diabetic rats were significant altered
are kidney and liver. STZ-diabetic rats obviously accumulated Zn in their livers and
kidneys. The percentages of body Zn distributed in these two organs in STZ-diabetic rats
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were significantly higher than that of their controls (P<0.01). STZ-diabetic rats also had
decreased percentage ofZn in plasma, blood, GI tract, spleen, muscles, and bone, and an
increased Zn content in pancreas, but, these alterations were not significantly different
from that of their controls (P>0.05).
On the ZD diet, STZ-diabetic rats had a further increased the accumulation ofZn
in liver, which was not significantly higher than their controls (P>0.05). Kidney Zn was
still significantly higher in STZ-diabetic rats than in control rats (P<0.05). STZ-diabetic
rats decreased significantly Zn content in their plasma (P<0.05), GI tract (P<0.05),
pancreas (P<0.05), spleen (P<0.01), and bone (P<0.01). These changes may be a results
of increased Zn content in muscle, which was nearly doubled in the STZ-diabetic rats than
those fed the NC and ZS diets. Both diabetic and control rats had a decreased Zn content
in the circulation, indicating when Zn deficiency existed, total Zn in plasma was affected.
There was no significant changes in Zn distribution in whole blood in both groups. The
percentage of pancreatic Zn was increased in both groups, however, the STZ-diabetic rats
had a lesser magnitude compared with their controls.
In animals fed the Zn supplemented diet, distribution ofZn among organs and
tissues of the STZ-diabetic rats was more comparable to that of their controls. The only
significant changes left were the significantly increased Zn in kidney (P<0.0001) and liver
(P<0.05), and significantly decreased Zn in plasma in the STZ-diabetic rats in comparison
with that of their controls (P<0.01). The distribution of total body Zn in other body
compartments were not significantly different between the STZ-diabetic and control
groups.
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4.3.5 The Effect of Diabetes and Dietary Zn Levels on Organ and Tissue Cu
Concentrations
The metabolism of Zn, Cu and Fe is mutually linked. There is evidence that they
may share common storage molecules and they do appear to compete with one another for
absorption (Craft and Failla 1983; Davis 1980; Flanagan et al. 1980; 1983; Hill 1988).
Because changes in Zn concentration in the diet may influence the absorption of Cu and
Fe. It was of interest to determine if their status was altered due to changes in dietary Zn
levels.
4.3.5.1 Cu Concentrations of Organs and Tissues of STZ-Diabetic Rats
Cu concentrations of organs and tissues of diabetic and control rats are presented
in Table 4.4 When fed the NC diet, STZ-diabetic rats had higher Cu concentrations in
nearly all organs and tissues analyzed, except muscle; these differences were significant in
liver (P<0.05), duodenum (PO.05), kidney (P<0.01) and pancreas (P<0.01) between the
STZ-diabetic rats and their corresponding controls. A similar trend held true when they
were on the ZS diet. When fed the ZD diet, STZ-diabetic rats still had the higher Cu
concentrations in all organs and tissues analyzed, except kidney, which was lower in STZ-
diabetic rats than in control rats.
There were no significant differences in plasma Cu concentrations between the
diabetic and control rats at any of the three dietary Zn levels. In STZ-diabetic rats, highest
plasma Cu concentration occurred when they were on the NC diet, while control rats on
the NC diet displayed the lowest plasma Cu concentration. The ZD diet did not
significantly affect plasma Cu in STZ-diabetic rats, as it did the control rats. STZ-diabetic
rats on the ZS diet showed a decrease of about 30% in plasma Cu concentrations than that
noted for those on the NC and ZD diets. The control rats fed both ZD and ZS diets
showed a slight increase in plasma Cu concentration when compared to those fed the NC
diet. All these changes in plasma Cu concentrations in both diabetic and control rats were
not significant as assessed by analysis of variance. Both STZ-diabetic and control rats had
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Table 4.4 Organ and Tissue Cu Concentrations of Diabetic and Control Rats
Dietary Groups Zn Deficient Normal Zn Supplement
Plasma (mg/L)
Diabetic 0.784+0.094 (4)
Control 0.621+0.076(10)
Whole Blood (mg/L)a@$
Diabetic 0.883+0.065 (6)
Control 0.782+0.042 (11)
Liver (ug/g wet wt)b@@
Diabetic 4.927+0.393 (5)
Control 4.096+0.090(11)
Kidney (ug/g wet wt)c@@$#
Diabetic 5.000+0.321 (5)
Control 5.712+0.3 14 (1 1)
Duodenum (ug/g wet wt)@
Diabetic 1.699+0.258 (5)
Control 1.690+0.046(11)
Pancreas (ug/g wet wt)b@@
Diabetic 1.103+0.061 (5)*
Control 0.902+0.049 (10)*
Spleen (ug/g wet wt)a@$$
Diabetic 2.012+0.388 (5)
Control 1.477+0. 139 (1 1)
Muscle (ug/g wet wt)a@#
Diabetic 1.564+0.318 (5)
Control 1.054+0.045 (11)
Femur (ug/g wet wt)@
Diabetic 2.654+0.0662 (5)
Control 2.448+0.099(11)
0.815+0.099(8) 0.564+0.069 (10)
0.549+0.040(10) 0.678+0.132(13)
0.792+0.049 (13) 0.780+0.020(10)*
0.740+0.031 (10) 0.643+0.048 (14)*
7.550+1.186 (13)* 7.080+1.218 (12)*
3.998+0.114(11)* 3.633+0.171 (13)*
13.414+2.353 (13)** 15.526+2.634 (10)**
5.108+0.217 (11)** 6.004+1.448 (13)**
1.859+0.115 (12)* 1.910+0.090(12)
1.550+0.066(11)* 1.623+0.123 (12)
1.129+0.146 (16)** 1.061+0.063 (10)***
0.649+0.046 (9)** 0.639+0.053 (11)***
1 .342+0.080 (1 1) 1.459+0. 101 (13)
1.261+0.049 (11) 1.232+0.107 (1 1)
1.152+0.059(13) 1.074+0.056(13)
1.177+0.068 (11) 1.083+0.098 (12)
2.565+0.135 (13) 2.576+0.053 (11)*
2.392+0.070 (10) 2.335+0.077 (12)*
* ** «**. p.-Q 05. p 0.01. and P' 0.0001 between diabetic and control groups from T-test. The following are from GLM: a..b. c: model
significance at P 0.05. 0.01 and 0.0001 level: $.$$.$$$: Diet effect at P 0.05. 0.01 and 0.0001 level: tt.HH.nttU: Significant interaction
between dietary Ztl level and diabetes at P 0.05. 0.01 and 0.0001 levels. i(p, @@, igvSKgi: Groups effect at P<0.05. 0.01 and 0.0001
levels, (number): number of rats.
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decreased whole blood Cu concentration as their dietary Zn levels increased. However,
STZ-diabetic rats had higher whole blood Cu concentrations than controls at all the three
dietary Zn range. The difference became significant in the ZS diet groups (P<0.05).
Analysis of variance indicated that both diabetes and dietary Zn levels were the significant
factors affecting whole blood Cu concentration. There was no significant interaction
between diet and diabetes.
STZ-diabetic rats had a nearly two fold increase in liver Cu concentrations when
compared with the controls when fed both the ZC and ZS diets (P<0.05). However, when
fed the ZD diet, liver Cu concentrations of both groups were comparable. STZ-diabetic
rats on the ZD diet decreased their liver Cu concentration about 40-50% when compared
with STZ-diabetic groups fed either the ZC or ZS diets. But this decrease in liver Cu
concentration was not seen in the control rats when they fed the ZD diet. Diabetes was the
only significant factor affecting liver Cu concentration as assessed by analysis of variance.
There was no significant interaction between the two variables.
Kidney Cu concentrations followed the same pattern as liver Cu concentration.
STZ-diabetic rats fed on the ZC and ZS diets had a kidney Cu concentration which was
more than double that of the control rats (P<0.01). The STZ-diabetic rats had a lower, but
not significantly so, kidney Cu concentration when fed the ZD diet compared with that of
their controls (P>0.05). Again, STZ-diabetic rats given the ZD diet showed a more than
50% decrease in their kidney Cu levels when compared to STZ-diabetic rats fed either the
ZC or ZS diets. This change was not present in the control rats. Analysis of variance
indicated that both diabetes and diet significantly affected kidney Cu concentration. The
effect of diet was also dependent on the condition of the animals as there was a significant
interaction between the two variables (P<0.05).
STZ-diabetic rats had 1 5% and 1 7% increase in their duodenum Cu concentration
compared with their controls on the ZS and ZC diet respectively (P<0.05). STZ-diabetic
rats also had higher (but not significantly so) duodenum Cu concentration when fed the
ZD diets than that of their controls. Diabetes had significant effect on duodenum Cu
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concentration as assessed by analysis of variance, there was no significant interaction
between the diabetes and dietary Zn levels.
Pancreatic Cu concentrations were consistently higher in the STZ-diabetic rats
than in their controls (P<0.05 for ZD, P<0.01 for NC, and PO.0001 for ZS). There was
little change in pancreatic Cu concentrations in STZ-diabetic rats when their dietary Zn
increased or decreased. However, in control rats, there was about 30% increase in their
pancreatic Cu concentration when fed ZD diet in comparison with that when they fed the
NC and ZS diets. Analysis of variance indicated that diabetes was the only factor affecting
pancreatic Cu concentration (P<0.001), the effect of dietary Zn was not significant, there
was no significant interaction between the two variables.
When fed the ZC and ZS diets, STZ-diabetic rats had about 5-15% higher spleen
Cu concentration than their controls. Both diabetic and control rats increased their spleen
Cu concentration when fed ZD diet compared with those given either ZC or ZS diets,
suggesting an antagonistic effect between Zn and Cu in this organ. The magnitude of this
increase was much greater in STZ-diabetic rats than in control rats. Analysis of variance
indicated that both diet and diabetes were significant factors affecting spleen Cu
concentration. No significant interactions existed between the two variables.
STZ-diabetic rats had comparable muscle Cu concentrations when fed either the
ZC or ZS diets as that of their controls, however, muscle Cu concentration increased
about 30% in STZ-diabetic rats fed the ZD diet than they were on ZC and ZS diets,
another antagonistic effect between the two metals occurred here. There was little change
in muscle Cu concentrations in control rats on the ZD diet. Diabetes was a significant
factor affecting muscle Cu concentration, there was also a significant interaction between
diet and diabetes.
STZ-diabetic rats had a consistently higher femur Cu concentrations when
compared with their controls, but the difference became significant when the ZS diet was
fed (P<0.05). There was little variation in their femur Cu concentration over the dietary
Zn range for both the STZ-diabetic rats and their controls. This was also confirmed by
analysis of variance. Dietary Zn levels were not a significant factor affecting femur Cu
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concentration, but diabetes significantly affected femur Cu concentration (P<0.05). There
was no significant interaction between diet and diabetes.
4.3.5.2 Total Cu Contents of STZ-Diabetic and Control Rats
Total body Cu contents of STZ-diabetic and control rats are presented in Figure
4. 13. The absolute amount ofCu was highest in STZ-diabetic rats on the normal Zn diet,
which was significantly higher than that in controls (P<0.05). The total body Cu contents
of STZ-diabetic rats and control rats were not different significantly when fed diets either
deficient for or supplemented with Zn.
4.3.5.3 Whole Body Mean Cu Concentration of STZ-Diabetic and Control
Rats
The whole body mean Cu concentration, as presented in Figure 4.14, showed that
STZ-diabetic rats had consistently higher Cu concentrations than their controls at each
levels of dietary Zn. In both STZ-diabetic and control groups, the whole body mean Cu
concentrations were not affected by dietary Zn levels, and remained relatively stable.
4.3.5.4 Body Cu Distribution among Selected Organs and Tissues
Cu distribution among organs and tissues of STZ-diabetic rats and their controls at
the three levels of dietary Zn is presented in Figure 4.15 and Table 4 in Appendix. The
distribution of Cu in body organs and tissues is obviously different from that for Zn.
Muscle is the major tissue that contains almost half of total body Cu. Liver is also another
major organ that contains 20-30% of total body Cu. Followed by bone which contained
about 20-25% of total body Cu. Kidney Cu constitutes about 5% to 6% of total body Cu
in control rats, but this figure was more than doubled in STZ-diabetic rats. GI tract
contained less than 5% of total body Cu. Cu in plasma and blood comprised 3-5% of total
body Cu. Cu in pancreas and spleen contain only about 0.2% and 0.4% of total body Cu
each.
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On normal dietary Zn, Cu distribution in STZ-diabetic was also characterized by
accumulation of Cu in liver and kidney in the STZ-diabetic rats compared with that of
their controls. STZ-diabetic rats also had a significantly decreased Cu in spleen
(P<0 0001). Muscle and GI Cu were significantly decreased in STZ-diabetics than in their
controls (P<0.01). Percentage of Cu in plasma, blood, pancreas did not have significant
difference between diabetic and control rats (P>0.05). On the ZD diet, Cu distribution
among these organs were not significantly different from that of their corresponding
controls. On the other hand, diabetic animals on ZS diet had a significantly increased Cu in
kidney (P<0.05) and liver (PO.01), significantly decreased Cu in muscle (P<0.01), GI
tract (P<0.05) and bone and marrow (P<0.05) compared with their controls. There were
no significant differences in Cu distribution in plasma, blood, pancreas and spleen
(P>0 05)
4.3.6 The Effect of Diabetes and Dietary Zn Levels on Tissue and Organ Fe
Concentrations
4.3.6.1 Fe Concentrations of Organs and Tissues of STZ-Diabetic and
Control Rats
Table 4.5 presents mean values of organ and tissue Fe concentrations of diabetic
and control animals, together with their statistical analysis. STZ-diabetic rats fed the
normal Zn diet had comparable Fe concentrations in all tissues except femur, which was
significantly higher when compared with their controls. Significantly increased Fe
concentrations in pancreas, muscle and femur were also observed in STZ-diabetic rats fed
the ZS diet compared with their controls. A significantly decreased duodenum Fe
concentration was also seen in STZ-diabetic rats on ZS diet in comparison with that of
their controls. When fed the ZD diet, STZ-diabetic rats had significantly increased femur
and liver Fe concentrations when compared with their controls. The detailed comparisons
are summarized below.
STZ-diabetic rats had a slightly but not significantly higher plasma Fe
concentration when fed either ZC or ZS diet than when the ZD diet. The plasma Fe
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Table 4.5 Organ and Tissue Fe Concentrations of Diabetic and Control Rats
Dietary Groups Zn Deficient Normal Zn Supplement
Plasma (mg/L)a$
Diabetic
Control
0.946+0.198 (4)
0.831+0.143 (10)
1.727+0.149 (8)
1.686+0.128 (10)
1.649+0.146(10)
1.498+0.131 (12)
Whole Blood (mg/L)
Diabetic
Control
464.313+17.454 (5) 435.221+17.554 (13) 432.833+8.380 (10)
434.574+14.166(11) 416.983+7.356(10) 415.662+7.548 (14)
Liver (ug/g wet wt)b$$@@
Diabetic 137.667+15.801 (5)* 96.830+10.837 (13) 83.997+5.180 (12)
Control 92.929+6.727(11)* 80.597+4.785 (11) 70.897+4.959 (12)
Kidney (ug/g wet wt)$
Diabetic 71.020+7.046(5)
Control 68.788+5.037 (11)
63.025+4.917 (13)
65.324+3.185 (11)
58.548+2.692 (11)
57.419+3.796(12)
Duodenum (ug/g wet wt)a@@
Diabetic 20.224+2.416(5) 25.271+3.104(13)
Control 24.997+2.846 (11) 31.200+1.872(11)
20.137+1.216(12)**
30.904+2.828 (12)**
Pancreas (ug/g wet wt)a@@
Diabetic 22.360+1.973 (6)
Control 20.923+3.249 (7)
30.925+6.353 (11)
21.300+1.534 (4)
25.881+1.928 (9)***
15.562+1.656(7)***
Spleen (ug/g wet wt)c$$$
Diabetic 304.578+35.844 (5) 206.710+11.404(13) 198.493+9.038 (14)
Control 279.330+27.327 (11) 189.489+6.984 (11) 190.626+10.111 (11)
Muscle (ug/g wet wt)c@@@$$$
Diabetic 22.952+5.660 (5)
Control 13.020+1.106(11)
15.253+0.858 (13)
15.421+0.588 (11)
16.592+0.689(12)***
12.685+0.702(12)***
Femur (ug/g wet wt)c@@$$##
Diabetic 107.241 + 16.513 (5)*
Control 54.089+8.847 (12)*
55.294+4.368 (13)*
41.688+1.738 (13)*
52.563+4.1677(13)*
40.221+1.764(12)*
* ** ***. p<0 05 P 0 01 andP 0 0001 between diabetic and control groups from T-test. The following are from GLM: a.,b. c: model
significance at P 0.05 0.0 1 and 0.000 1 level- $. $$. $$$: Diet effect at P 0.05. 0.0 1 and 0.000 1 level; #. ##. ###: Significant
interaction
between dietary Zn level and diabetes at P 0.05. 0.01 and 0.0001 levels. @, @@, @@@: Groups effect at P<0.05. 0.01 and 0.0001
levels, (number): number of rats.
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concentrations of STZ-diabetic rats were also higher than that of their controls when given
either the ZC or ZS diets. Feeding the ZD diet caused their plasma Fe concentration to
decrease nearly 45% to 50% respectively in both diabetic and control rats. Analysis of
variance indicated that diet, but not diabetes significantly affected plasma Fe
concentration. There was no significant interaction between diet and diabetes on plasma
Fe levels.
Whole blood contained the highest amount of Fe amongst the organs and tissues
analyzed. STZ-diabetic rats had a slightly higher (about 4-5% more) whole blood Fe than
their controls at all the three dietary Zn levels, the differences were not significant
(P>0.05). Both STZ-diabetic rats and their controls fed the ZD diet had a slight increase in
whole blood Fe than when fed either ZC or ZS diets. Analysis of variance indicated that
neither diet, nor diabetes had significant effect on whole blood Fe concentration.
Liver Fe concentrations of STZ-diabetic rats increased as their dietary Zn levels
decreased. An increase in liver Fe concentration in control rats on the ZD diet was
also observed, but the magnitude was much smaller than that of the STZ-diabetic rats.
STZ-diabetic rats had a 30% more liver Fe concentration compared to controls fed the ZD
diet (P<0.05), and 20% more liver Fe than when given the ZC and ZS diets, but the
differences were not significant. However, analysis of variance indicated that both diabetes
and diet had very significant effect on liver Fe concentration (P<0.01). There was no
significant interaction between the two variables.
Kidney Fe concentration of both STZ-diabetic and control rats increased slightly
with decreasing dietary Zn. However, there were no significant differences between the
two groups at any of the three dietary Zn levels. Analysis of variance indicates that dietary
Zn level significantly affects kidney Fe levels.
Duodenum Fe concentration was slightly lower in STZ-diabetic rats compared
with control rats fed the ZC diet. The difference was about 25%, however, this difference
was not significant (P>0.05). Both ZD and ZS diets caused about 25% decrease in
duodenum Fe concentration in STZ-diabetic rats. However, feeding ZS did not affect
duodenum Fe concentration in control rats as much as it did in the STZ-diabetic rats. Thus
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the difference between the two groups fed the ZS was significant (P<0.05). While both
groups decreased their duodenum Fe concentrations when fed the ZD diet, there was no
significant difference between the two groups. As assessed by analysis of variance, only
diabetes, but not diet, had significant effect on duodenum Fe concentration.
The highest pancreatic Fe concentration observed in STZ-diabetic rats was when
they were on ZC diet; STZ-diabetic rats on both the ZD and ZS diets had decreased
pancreatic Fe concentrations compared with those on the ZC diet. The highest pancreatic
Fe concentration in control rats was observed when they were fed the ZC diet. Pancreatic
Fe concentrations in STZ-diabetic rats were higher than those of control rats at all the
three dietary Zn levels, and the difference became significant when they were on the ZS
diet (P<0.0001). Analysis of variance indicated that only diabetes had significant effect on
pancreatic Fe concentration.
STZ-diabetic rats had a slightly higher spleen Fe concentration at all three dietary
Zn levels when compared with their corresponding controls, but the differences were not
significant. Both STZ-diabetic rats and control rats increased their spleen Fe
concentrations when they were fed the ZD diet. Analysis of variance indicated that dietary
Zn levels had a significant effect on spleen Fe concentration, while diabetes did not affect
spleen Fe, nor was there any significant interaction between the two variables.
Muscle Fe concentration was not different between the two groups on the ZC diet.
However, feeding both the ZD and ZS caused the muscle Fe concentration of STZ-
diabetic rats to increase, while that of control rats to decrease. The highest spleen Fe
concentration was in STZ-diabetic rats fed the ZD diet, but it was not significantly
different from that of control rats. STZ-diabetic rats had a very significantly higher spleen
Fe concentration than that of their controls when fed the ZS diet (PO.0001). Analysis of
variance indicates that both dietary Zn levels and diabetes had significant effect on muscle
Fe concentrations.
STZ-diabetic rats had consistently significantly higher femur Fe concentration than
their corresponding controls at all the dietary Zn levels (PO.05). Decreasing dietary Zn
levels caused femur Fe concentrations of both groups to increase. Analysis of variance
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indicated that both diet and diabetes had significant effect on femur Fe concentrations,
there was no significant interactions between the two variables.
4.3.6.2 Total Body Fe Contents of STZ-Diabetic and Control Rats
The total body Fe contents of STZ-diabetic and control rats at each dietary Zn
level are presented in Figure 4. 1 6. STZ-diabetes decreased total body contents in STZ-
diabetic rats when compared with control rats, but the differences were not significant
(P>0.05). GLM analysis indicates that STZ-diabetes was not a significant factor affecting
total body Fe contents, but the effect of dietary Zn levels was very significant (P<0.01).
4.3.6.3 Whole Body Mean Fe Concentration of STZ-Diabetic and Control
Rats
Figure 4.17 illustrates whole body mean Fe concentration of STZ-diabetic rats in
comparison with that of their controls. Similar to Zn and Cu, whole body mean Fe
concentrations of STZ-diabetic rats on the diet marginal for Zn was the highest among the
groups. The whole body mean Fe concentration in STZ-diabetic rats was significantly
higher than that of their controls when both were on the diet marginal for Zn. The
significant difference in whole body mean Fe concentration was presented in both STZ-
diabetic and control rats fed the diet supplemented with Zn (P<0.01). When they were on
diet containing normal amount of Zn, their whole body mean Fe concentration was not
different significantly.
4.3.6.4 The Effect of Diabetes and Dietary Zn Levels on Body Fe Distribution
among Selected Organs and Tissues
Fe distribution among organs and tissues of diabetic and control rats on the three
dietary Zn levels is summarized in Figure 4. 1 8 and Table 6 in Appendix. Different from
that of Zn and Cu distribution, blood is the major tissue that contains about more than
40% of the total body Fe. Followed by bone and marrow (20%), muscle (16-18%), liver
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(11-13%), GI tract (5-8%), kidney (2-5%), spleen (2%), pancreas (0.2%). Plasma
contains negligible amount of Fe (0.05%).
On the normal dietary Zn intake, STZ-diabetic rats had increased Fe accumulation
in kidney (P<0.01), and a significantly decreased Fe concentrations in muscle (P<0.05)
and GI tract (P<0.01) when compared with that of the control rats. Fe distribution in other
remaining organs and tissues was not significantly different between the diabetic and
control groups.
When the ZD diet was fed, significant change in Fe distribution occurred in blood.
In the diabetics there was a 30% decrease in total blood Fe distribution (compared with a
5% decrease in control rats). STZ-diabetic rats also had significantly decreased Fe in GI
tract (P<0.05) and spleen (P<0.01). There were no other significant differences among
other organs and tissues between the STZ-diabetics and the controls. STZ-diabetic rats
fed the ZD diet had a 50% increase in percentage of Fe in bone and marrow (P<0.01)
compared to those fed the ZC and ZD diets. This increase did not occur in controls. The
percentage of muscle Fe decreased by a third in control rats, but not in the diabetics.
Zn supplementation caused increased Fe accumulation in kidney (P<0.01), liver
(P<0.05), and pancreas (P<0.05) in STZ-diabetic rats compared with their controls. The
differences of Fe distribution in other organs and tissues was not significant between the
STZ-diabetic and control groups.
Because levels of dietary Zn above requirement had no effect on Fe distribution, it
is reasonable to conclude that higher levels of dietary Zn had no effect on Fe metabolism.
When STZ-diabetic rats were fed the ZD diet, the percentage of blood Fe decreased
significantly (P<0.05), suggesting a possible risk of Fe depletion.
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4.4 Discussion
4.4.1 Increased Whole Body Mean Zn Concentration Excludes Zn Deficiency in
STZ-Diabetic Rats
The finding that STZ-diabetic rats contained significantly higher Zn concentration
per gram of body weight (Figure 4. 1 1) excludes any possibility that Zn deficiency existed
in STZ-diabetic rats. This finding is consistent in that all STZ-diabetic rats contained more
Zn per gram body weight independent of their dietary Zn levels. A possible Zn toxicity in
diabetes occurring is thus hypothesized for the first time. The increased whole body Zn
concentration may be the ultimate result of increased Zn absorption, body catabolism,
tissue breakdown and slower growth in body weight occurred in diabetes. The other
findings that increased 65Zn turnover rates and increased fecal excretion of 65Zn, and
higher Zn concentrations in all the tissues and organs analyzed when fed diets with normal
and increased Zn contents all are evidence that there is more Zn in the diabetic body.
The finding that there is an increased Zn concentration in the STZ-diabetic rats
leads naturally to reevaluation of many studies on Zn metabolism in both diabetic humans
and animals. Previous studies in this laboratory (Fu 1991, Cunningham et al. 1994)
showed that human IDDMs did not have decreased Zn levels in plasma, leukocytes,
erythrocyte, and that Zn supplementation in a dose of 50 mg per day for 30 days to
IDDMs did not show any beneficial effect as compared with their controls. On the other
hand, Zn supplementation did aggravate their glycemic control as their glycosylated
hemoglobin became worse as the study continued. There are other studies that showed
that either an increased plasma Zn levels in diabetic subject (Heise et a. 1988, Canfield et
al. 1984); or there is no significant difference in plasma Zn levels between IDDMs and
controls (Kiilerich and Christiansen 1985; Hagglof et al. 1983; Chooi et al. 1976, Pidduck
et al. 1971, Prout et al. 1969 and Rosner and Gorfien 1968). There is no evidence of zinc
deficiency in diabetes as indicated in all these studies.
The decreased 65Zn retention and absorption in human diabetic subjects as reported
by Kiilerich et al. (1990) should be also the evidence that there was no Zn deficiency
existed in these subjects.
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4.4.2 Altered Zn Distributions and Concentrations at the Tissue Level
There was a peculiar change in body compartmental Zn distribution in STZ-
diabetic rats, which reflect the natural result of this increased whole body mean zinc
concentration (Figure 4. 12). This altered tissue distribution was characterized by
sequestration of more body Zn by kidney and liver when their dietary zinc levels were both
adequate or increased. During zinc deficiency, muscle catabolism released large amount of
Zn, thus Zn distributed into other tissues such as GI tract, spleen, pancreas, and femur
decreased, but sequestration ofZn by their livers and kidneys still existed. The percentages
ofbody Zn distributed to plasma were decreased in STZ-diabetic rats at all levels of
dietary Zn (Figure 4. 12 and Table 2. in Appendix). A decreased circulating Zn relative to
other body compartments may be hypothesized.
When STZ-diabetic rats fed the diets either adequate for Zn or supplemented with
Zn, their tissue or organ Zn levels were all elevated when compared with controls. On the
other hand, despite the increased mean Zn concentration, STZ-diabetic rats when fed the
diet marginal for Zn still had decreased Zn concentrations in some organs and tissues, such
as plasma, femur, pancreas, GI tract and spleen (Table 4.3). These results may suggest
that diabetic animals may have a peculiar change in Zn metabolism during Zn deficiency.
Plasma Zn concentration did not reflect dietary Zn intake in both STZ-diabetic and
control rats. The plasma Zn concentrations were elevated in STZ-diabetic rats on normal
Zn diet, but was decreased when STZ-diabetic animals fed diets either marginal for Zn or
supplemented with Zn. Both Zn depletion and Zn supplementation did not significantly
alter plasma Zn concentrations in the control rats, indicating plasma Zn is fairly tightly
controlled in healthy rats (Table 4.4). However, this homeostatic regulation of plasma Zn
seemed to be impaired in the STZ-diabetic rats as a decreased plasma Zn in STZ-diabetic
rats when they fed either Zn deficient diet or Zn-supplemented diet.
Whole blood Zn concentration in STZ-diabetic rats fed all three levels of dietary
Zn were increased but not significantly. Whole Blood Zn concentrations seemed to be not
influenced by dietary Zn intake, neither by diabetic condition (Table 4.3). This lack of
change in whole blood Zn levels in response to changes in dietary Zn intake may be due to
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the relative short period of time covered in the present study. It is known that rat
erythrocytes have a turnover rate of 30-40 days (Thompson 1991) and is not easily
depleted within up to 9 weeks in human study (Baer and King 1984). The percentage of
Zn in whole blood was also not different significantly between STZ-diabetic and control
rats, indicating whole blood Zn levels were not affected by both diabetes and dietary Zn
levels.
The present study found that the major change in Zn metabolism in diabetic
animals was the increased liver and kidney Zn concentrations (Table 4.3). Since whole
body Zn mean concentration was elevated in STZ-diabetic rats, the function of this Zn
sequestration by liver and kidney may be beneficial in two aspects: one is to make free Zn
in circulation less toxic to the body, another is to excrete quickly through kidney. This
alteration in Zn metabolism in diabetes has been compared to stress stimulation (Hallmans
and Lithner 1980). The sequestration of Zn by the liver and kidney was explained to be
simply an adaptative response.
The increased mean Zn levels and increased kidney concentration in STZ-diabetic
rats may lead to the conclusion that hyperzincuria may function to excrete more unwanted
Zn from the Zn-over-saturated diabetic body. The statement that hyperzincuria in diabetes
depletes body store of Zn seemed to be unwarranted.
Zn is absorbed through entire small intestine and duodenum is the major site ofZn
absorption (Cousins 1985) and regulating site ofZn metabolism (Wastney et al. 1986).
Analysis of duodenum Zn concentration reflects both Zn absorption and endogenous
secretion. Intestinal Zn concentration was significantly higher in STZ-diabetic rats on both
normal and Zn-supplemented diets, and decreased in STZ-diabetic rats on Zn-depleted
diet. Changes in Zn concentrations in duodenum in both STZ-diabetic and control rats in
response to dietary Zn intakes may indicate that both absorption and endogenous secretion
ofZn are normally functioning in regulating body Zn metabolism.
Pancreas Zn concentrations in STZ-diabetic rats did not differ significantly
between STZ-diabetic and control rats (Table 4.3). The possibility that insulin metabolism
and function due to Zn deficiency did not exist in the present study.
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Muscle Zn concentration in STZ-diabetic rats was elevated significantly in animals
fed the diet marginal for Zn (Table 4.3). Since control rats did not have similar increase in
muscle Zn concentration, it seems the elevation of muscle Zn is the unique response in
STZ-diabetic rats in facing Zn deficiency. It is possibly an indication of tissue catabolism.
Muscle Zn concentration did not reflect body store of Zn and Zn intake as observed in this
study (Table 4.4 and Figure 4.8). This point of view is also shared by Cunnane (1988b),
Giugliano and Millward (1984), who found that dietary Zn did not have any effect on
muscle Zn level. Studies on humans also support that the mass of Zn in muscle is tightly
regulated (Wastney et al. 1986, Brown et al. 1985)
A greater change in femur Zn concentrations was observed in STZ-diabetic rats.
Higher femur concentrations of Zn occurred when fed the diets contained normal or
increased amount of Zn, while it decreased when fed the diet marginal for Zn (Table 4.3
and Figure 4.9). However, femur Zn concentration in control rats did not change as much
as it did in STZ-diabetic rats. The result from the present study seems supports the view of
Levine et al. (1983) that bone Zn is a useful measure of Zn status in diabetes, however, it
is not a particularly accessible tissue for in vivo study.
The results of present study agree generally with other studies in which tissue Zn
concentration has been expressed as per gram of dry weight (Failla and Kiser 1981;
Donaldson et al. 1987). This may exclude the influence of a possible dehydration of
diabetic tissues on the tissue Zn analysis in the STZ-diabetic rats in the present
study.
4.4.3 Alteration of Cu Metabolism of STZ-Diabetic Rats
Similar to Zn, total body Cu content was smaller in STZ-diabetic rats (Figure
4. 13), but their whole body Cu concentration was elevated too (Figure 4. 14). Alteration of
tissue Cu concentrations was also characterized by increased concentrations of Cu in
diabetic livers and kidneys when animals fed diets containing normal or increased levels of
Zn. Zn supplementation in STZ-diabetic rats further aggravated the higher kidney Cu
concentration (Table 4.5); On the other hand, when fed the diet marginal for Zn, the
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accumulation of Cu in the diabetic kidney and liver was totally reversed. The similar but
much lesser changes in Cu metabolism in STZ-diabetic suggests the similar influence of
diabetes on both metals. The observation that feeding the diet marginal for Zn moved
tissue Cu concentration and body Cu distribution toward that of control rats indicates an
antagonizing effect between the two metals and Zn supplementation does affect Cu
metabolism in STZ-diabetic rats.
4.4.4 Changes in Fe Metabolism of STZ-Diabetic Rats
The present study revealed that, similar to Zn and Cu, Fe metabolism in STZ-
diabetic rats was also altered but not significantly as noted previously for Zn and Cu. The
findings that the whole body mean Fe concentrations were also increased significantly in
STZ-diabetic rats at all three dietary zinc levels suggest an alteration in Fe metabolism,
which was similar with that of Zn and Cu (Figure 4.17). An antagonizing effect also exists
between Zn and Fe as STZ-diabetic rats fed the diets either marginal for Zn or doubling
the normal amount of dietary Zn caused whole body mean Fe concentration to increase
significantly.
There was no significant effect of diabetes on Fe status when dietary Zn intake was
normal. The most significant change was the increase in femur Fe concentration in STZ-
diabetic rats persistently and significantly at all three dietary Zn levels.
There were no significant alteration in liver and kidney Fe concentrations in STZ-
diabetic rats at all three dietary Zn levels, except liver Fe concentration was significantly
increased in STZ-diabetic rats fed Zn deficient diet (Table 4.5).
Zn supplementation affected muscle Fe metabolism as seen that muscle Fe
concentration continued to decrease in both STZ-diabetic rats and controls.
Zn supplementation may have an antagonistic effect on Fe metabolism in normal
rats as seen in their decreased pancreatic, muscle and femur Fe. However, the effect ofZn
supplementation on tissue levels of Fe in STZ-diabetic rats seems to be less obvious
compared with those for Cu. On the other hand, Zn depletion selectively increase Fe
concentration in femur, muscle, spleen and liver in both STZ-diabetic and control rats. The
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significance of these effects is not clear and may be tied to the mutual interactions known
for Zn, Cu and Fe (Davis 1980; Flanagan et al. 1980; 1983; Hill 1988).
In summary, Diabetes leads to alterations in Zn, Cu and Fe metabolism. A
significant increase in whole body mean Zn, Cu and Fe concentrations was observed.
Hyperzincuria in diabetes is not a depleting culprit, but an active and protective
mechanism to eliminate extra unwanted Zn resulting from tissue catabolism. In diabetes
mellitus, most tissues undergo catabolism, liver and kidney may function in both
sequestration of circulating free Zn to decrease the harmful effect of free Zn or excrete
extra body Zn via urine respectively. However, since STZ-diabetic rats when fed the diet
marginal for Zn, which severely retarded their body growth, still had an increased whole
body mean Zn concentration, this may suggest a disorder in utilization of Zn, Cu and Fe in
diabetes.
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CHAPTER 5
KINETIC STUDY ON ZINC METABOLISM IN
INSULIN-DEPENDENT DIABETES MELLITUS
5.1 Introduction
This study was to measure the kinetic changes in 65Zn distribution in STZ-diabetic
and control rats at both the whole body and at the tissue levels for 12 days post 65Zn
loading. It is assumed that, after 65Zn loading, its distribution among different tissues
would have a characteristic distribution profile. The dynamic change and kinetics of this
distribution can be followed and monitored. The differences in the distribution of 65Zn
within each tissue at each time point can be compared between the STZ-diabetic and
control rats. The persistent changes or differences between the two groups should be due
to the effect of diabetes mellitus and may reflect the changes of Zn metabolism in diabetes
mellitus. The study would also provide more detailed data on changes, with time, in Zn
metabolism in diabetes mellitus.
5.2 Methods and Study Design
5.2.1 Animals
Animals, induction of diabetes, animal diets and maintenance of animals were the
same as described in Chapter 4.2.1. and 4.2.2. Animals on the ZC and ZS diets had a two
week period of adaptation before injection of STZ; while a six week of adaptation were
used for animals on ZD diet due to their slower growth in body weight.
5.2.2 Procedure of 6SZn Loading, Tissue Sampling and
65Zn Counting
65Zn solution was prepared by dilution with sterilized saline solution to a final
concentration of 20 uCi 65Zn containing -3.0 ug Zn per ml. Two hundred microliter
isotope solutions were injected intraperitoneally into diabetic and control rats. Immediately
after introduction of the 65Zn solution , the animals were put into the counting chamber
under the Nal-detector for whole body total radioactivity detection. Animals were then
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put back into the metabolic cages for various periods of time. Then each rat was counted
for radioactivity for 10 to 15 minutes daily thereafter. Animals were allowed to eat and
drink freely throughout the entire study. At each period, urine and fecal samples were
collected for later radioactivity counting.
Animals were sacrificed on the scheduled day after the last whole body counting
under anesthesia by injection 0.5 ml of 0.3% sodium pentobarbital solution. The following
tissues were taken for both 65Zn counting: liver, kidney, pancreas, spleen, a section of
duodenum, leg muscle (muscle vastus lateris, flexor digitorum profundus, and muscles
covering the femur), and femur, together with urine and feces. These tissues were weighed
immediately and then put in the counting vessels to count the radioactivity by a
scintillation counter (Gamma 4000 Counting System, Gamma Counting Spectrometer,
Beckman Instrument Inc.) for 10 minutes. One ml of whole blood sample was used for
whole blood radioactivity counting. Plasma was separated by centrifugation at 1380 g for
1 5 minutes, and 1 ml was used for counting.
Data were expressed as percentage of count per tissue out of original dosing
introduced. Total count for each tissue or organ was calculated based on the organ weight
multiplied by counts/g of that tissue. For liver, kidney, spleen, and testes, the actual organ
weight was used; and for muscle, bone, pancreas and gastrointestinal tract, organ weight
was calculated according to Owen, (1964). The specific radioactivity of
65Zn in tissues
was calculated and expressed as CPM 65Zn/g tissue divided by total ug Zn/g tissue. Tissue
Zn concentration was analyzed according to the procedures described in section 3.2.4.
5.2.3 Whole Body 65Zn Turnover Rate
The rate of 65Zn turnover (% dose/day) was measured by using the formula:
0.693/k, k = In (reading of point one/reading of point 2)/length of time between the two
points of time.
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5.2.4 Statistical Treatment of Data
The total body counts were not the original dose introduced at 0 time, but the first
day's count. This was due to the instability of the first day's count. The highest whole
body count for most animals was attained 24 hours later. The data were expressed as the
percentages of each organ count out of total body count. Mean values were based on
values of 1 to 4 animals at each time point as indicated in Table 5. 1 . For calculating the
total organ or tissue counts, either the actual weight of the organ was used (liver, kidney,
spleen) or calculated based on the body weight (See Chapter 4.2.4). The percentage of
each organ or tissue was plotted against each time point. Except for whole body count, no
attempt was made to analyze the difference among the percentages of each organ or tissue
at each time point. Radioactive decay were adjusted based on counts of the standard
counts. Background counts were recorded and subtracted from the total counts each day.
The differences in percentage of 65Zn retained for whole body and turnover rates
between STZ-diabetic rats and control rats was analyzed by a T-test procedure by using
the SAS Statistical Software (SAS Institute, Cary, NC).
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5.3 Results
5.3.1 Kinetics of Whole Body 65Zn in STZ-Diabetic Rats Compared to
Controls
5.3.1.1 Whole Body Counting of 65Zn in STZ-Diabetic Rats
Figure 5. 1 presents the kinetics of whole body 65Zn counting. Data are plotted as
the percentage of the first day's count. Theoretically, the highest count should be the
count immediately after 65Zn loading, however, due to the slow distribution and exchange
of 65Zn within the animal body compartments and consequently the counting efficiency
was gradually increased up to the highest at the first day's counting for most animals.
Thus, each animal was calculated against their first day's counting value. The data of
counting values at zero day and four hours after 65Zn loading are also available for most
animals, and are included in the Figures. The same applies for all the calculations and
Figures which follow.
All three groups of STZ-diabetic rats retained less 65Zn than their three
corresponding control groups (Figure 5.1). This became more distinct from day 6 on till
the end of the study. Dietary Zn levels affected 65Zn retention in control rats, as can be
seen that the highest 65Zn retention was in the control rats on the ZS diet, followed by
control rats on NC diet, and the lowest was in control rats on ZD diet. While in the STZ-
diabetic rats, the effect of dietary Zn levels was not clear-cut. The lowest retention was in
the STZ-diabetic rats on ZD diet. The highest was in the STZ-diabetic group on NC diet.
At the end of the 12 day's study, control rats on the ZD, NC, and ZS diets retained
62.4%, 65 .4% and 67% of their 65Zn respectively based on the first day's count, while for
STZ-diabetic rats, the retained 65Zn was 46.5%, 52.3% and 49.8% of their first day's
value respectively. The retention rates were significantly lower in STZ-diabetic rats than
that of their corresponding controls from day 6 (PO.05).
5.3.1.2 Whole Body 65Zn Turnover Rates in STZ-Diabetic Rats
As seen from Figure 5.2 diabetic rats had a significant increase in their turnover
rate of 65Zn. The normal rats had a turnover rate of 412 hour (17.2 days), while this
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turnover rate decreased to 262 hours for STZ-diabetics. Both Zn depletion and Zn
supplementation decreased the turnover rates slightly in control rats. However, STZ-
diabetic rats on the normal Zn diet had the fastest turnover rate than when they were
either on Zn depleted diet or Zn supplemented diet. The difference among the turnover
rates within either STZ-diabetic groups or control groups is much smaller than that
between the STZ-diabetic groups and control groups. It may thus be concluded that
diabetes mellitus has its effect on 65Zn turnover rate. On the other hand, dietary Zn levels
seemed to have little effect on fi5Zn turnover.
5.3.1.3 The Effect of Diabetes on 65Zn Elimination
Figure 5.3 and Figure 5.4 present cumulated fecal and urine 65Zn eliminated from
the body. The percentage of 65Zn excreted in urine was significantly higher for all three
STZ-diabetic groups than for their corresponding control groups. Dietary Zn levels was
not related to the percentage of 65Zn excreted in urine of the three STZ-diabetic groups,
nor in the three control groups. The highest percentage of urine 65Zn excretion in the STZ-
diabetic groups may indicate a higher catabolic status.
On the ZS diet, the percentage of fecal excretion of 65Zn was nearly similar in
STZ-diabetic and its control group throughout the study (Figure 5.4). However, when
they were on the ZC diet, significantly higher fecal 65Zn excretion was noted from the
STZ-diabetic rats than from their control group (P<0.05). The percentage of fecal 63Zn
excretion was greater from both STZ-diabetic rats and control rats on the ZS diet than
they fed the ZC diet within the 7 days of the study. However, the percentage of fecal 65Zn
in STZ-diabetic rats fed the NC diet became significantly higher than both STZ-diabetic
rats and their controls fed the ZS diet. At the end of the study, both STZ-diabetic group
and control group on the Zn supplemented diet excreted about 22% of 65Zn from feces.
The STZ-diabetic rats on the normal Zn diet excreted the highest fecal 65Zn (24%) among
the four groups, while the control rats on the NC diet excreted the lowest fecal 63Zn
(16%). It is apparent that the STZ-diabetic rats increased not only their urinary Zn
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excretion, but also endogenous Zn secretion. There was no compensation of hyperzincuria
through decreasing their fecal Zn excretion.
For control rats, the major route of Zn excretion was via feces (95%) with urinary
excretion of 65Zn accounting for only 4-5% of total 65Zn excreted from the body.
However, urine 65Zn excretion increased to more than 30% of total body 65Zn loss for the
STZ-diabetic rats with 70% of 65Zn eliminated from feces. These data indicate that the
urinary Zn excretion increased substantially for STZ-diabetic rats, but major route of Zn
excretion is still through the feces for both normal and diabetic rats (Table 5.1).
Table 5.1 The Ratio of Urine to Fecal Zn Elimination
STZ-Diabetics Control
ZD Diet
NC Diet 35.342+3 1 17 (50)*** 3.976+0.458 (43)***
ZS Diet 31.243+2.492 (47)*** 5.156+1.941 (45)***
*** Significant difference between STZ-diabetic and control rats at P<0.0001.
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5.3.2 Partition of 65Zn in Organs or Tissues
5.3.2.1 The Kinetics of Plasma 65Zn
Figure 5.5 present kinetics of plasma 65Zn of STZ-diabetic rats in comparison with
that of their controls. The data is expressed as percentage of plasma 65Zn count over first
day's total body count. Plasma 65Zn was not a major site of 65Zn within the body in that it
comprises less than 0.6% of total body 65Zn. The percentage value of plasma 65Zn of both
STZ-diabetic groups and control groups underwent a dynamic change and maintained at
about 0. 1 5% of total body 65Zn, suggesting a constant exchange of plasma Zn with other
body compartments.
If the percentage values of plasma 65Zn between STZ-diabetic group and control
group are compared at each dietary Zn level, all three STZ-diabetic groups had
consistently lower values. However, dietary Zn levels seemed inversely related to their
percentage values of plasma 65Zn in either STZ-diabetic groups or control groups. At the
first day, STZ-diabetic rats on the ZD diet had the lowest percentage of plasma 65Zn
counts, however, a peak emerged at day 2. From day 5 until day 12 there was neither
increase nor decrease in percentage of plasma 65Zn count in STZ-diabetic rats on ZD diet.
The control rats on ZD diet had persistently higher percentage value of plasma 65Zn
among the six groups. For the rest of the data, STZ-diabetic rats on both ZS and NC diets
at the first day had lower percentage of plasma 65Zn count compared with that of their
corresponding controls. Generally, on each diet, control rats had a higher value than that
of STZ-diabetic rats.
5.3.2.2 The Kinetics of Whole Blood 65Zn
Figure 5.6 presents data for whole blood 65Zn from STZ-diabetic rats compared
with that of their controls. Whole blood 65Zn was also not a major source of 65Zn as it
constituted only less than 0.2% of total body 65Zn. Notice that at each time point, all the
three STZ-diabetic groups had a lower percentage of whole blood
65Zn compared with
that of their corresponding controls. This possibly indicates a slower entry of
65Zn into
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blood cells. The relationship between dietary Zn intake and whole blood 65Zn was not
clear-cut as seen from the Figure.
5.3.2.3 The Kinetics of Liver 65Zn
The kinetics of liver 65Zn of STZ-diabetic rats on three different dietary Zn levels in
comparison with those of their controls are presented in Figure 5.7. Liver 65Zn was one of
the major source of body 65Zn as it constituted about 15% of total body 65Zn .Notice that
STZ-diabetic on all three different levels of dietary Zn generally had higher percentage of
liver
65Zn count than their corresponding controls for the first 8 days of the study. At the
end of the study, STZ-diabetic rats on ZD diet seemed to have exhausted its liver 65Zn
storage, while STZ-diabetic rats on the other two diets remained still higher than that of
their controls. This difference was more obvious for the STZ-diabetic rats and their
control rats on the ZD diet. The accumulation of 65Zn by the liver of STZ-diabetic rats
may inversely related to dietary Zn intake as seen from the Figure that animals on the ZD
diet had generally the highest liver 65Zn
,
the lowest liver 65Zn was in the rats on ZS diet.
5.3.2.4 The Kinetics of Kidney 65Zn
Kidney 65Zn constituted about 2-5% of total body 65Zn and STZ-diabetic rats had
the higher amount of 65Zn than their controls throughout the study (Figure 5.8). This may
indicate an increased excretion of
65Zn through the diabetic kidney, rather than reflected an
accumulation of Zn.
5.3.2.5 The Kinetics of Gastrointestinal Tract 65Zn
Figure 5.9 presents the kinetics of gastrointestinal tract (GI)
65Zn of STZ-diabetic
rats and their controls on the three dietary Zn diets.
65Zn in gastrointestinal tract may
represent a secretion of endogenous Zn into the feces. In this regard it may be concluded
that STZ-diabetic rats on ZD diet have a decreased endogenous secretion of
65Zn into the
feces within the second day of the study. However, their GI
65Zn increased up to the levels
of STZ-diabetic rats on the NC and ZS diets. STZ-diabetic rats on other two diets had a
119
higher GI 65Zn than their corresponding controls within the first 5 days of the study, which
may indicate that STZ-diabetic rats still have an increased endogenous secretion ofZn
under normal and increased Zn intake, but decreased endogenous secretion ofZn during
Zn depletion.
5.3.2.6 The Kinetics of Pancreatic 65Zn
The kinetics of pancreatic 65Zn of STZ-diabetic rats on the three different Zn diets
and their corresponding control groups are presented in Figure 5.10. Higher values are
generally in the rats with higher dietary Zn intakes at the beginning of the study. The STZ-
diabetic rats had generally higher value at the first day of the study. A peak occurred at
day 5 when the pancreatic 65Zn was much higher in both STZ-diabetic and their control
rats on ZS diet and a control group on ZD diet. The trend reversed from the 8th day until
the end of the study.
5.3.2.7 The Kinetics of Spleen 65Zn
The kinetics of spleen 65Zn of STZ-diabetic rats and their controls are presented in
Figure 5.11 Notice that STZ-diabetic rats on the NC deficient diet had generally the
lowest percentage of spleen 65Zn. STZ-diabetic rats on a ZS diet had a surge of spleen
65Zn at the 5th day of the study. The influence of either dietary Zn levels or diabetes on the
kinetics of spleen 65Zn was not clear.
5.3.2.8 The Kinetics of Muscle 65Zn
The kinetics of muscle 65Zn of STZ-diabetic rats and their controls on the three
different dietary Zn are presented in Figure 5.12. Notice that at the beginning of the study,
muscle 65Zn was lower in all the STZ-diabetic rats, which may indicate a slower entry of
Zn into the muscle in diabetes. However, from the 2nd day of the study until the end STZ-
diabetic rats on ZD diet gradually increased their muscle 65Zn; and the STZ-diabetic rats
on the ZS diet had the highest muscle 65Zn at the end of the study. It seems that diabetes
does not necessarily deplete muscle Zn, and diabetes may increased muscle Zn
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concentration when rats were fed at increased or decreased dietary Zn. The higher muscle
65Zn of STZ-diabetic rats fed the ZD diet may reflect a greater catabolic status of these
rats.
5.3.2.9 The Kinetics of Bone 65Zn
Kinetics of bone 65Zn of STZ-diabetic rats and their control rats on three dietary
Zn levels are presented in Figure 5.13. Notice that diabetes at all levels of dietary Zn
clearly resulted in decreased bone 65Zn. The trend was persistent throughout the study,
and the lowest value was in STZ-diabetic rats on the ZD diet. However, the highest
reading was in control rats on ZD diet. The data may indicate that diabetes selectively
suppress entry of 65Zn into bone, and the lower bone 65Zn in three STZ-diabetic groups
may present as a sign of Zn deficiency due to a slower entry of Zn, particularly when STZ-
diabetic rats were fed a marginal Zn deficient diet. This feature may be one of the most
important feature of altered Zn metabolism in diabetes mellitus.
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5.4 DISCUSSION
5.4.1 Accelerated Turnover of Whole Body 65Zn in STZ-Diabetic Rats
Whole body 65Zn kinetics analysis revealed that the STZ-diabetic rats retained
significantly less
65Zn at all the three dietary Zn levels (Figure 5.1), indicating an
accelerated excretion of body 65Zn. These data are in agreement with the human IDDMs
65Zn absorption reported by Kiilerich et al. (1990). The diabetic human retained less 65Zn
when compared with their controls. The decreased retention of whole body 65Zn in these
STZ-diabetic rats was mainly the result of faster whole body turnover of 65Zn. The
calculated turnover rates in the three STZ-diabetic groups were about a third faster than
their controls. Dietary Zn intake seemed to have no significant effect on whole body 65Zn
turnover in both the STZ-diabetic and control groups.
5.4.2 Increased Ratios of Urine to Fecal 65Zn Elimination in STZ-Diabetic Rats
The major route of 65Zn elimination from body was the fecal secretion in both
STZ-diabetic and control rats (Figure 5.4). The urinary excretion of 65Zn accounted for
only less than 5% of total body elimination of 65Zn in control rats, while in the STZ-
diabetic rats, the figures increased to about 35%. The total 65Zn excreted in feces during
the 1 2 days of study was not significantly different between the STZ-diabetic and control
groups fed the normal zinc diet. However, STZ-diabetic rats had significantly increased
their fecal
65Zn when they were on the Zn supplemented diet. These results agree also with
the conclusion by Johnson and Canfield (1985) that STZ-diabetic rats had an increased
endogenous secretion of 65Zn (The authors concluded that their STZ-diabetic rats had
decreased endogenous secretion, but their results showed an increased fecal 65Zn).
5.4.3 Changes in 65Zn kinetics of Tissues in STZ-diabetic Rats
The most obvious changes in tissue 65Zn kinetics of STZ-diabetic rats were their
decreased 65Zn retention in bone tissue (Figure 5 .13). The decreased percentages of bone
65Zn in STZ-diabetic rats were consistent at all dietary Zn levels. However, the bone of
STZ-diabetic rats fed the ZD diet retained the least percentage of original 65Zn dose,
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followed by STZ-diabetic rats fed the Zn supplemented diet. The results suggest that
dietary Zn did not affect bone 65Zn kinetics in a linear manner.
The plots of liver and kidney 65Zn kinetics revealed that at the first day after 65Zn
loading, the diabetic livers and kidneys contained the higher percentage of original 65Zn
dose. This may indicate that the absorbed 65Zn was rapidly sequestrated by these two
organs. The r°Zn retained in these two organs in the STZ-diabetic rats was also eliminated
faster than that of their control rats. This may suggest an increased 65Zn turnover within
these two diabetic organs.
Compared to control rats, muscles of STZ-diabetic rats retained greater
percentages of total dosed 65Zn on diets containing either marginal Zn or supplemented
Zn, but not on normal Zn diet. This may indicate that the increased muscle Zn contents in
STZ-diabetic rats came from both sources: from increased absorption and from tissue
catabolism. The kinetics of other tissues were generally not distinguished.
5.4.4 Changes in Tissue 65Zn Specificity in STZ-Diabetic Rats
The following organs of STZ-diabetic rats had increased tissue 65Zn specificities:
pancreas, kidney, liver, and plasma. The STZ-diabetic rats had consistently decreased bone
65Zn specificity at all three dietary Zn levels. It seems the bone of the STZ-diabetic rats
may be the special tissue with decreased utilization of total body Zn (See Figure 5.14).
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CHAPTER 6
DISCUSSIONS AND CONCLUSIONS
6.1 The Zn Status of Stz-Diabetic Rats Has Been Altered but Is Not Deficient
The objective of this study was to find out whether Zn deficiency exists and what
are the alterations of tissue Zn concentrations in diabetes mellitus. The significance of the
present study is the findings that the WBMZCs in the STZ-diabetic rats were increased
consistently and significantly. The major contributors of this increase in WBMZC in STZ-
diabetic rats were liver and kidney when STZ-diabetic rats fed the Zn deficient diet; while
the increased WBMZCs in STZ-diabetic rats fed the diets either adequate for Zn or
supplemented with Zn were contributed by increased Zn concentrations of all organs and
tissues.
The sources of this increased WBMZC in STZ-diabetes mellitus mainly came from
the increased tissue breakdown resulting from greater body catabolism and decreased
growth velocity, and was also contributed in part by their increased absorption due to
greater dietary intake. However, this increased WBMZC can not be accounted for by
decreasing endogenous secretion of Zn into feces since their fecal 65Zn excretion was not
decreased.
The findings of the present study lead to the revaluation of Zn status of the
diabetics, their hyperzincuria, and the nature of accumulation of Zn in liver and kidney
6.2 Hyperzincuria in Diabetes Mellitus Is the Natural Consequence of Increased
Total Body Zn Content
Hyperzincuria in diabetes has been regarded as the culprit depleting body Zn stores
in diabetics The results of the present study lead to the believe that hyperzincuria in
diabetes is the consequence of Zn accumulation resulting from both the increased
absorption and body catabolism. It can be envisioned that in diabetes most tissues,
especially muscles, undergo catabolism and release Zn, at the same time liver is saturated
with sequestrated Zn from circulation, while kidney is overloaded with unwanted extra Zn
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needing for excretion. Hyperzincuria is the natural result of this readjusted Zn homeostasis
in the diabetic body. It is thus not a culprit depleting body Zn stores, but an active and
protective process, and an important component of Zn homeostasis in diabetes mellitus.
Similarly, the increased urinary Cu and Fe excretion in diabetes mellitus (Lau and Failla
1984) can also be explained by the same mechanism
6.3 The Adaptive Nature and Mechanisms of Increased Zn Levels in Diabetic
Kidneys and Livers
Several alterations in diabetic rats have been identified. The most prominent of
which is the accumulation or sequestration of Zn in the diabetic livers and kidneys. The
absolute increase in Zn contents in these two organs are contributed by both increased
concentration and organ volume or tissue hypertrophy.
The mechanism of the accumulation of Zn by diabetic livers and kidneys has been
hypothesized to be previously related to hormone imbalance and stress reaction (Failla and
Riser, 1983; Hallmans, et al. 1984). However, The results of the present study for the first
time challenge this view. The elevated WBMZC leads reasonably to the conclusion that
these accumulations of Zn (and Cu) in the diabetic livers and kidneys may be the natural
consequence of diabetic catabolism. The release of large amount of Zn from tissue
catabolism lead to the increased amount of these metals in the circulation, which needs
either to be stored in the liver for detoxification or excreted through the kidney.
Another finding of the present study is that decreased dietary Zn intake per se also
leads to Zn concentration in the liver (but not kidney) in both normal and STZ-diabetic
rats. It may also be possible that accumulation of Zn in the diabetic livers during Zn
deficiency services a more vital function.
The present study found that the accumulation of Zn by the STZ-diabetic liver was
not affected by the levels of Zn in the diet. Zn toxicity due to greater release of Zn from
tissue catabolism is thus not existed. If Zn toxicity was present in the STZ-diabetic rats,
Zn concentrations of livers of STZ-diabetic rats should fall when they fed the diet marginal
for Zn. One possible explanation is that Zn accumulated in the liver may not be easily
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eliminated by a reversible process. Whether this Zn accumulated in the diabetic liver is
reusable or not needs further clarification. It may also be possible that it is a very slow
process for the liver to eliminate stored Zn.
6.4 Zn Absorption in Diabetic Rats Is Not Altered
The percentage of 65Zn absorption and retention were not significantly different
between the STZ-diabetic rats and controls. However, STZ-diabetic rats absorbed more
Zn due to their increase in food intake. The findings that STZ-diabetic rats can increase
65Zn absorption when "post-fasted" indicate that the diabetics are capable of absorbing and
retaining enough Zn to meed their body needs of Zn.
The findings of feeding pattern influenced 65Zn absorption and retention in the
present study may have significant implications in several aspects First, the total amount
of Zn absorbed is determined by the duration of post-fasting. Second, this is also a factor
that may account for different results observed by different studies (Kiilerich et al. 1990,
Craft and Failla 1983); Third, these findings are also important in future studies in which
feeding pattern should be considered in study designs.
6.5 Endogenous Excretion of Zn Changes with Dietary Zn Intake in Stz-Diabetic
Rats; and Endogenous Zn Excretion Does Not Decrease in Stz-Diabetic Rats
Fecal 65Zn excretion was not increased in STZ-diabetic rats when fed the diet
containing normal level of Zn, suggesting under normal conditions, endogenous secretion
of Zn in diabetics is not decreased. Analysis of duodenal Zn concentration revealed that a
significant increase in duodenal Zn concentration occurred in STZ-diabetics, which was
also dependent on dietary intake of Zn. The observation may also support the view that
endogenous secretion of Zn in diabetics is not decreased. This finding suggests that the
increased WBMZC is not due to decreasing endogenous Zn secretion as suggested by
Johnson and Canfield (1985). The findings that both endogenous Zn secretion and Zn
absorption were not significantly altered in STZ-diabetic rats suggests that the major
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source of increased WBMZC and Zn accumulation in liver and kidney comes from body
tissue catabolism.
6.6 Muscle Zn Increased Significantly in Stz-Diabetic Rats During Zn Deficiency,
Suggesting Greater Catabolism, and Release of Large Amount of Zn
Muscle Zn concentrations in STZ-diabetic rats were generally higher than that of
their controls. The observation that muscle Zn concentration in STZ-diabetic rats when
fed the diet marginal for Zn increased significantly, but this phenomenon was not observed
in control rats, indicating that an altered Zn metabolism in muscle tissue in diabetics The
increased muscle Zn concentration in STZ-diabetic rats during Zn deficiency may indicate
a greater catabolism of the tissue and it also becomes the major source of increased
WBMZC and complements increases in Zn contents of liver and kidney, and urine loss.
The findings from the kinetic study that the muscle from STZ-diabetic rats also contained
greater amount of 65Zn may indicate that a greater amount of absorbed Zn goes to
muscles.
The findings from the present study indicate that muscle Zn concentration does not
reflect food Zn intake and is also not a valid indicator of Zn status.
6.7 Plasma Zn Levels Do Not Reflect Dietary Zn Intakes and Do Not Reflect
Whole Body Mean Zn Concentration
The present study observed that plasma Zn levels did not respond to dietary Zn
intake in both STZ-diabetic rats and controls. Plasma levels of Zn and
65Zn in STZ-
diabetic rats were observed to be affected by feeding pattern as observed in the kinetic
study. The results that plasma Zn levels did not reflect dietary Zn intake confirmed again
that plasma Zn concentration is not a good indicator ofZn status.
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6.8 Zn Utilization by Diabetic Bone May Be Compromised as Bone 65zn
Turnover Is Lower in STZ-Diabetic Rats
The STZ-diabetic rats had consistently lower percentages of 65Zn in bones. This
finding agrees well with the results of decreased bone 65Zn specificity in the diabetic bone
in all three STZ-diabetic rat groups. The observations that severely retarded body growth,
significantly higher WBMZC, and the lower 65Zn specificity in diabetic bone exist
simultaneously in STZ-diabetic rats when they fed a diet marginal for Zn may represent a
disorder of Zn utilization in diabetes mellitus.
6.9 Future Studies
The above 8 conclusion drawn based on the animal study may be valid for STZ-
diabetic rats only, whether these changes occur also in human diabetes have to be
confirmed. It may be possible that all these alterations of zinc concentration and
distribution, particularly that occurred in diabetic livers and kidneys, observed in the STZ-
diabetic rats may be the results of toxic effect of streptozotocin. Thus all these
observations may not represent what happens in human diabetes. Future studies may
continue to explore the mechanisms of these changes in zinc, copper and iron metabolism
as observed in the present study.
1 Determine whether these changes in STZ-diabetic rats reflect true changes in
human diabetes This can be done by analyzing livers and kidneys from human diabetic
subjects. The possible toxic effect of STZ could be ruled out
2. Determine whether changes in zinc concentration and distribution, particularly
changes in diabetic livers, kidneys and muscle, reflect the natural results of catabolism;
This could be done by fasting the animals to see whether similar changes occur.
3 Confirm whether increases in zinc concentration and alteration in diabetic livers
and kidneys are reversible. This can be done in normal animals by insulin clamp
techniques.
4 Confirm whether increases in trace element concentrations in diabetic livers and
kidneys provide any beneficial effect to diabetic animals and humans.
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5 Determine how STZ-diabetic animals increased their total body mean zinc, copper
and iron concentrations
6 Characterize changes in the diabetic bone. To explain why zinc concentration was
lower even if STZ-diabetic animals had increased total body mean zinc, copper and iron
concentration, and
7. To distinguish whether changes in Zn concentration and distribution, as well as
increased WBMZC of STZ-diabetic rats are toxic effect of STZ or purely result of
diabetes
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APPENDIX
ADDITIONAL TABLES
Table 1. Zinc Contents of Selected Organs or Tissues of STZ-Diabetic Rats
Table 2. Zinc Distribution among Organs and Tisssues in STZ-Diabetic Rats
Table 3. Copper Contents of Selected Tissues of STZ-Diabetic Rats
Table 4. Copper Distributions Among Tissues in STZ-Diabetic Rats
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Table 6. Iron Distribution among Organs and Tissues of Diabetic Rats
Table 7. Whole body Mean Zinc, Copper and Iron Contents and
Concentration of STZ-Diabetic Rats
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Table 1 Zinc Contents of Organs and Tissues in STZ-Diabvetic Rats
Diet ZD Diet ZC Diet ZS Diet
Plasma Zinc (ug)b$$@@
STZ-Diabetics 3.1+0.3(4)** 7.8+0.9(9) 5.9+0.6(9)**
Controls 7.0+0.9(7)** 8.9+0.9(6) 8.6+0.7(9)**
Blood Clot Zinc (ug)a@@
STZ-Diabetics 15.4+1.5(4)** 21.7+1.5(9) 21.3+0.9(9)
Controls 23.9+1.5 (7)** 23.5+2.0(6) 24.0+1.4(9)
Liver Zinc (ug)
STZ-Diabetics 223.5+16.3 (4) 286.0+15.0(9) 265.5+9.4 (9)
Controls 260.4+25.4(7) 262.9+13.6(6) 269.0+9.0(9)
Kidney Zinc (ug)c$$@@@##
STZ-Diabetics 39.0+0.9 (4) 50.1+1.7(9)*** 49.0+1.4(9)***
Controls 38.5+0.1 (7) 38.4+1.0 (6)*** 38.6+0.6(9)***
GI Tract Zinc (ug)c$$$@@@
STZ-Diabetics 43.8+4.7 (4)** 88.4+5.4 (9)* 95.2+5.6(9)
Controls 79.6+5.3 (7)** 103.6+4.2(6)* 109.2+4.0(9)
Spleen Zinc (ug)c$$$@@@
STZ-Diabetics 3.10+0.49(4)** 9.4+0.9(9)* 9.0+1.0(9)*
Controls 8.38+0.98 (7)** 12.0+0.7(6)* 11.4+0.4(9)*
Pancreas Zinc (ug)a@@#
STZ-Diabetics 5.6+0.5(4)* 8.7+0.5(9) 7.7+0.4(9)
Controls 11.8+2.2(7)* 8.6+0.7(6) 8.7+0.5(9)
Muscle Zinc (ug)a#
STZ-Diabetics 878.6+95.3 (4) 772.2+57.4(9) 761.5+39.1 (9)
Controls 667.3+34.0(7) 866.0+64.7 (6) 889.0+47.6(9)
Bone Zinc (ug)b$$@@
STZ-Diabetics 1101.3+37.7(4)** 1774.9+139.9(9) 1865.1+110.8 (9)
Controls 1808.3+162.2 (7)** 1978.7+137.4(6) 2146.4+130.0(9)
* »* p , o.o5. P 0.01. and P- 0.0001 between diabetic and control groups from T-test. The following are from GLM: a..b. c: model
significance at P 0.05. 0.01 and 0.0001 level: $.$$.$$$: Diet effect at P- 0.05. 0.01 and 0.0001 level: U.ntt.UUH: Significant interaction
between dietary Zn level and diabetes at P^0.05. 0.01 and 0.0001 levels. @, @@, ta}ta>ta>: Groups effect at P<0.05. 0.01 and 0.0001
levels, (number): number of rats.
141
Table 2 Zinc Distribution among Organs and Tisssues in STZ-Diabetic Rats
**
Diet ZD Diet ZN Diet ZS Diet
Plasma Zinc (%)b$$@@
STZ-Diabetics 0.14+0.02 (4)** 0.26+0.02(9) 0.19+0.01 (9)**
Controls 0.24+0.02(7)** 0.27+0.02 (6) 0.25+0.02(9)
Blood Clot Zinc(%)
STZ-Diabetics 0.67+0.07 (4) 0.73+0.04 (9) 0.70+0.03 (9)
Controls 0.83+0.02 (7) 0.72+0.07(6) 0.70+0.05 (9)
LiverZinc (%)a$@@
STZ-Diabetics 9.68+0.69(4) 9.62+0.43 (9)** 8.69+0.24 (9)*
Controls 8.85+0.34(7) 8.02+0.28 (6)** 7.76+0.29(9)*
Kidney Zinc (%)c@
STZ-Diabetics 1.69+0.07(4)* 1.72+0.13 (9)** 1.62+0.07(9)***
Controls 1.37+0.11 (7)* 1.18+0.06(6)** 1.12+0.05 (9)***
GI Tract Zinc (%)c$$@@@###
STZ-Diabetics 1.91+0.24(4)* 2.95+0.09(9) 3.09+0.06(9)
Controls 2.76+0.09 (7)* 3.17+0.12 (6) 3.15+0.12(9)
Spleen Zinc (%)
STZ-Diabetics 0.14+0.02(4)** 0.31+0.02 (9) 0.29+0.03 (9)
Controls 0.29+0.03 (7)** 0.37+0.02(6) 0.33+0.02 (9)
Pancreas Zinc (%)b##
STZ-Diabetics 0.24+0.02(4)* 0.29+0.01 (9) 0.25+0.01 (9)
Controls 0.40+0.06(7)* 0.26+0.02 (6) 0.25+0.02 (9)
Muscle Zinc (%)c$$$@@@###
STZ-Diabetics 37.79+2.95 (4)** 25.58+0.52 (9) 24.77+0.47 (9)
Controls 23.61 + 1.70 (7)** 26.23+0.95 (6) 25.42+0.72 (9)
Bone Zinc (%)c$$$@@@###
STZ-Diabetics 47.74+1.91 (4)** 58.54+0.63 (9) 60.41+0.69 (9)
Controls 61.66+1.54 (7)** 59.79+1.21 (6) 61.02+1.01 (9)
* ** ***. p, o os p- 0 01 and P 0 0001 between diabetic and control groups from T-lest. The following
are from GLM: a..b. c: model
significance at M.05, 0.01 and 0.0001 level- $. $$. $$$: Diet effect at P< 0.05. 0.01 and 0.0001 level; #.
Significant interactaon
between dietary Zn level and diabetes at P<0.05, 0.01 and 0.0001 levels. @, @@, @@@- G™ips effect at P<005 > 0 01 «nd 0
0001
levels, (number): number of rats.
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Table 3 Copper Contents of Selected Tissues of STZ-Diabetic Rats
Diet Zinc Deficient Normal Zinc Supplement
Plasma Copper (ug)
STZ-Diabetics 2.7+0.4 (4)
Controls 3.4+0.3(10)
4.9+0.8 (6)
3.7+0.3 (7)
3.2+0.4 (10)
4.5+1.1 (11)
Blood Clot Copper (ug)@
STZ-Diabetics 2.4+0.1(4)***
Controls 4.0+0.2(10)***
4.1+0.4(6)
5.0+0.8 (7)
3.7+0.2(10)
4.6+0.7(11)
Liver Copper (ug)c$$@@###
STZ-Diabetics 40.2+3.5 (4)*
Controls 53.8+3.7(10)*
88.7+10.8 (6)**
46.2+4.1 (7)**
65.6+3.8 (10)**
48.1+2.9(11)**
Kidney Copper (ug)b$@@
STZ-Diabetics 10.6+1.3(4)
Controls 12.3+0.4(10)
36.5+8.7(6)*
10.1+0.6(7)*
37.2+7.3 (10)*
16.6+4.5 (11)*
GI Tract Copper (ug)a$$@
STZ-Diabetics 5.6+1.1(4)*
Controls 8.9+0.6(10)*
9.3+0.6 (6)
9.4+0.8 (7)
9.3+0.8 (10)
10.3+0.8 (11)
Spleen Copper (ug)a$@@
STZ-Diabetics 0.5+0.1(4)**
Controls 0.8+0.1(10)**
0.9+0.1 (6)
1.1+0.1 (7)
0.9+0.1 (10)
1.0+0.1 (11)
Pancreas Copper (ug)#
STZ-Diabetics 0.4+0.03 (4)*
Controls 0.6+0.1(10)*
0.6+0.1 (6)
0.5+0.04(7)
0.6+0.03 (10)
0.5+0.03 (11)
Muscle Copper (ug)c@@@
STZ-Diabetics 90.4+14.7 (4)
Controls 94.8+7.1(10)
104.8+10.4(6)
110.8+10.8 (7)
88.5+6.6 (10)*
115.5+10.4(11)*
Bone Copper (ug)a$$@@
STZ-Diabetics 35.7+0.8(4)*
Controls 51.7+5.1(10)*
51.8+5.1 (6)
60.6+3.7 (7)
52.7+2.5 (10)
60.7+3.5 (11)
* ** ***.p<oo5 P 0 01 andP 0 0001 between diabetic and control groups from T-test. The following are
fromGLM: a.,b. o.. model
significance at P- 0.05. 0.01 and 0.0001 level: S. $$. $$S: Diet effect at P' 0.05 0.01 aiidOOOOl
level; #, #M#* Significant mterachon
between dietary Zn level and diabetes at P 0.05. 0.01 and 0.0001 levels. @, @@, @@@: Groups effect at P< 0.05. 0.01
and 0.0001
levels, (number): number of rats.
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Table 4. Copper Distributions Among Tissues in STZ-Diabetic Rats
Diet Zinc Deficient Normal Zinc Supplement
Plasma Copper (%)
STZ-Diabetics 1.44+0.20(4) 1.63+0.26(6) 1.22+0.11 (10)
Controls 1.55+0.21 (10) 1.54+0.19 (7) 1.59+0.34 (11)
Blood Clot (%)a(i
STZ-Diabetics 1.32+0.11(4)* 1.35+0.11 (6)* 1.43+0.06(10)
Controls 1.76+0.04(10)* 1.99+0.23 (7)* 1.68+0.20(11)
Liver Copper (%)c@@@##
STZ-Diabetics 21.36+1.31 (4) 29.43+3.54(6)* 24.95+0.92(10)***
Controls 23.37+0.65 (10) 18.59+0.86 (7)* 18.67+0.50 (1 1)* 3*
Kidney Copper (%)b@@
STZ-Diabetics 5.75+0.80(4) 12.40+3.38 (6)* 14.42+3.02(10)*
Controls 5.60+0.49(10) 4.15+0.13 (7)* 6.07+1.24 (11)*
GI Tract Copper (%)a@@
STZ-Diabetics 3.13+0.73 (4) 3.06+0.10(6)** 3.54+0.21 (10)
Controls 3.88+0.13 (10) 3.83+0.18 (7)** 4.02+0.20 (11)
Spleen Copper (%)a@@
STZ-Diabetics 0.27+0.05 (4) 0.29+0.02(6)** 0.34+0.04(10)
Controls 0.38+0.03 (10) 0.44+0.02 (7)** 0.39+0.03 (11)
Pancreas Copper (%)b$
STZ-Diabetics 0.22+0.01(4) 0.19+0.01(6) 0.21+0.01(10)
Controls 0.24+0.01(10) 0.19+0.01(7) 0.18+0.01(11)
Muscle Copper (%)b$@##
STZ-Diabetics 47.187+3.930 (4) 34.51+2.92 (6)* 33.76+2.32 (10)**
Controls 40.875+1.088 (10) 44.43+1.59(7)* 43.28+1.70(11)**
Bone Copper (%)b@@
STZ-Diabetics 19.31+1.57(4) 17.14+1.56 (6)** 20.13+0.69(10)*
Controls 22.34+1.43 (10) 24.86+1.17 (7)** 24.12+1.61 (11)*
* ** ***. p 00 s p 0 01 nndP' 0 0001 between diabetic and control groups from T-test. The following are from GLM: a..b. c: model
significance at P 0 05. 0.01 and 0.0001 level: 1 $$. Diet effect at P'0.05. 0.01 and 0.0001 level: #. ##. ###: Significant interaction
between dietary Zn level and diabetes at P 0.05. 0.01 and 0.0001 levels. @, @@, ®@@: Groups effect at P<0.05. 0.01 and 0.0001
levels, (number): number of rats.
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Table 5 Iron Contents of Selected Organs or Tissues of STZ-Diabetic Rats
Diet Zinc Deficient Normal Zinc Supplement
Plasma (ug)c$@@@
STZ-Diabetics
Controls
3.26+0.69 (4)
4.47+0.75 (8)
8.97+1.06 (9)
11.43+0.95 (9)
8.13+0.74(10)
10.84+1.30(8)
Blood (ug)c$$@@(g
STZ-Diabetics
Controls
I
1777+69 (4)***
2792+141(8)***
2649+181(9)*
3247+140 (9)*
1005+74(11)
1080+80 (7)
Liver (ug)
STZ-Diabetics
Controls
1184+93.76 (4)
1180+94 (8)
929+134(9)
949+79 (9)
982+56 (10)
990+78 (8)
Kidney (ug)b@@
STZ-Diabetics
Controls
141.86+11.96 (4)
143.57+7.23 (8)
190.52+16.37 (9)*
143.63+7.89 (9)*
186.26+ 10.00(10)*
141.25+11.93 (8)*
GI Tract (ug)c$$$@
STZ-Diabetics
Controls
@
196.39+26.15 (4)*
382.489+58.53 (8)*
329.98+59.31 (9)**
689.10+71.98 (9)**
321.99+30.06 (10)**
641.19+81.55 (8)**
Pnacreas (ug)a$$
STZ-Disbetics
Controls
8.26+0.77 (4)*
11.13+0.83 (8)*
13.74+1.45 (9)
14.33+0.57 (9)
14.80+1.60(10)
12.65+1.31 (8)
Spleen (ug)a@@#
STZ-Diabetics
Controls
65.71 + 14.73 (4)**
147.35+20.12(8)**
111.15+8.83 (9)
140.31 + 1 1.64 (9)
115.73+13.20 (10)
121.81+10.08 (8)
Muscle (ug)a#
STZ-Diabetics
Controls
1253+338 (4)
1018+104 (8)
1109+133 (9)*
1518+97 (9)*
1417+93 (10)
1339+93 (8)
Bone Iron (ug)
STZ-Daibetics
Controls
1439+260 (4)
1249+245 (8)
988+113 (9)
1034+63 (9)
967+70(10)
1119+79(8)
* ** »**.p, f)0S p ooi and P 0 0001 between diabelic and control groups from T-test. The following are from GLM: a.,b. c: model
significance at P-0.05. 0.01 and 0.0001 level; $. $$. $$$: Diet effect at P 0.05. 0.01 and 0.0001 level; #. ##, Significant
interaction
between dietary Zn level and diabetes at P 0.05. 0.01 and 0.0001 levels. @, @@, @@@; Groups effect at P<0.05. 0.01 and 0.0001
levels, (number): number of rats.
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Table 6 Iron Distribution among Organs and Tissues of Diabetic Rats
Dietary groups Zinc Deficient Normal Zinc Supplement
Plasma (%)$$
Diabetic
Control
0.014+0.003 (4)
0.016+0.002 (8)
0.042+0.006 (9)
0.050+0.012 (7)
0.042+0.009 (9)
0.040+0.006 (8)
Blood (%)$$,#
Diabetic
Control
27.222+2.671(4)*
38.209+2.379 (8)*
40.758+2.777 (9)
40.627+0.924 (7)
37.919+0.761 (9)
40.834+1.674 (8)
Liver (%)$$
Diabetic
Control
17.794+0.857(4)
16.020+1.111 (8)
13.216+1.515 (9)
11.248+0.840 (7)
14.398+0.821 (9)*
11.923+0.790 (8)*
Kidney (%)#
Diabetic
Control
2.127+0.082 (4)
1.987+0.160 (8)
2.927+0.238 (9)**
1.818+0.128 (7)**
2.741+0.163 (9)***
1.622+0.100(8)***
GI Tract (%)$$
Diabetic
Control
3.060+0.559(4)*
5.061+0.599 (8)*
4.554+0.556 (9)**
7.599+0.474 (7)**
4.446+0.268 (9)**
7.752+0.716(8)**
Pancreas (%)$$, #
Diabetic
Control
0.124+0.011 (4)
0.151+0.012 (8)
0.204+0.009 (9)
0.183+0.012 (7)
0.213+0.023 (9)*
0.149+0.013 (8)*
Spleen (%)#
Diabetic
Control
0.977+0.184 (4)**
1.954+0.203 (8)**
1.679+0.069 (9)
1.710+0.179 (7)
1.652+0.186 (9)
1.568+0.144 (8)
Muscle (%)#
Diabetic
Control
18.285+3.911 (4)
13.600+1.112 (8)
16.129+0.644 (9)*
18.742+0.820(7)*
18.987+1.137(9)
16.844+0.976(8)
Bone system (%)$$
Diabetic
Control
30.399+4.719(4)
23.002+3.100(8)
20.491 + 1.118 (9)
18.023+0.621 (7)
19.601 + 1.307 (9)
19.268+0.628 (8)
*. **. ***: p 0.05. P 0.01. and P- 0.0001 between diabetic and control groups from T-test. The following are from GLM: a..b. c.: model
significance at P 0.05. 0.01 and 0.0001 level: $. $$. $$$: Diet effect at P 0.05. 0.01 and 0.0001 level: #. #*. Significant interaction
between dietary Zn level and diabetes at P 0.05. 0.01 and 0.0001 levels. @, @@, @@@: Groups effect at P< 0.05. 0.01 and 0.0001
levels, (number): number of rats.
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Table 7. Whole body Mean Zinc, Copper and Iron Contents and
Concentration of STZ-Diabetic Rats
Diet Zinc Deficient Normal Zinc Supplement
Whole Body Zinc (ug)a$$@
STZ-Diabetics 2313+87 (4)*
Controls 2905+211 (7)*
3019+214 (9)
3303+207 (6)
Whole Body Mean Zinc Concentation (ug/g wet wt)c$$@@@
STZ-Diabetics 17.54+0.88 (4)* 14.69+0.36(9)**
Controls 13.99+0.40(7)* 12.85+0.37(6)**
Whole Body Copper (ug)b$$#
STZ-Diabetics 188.6+15.6 (4) 301.4+9.4(6)*
Control 230.3+15.1 (10) 247.3+19.1 (7)*
3080+162 (9)
3505+176 (9)
15.39+0.42 (9)**
13.34+0.27 (9)**
261.8+8.7(10)
261.8+19.1 (11)
Whole Body Mean Copper concentration (ug/g Wet Wt)c@(fl}
STZ-Diabetics 1.431+0.135 (4) 1.410+0.112 (6)*
Controls 1.051+0.025 (10) 0.978+0.061 (7)*
1.305+0.054(10)**
1.029+0.075 (11)**
Whole Body Iron (ug)$$
STZ-Diabetics 6069+454 (4) 6328+564
Controls 6928+407 (8) 7747+371
6760+204(11)
7564+388 (7)
Whole Body Mean Iron concentration (ug/g Wet Wt)c
STZ-Diabetics 46.12+4.23 (4)* 30.85+1.98 (9)
Controls 32.94+2.17(8)* 29.97+0.66(9)
33.62+1.09(11)**
28.49+0.90 (7)**
* ** ***. p-o.05. P'0.01. and P- 0.0001 between diabetic and control groups from T-test. The following are from GLM: a .b. c: model
significance at P 0.05. 0.01 and 0.0001 level: $. $$. $$$: Diet effect at P<0.05. 0.01 and 0.0001 level: #. ##. #«#: Significant interaction
between dietary Zn level and diabetes at P-O.05. 0.01 and 0.0001 levels. @, @@, @@@: Groups effect at P<0.05. 0.01 and 0.0001
levels, (number): number of rats.
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